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 Nogo/RTN4 belongs to the Reticulon (RTN) family, which comprises of four 
members, RTN 1-4. There are three major splice isoforms of Nogo/Rtn4, namely 
Nogo-A, -B and -C. Nogo is first discovered as a myelin-associated neurite outgrowth 
inhibitor localized at the oligodendrocytes where it interacts with its neuronal 
receptor, NgR, to elicit its neurite growth inhibitory effect. However, the endogenous 
physiological role of Nogo has remained unknown. 
In our studies, we have generated specific antibodies against Nogo-A, showed 
that it is enriched in the paranodal region, and that it interacts with the neuronal axon-
glial junction protein Caspr. Nogo-A’s interaction with Caspr implied a function at 
the axon-glial junction, but comparative analysis did not reveal significant changes in 
the structural organization of the node in Nogo-deficient mice. Nogo-A also interacts 
with RTN3, another member of the RTN family. We demonstrated that this 
interaction is stronger than Nogo-A’s low affinity to RTN1 and RTN2, and have 
molecularly dissected the interaction domains involved in Nogo-A-RTN3 interaction.  
As Nogo-A levels are elevated in neurons (but not oliodendrocytes) in brain 
injuries and ischemia, we investigated if elevated Nogo-A could have a 
neuroprotective effect. Moderate Nogo-A expression could protect SH-SY5Y 
neuroblastoma cells against a myriad of pro-apoptotic stimuli such as H2O2, serum 
deprivation, staurosporine and etoposide. Tunicamycin-induced cell death, however, 
is enhanced by Nogo-A expression. The same effects are also observed by Nogo-B 
expression. On the other hand, while Nogo-C and RTN3 confer some degree of 
protection against serum deprivation, staurosporine and etoposide, they are not 
effective against apoptosis induced by H2O2.  
x 
 
Stable Nogo-A expression does not intrinsically induce upregulation of anti-
apoptotic proteins such as Bcl-2 and Bcl-xL, but instead causes downregulation of 
pro-apoptotic Bid truncation and AIF. Nogo-A expression also increases the basal 
levels of total and activated Bax. This correlates with increased basal levels of 
activated caspase-3. Indicators of the unfolded protein response (UPR), one type of 
ER stress responses, are, however, not significantly elevated. Focusing on H2O2 
induction of cell death, we investigated on the possible neuroprotective mechanisms 
of Nogo-A. We show that Akt and Erk are not necessary for Nogo-A’s protective 
effect against H2O2. Any UPR-based preconditioning is also found not to be 
accountable for Nogo-A’s protection. Interestingly, Nogo-A expression is able to 
attenuate caspase-3 and -9 activation upon H2O2 treatment. This implies that Nogo-A 
may protect by the attenuation of the intrinsic pathway and the subsequent caspase-
dependent apoptosis. We also observe some differences in terms of nuclear 
translocation of p65/RelA subunit of NF-қB between the Nogo-A expressing and 
control cells, which may, at least partly, contribute to Nogo-A’s neuroprotective 
function.  
The work presented in this thesis provided insights into possible cell 
autonomous functions of Nogo-A other than its role in neurite outgrowth inhibition. 
In line with earlier observations that Nogo-A is elevated during brain injury, Nogo-A 
may thus have a role as a component of the neuron’s injury response and survival 
preservation mechanism.   
xi 
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Chapter 1 Introduction 
 
1.1  Discovery of Nogo-A: an inhibitor of neuronal regeneration 
1.1.1  Neuronal regeneration is limited in adult CNS 
 Adult mammalian central nervous system (CNS) has been notoriously known 
by its inefficiency to regenerate and self-repair. This inability is especially crucial in 
situations where the CNS is „damaged', like in physical injuries such as spinal cord 
injuries and brain trauma, or in non-physical ones such as neurodegenerative diseases. 
As axons are usually severed or degenerated in these instances, recovery of function is 
therefore greatly dependent on the ability of the axons to regenerate. Patients who 
suffer from physical severing of axons may have to endure with paralysis for the rest 
of their lives, while those who suffer from neurodegenerative disorders will gradually 
lose either or both of their sensory and motor functions, and eventually premature 
death. Exceptions may only be observed in specific pathways, such as those in the 
hippocampus (Chauvet et. al., 1998) and olfactory bulb (Monti et. al., 1980; Morrison 
and Costanzo, 1995). In contrast, the adult peripheral nervous system (PNS), the other 
nervous system in the body, is more than capable of regeneration. When a PNS 
neuron is severed, its axon is able to regenerate, and in many cases, able to 
reinnervate target tissues.  
 There are two possibilities for the differing regenerative capacities of the two 
nervous systems. One reason could be that CNS neurons are intrinsically incapable of 
regeneration as compared to PNS ones. However, this notion appears not to be 
entirely true. Ramón y Cajal, commonly regarded as „the father of neuroscience‟ and 
the one who coined the term „neuronal plasticity‟, observed that CNS neurons were 
not intrinsically unable to regenerate but exhibited only limited regeneration (Ramón, 
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1928). Another report showed that the CNS branch of dorsal root ganglion (DRG) 
axons had better growth capacity after preconditioning lesions were carried out, which 
also suggests that CNS neurons are intrinsically capable of regenerating (Neumann 
and Woolf, 1999).  
A second plausible reason for the lack of regeneration in the CNS is that the 
environment in CNS is growth-inhibitory and not growth-promoting. It became 
evident that the tissue environment indeed played a crucial role during regeneration, 
with studies showing injured CNS neurons, although unable to regenerate when in a 
CNS environment, being able to do so in the presence of a peripheral nerve 
environment when PNS grafts were inserted into different regions of the CNS (Dam-
Hieu et. al., 2002; David and Aguayo, 1981; Richardson et. al., 1980; Schwab and 
Thoenen, 1985). Schwab and Thoenen (1985) observed that newborn rat sympathetic 
or sensory neurons, when placed in the middle of a three-compartment chamber with 
sciatic and optic nerve explants on either side, were able to grow out of the former but 
not the latter. This observation convincingly demonstrated the non-permissive 
substrate conditions that pervade the CNS. This was performed in the presence of 
optimal amounts of nerve growth factor, which suggested that a lack of trophic factors 
in CNS was at least not the major reason for the lack of regeneration in CNS. 
 
1.1.2 The adult CNS environment is non-permissive to neuronal growth and 
regeneration 
It has been suggested that after CNS injury, glial scars which serve to contain 
the wound site and confine inflammation and cellular degeneration (Faulkner et. al., 
2004), also inevitably act as a mechanical barrier that prevents axonal growth and 
reconnection (Ramón, 1928; Reier et. al., 1983; Silver and Miller, 2004). Neurite 
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outgrowth was inhibited in studies using in vitro glial scar models, thus confirming 
that the presence of glial scars formed during CNS injury does play a role in limiting 
axonal regeneration (Rudge and Silver, 1990; Wanner et. al., 2008). When injury is 
inflicted in the CNS, proliferation and activation of astrocytes (astrogliosis) in the 
vicinity of the injury site occur, together with the recruitment of other cell types such 
as the microglia, oligodendrocyte precursors and meningeal cells to the injury site. 
This eventually resulted in the formation of a glial scar (Fig 1.1).  
The reactive astrocytes present at the glial scar become hypertrophic and 
secrete extracellular matrix molecules collectively known as chondroitin sulphate 
proteoglycans (CSPGs) (including molecules such as aggrecan, brevican, versican and 
NG2). These CSPGs are known to be inhibitory to neuronal regeneration (McKeon et. 
al., 1991; Asher et. al., 2001). Removal of CSPGs by treatment with glycan trimming 
chondroitinase ABC resulted in improved regeneration (Bradbury et. al., 2002; Moon 
et. al., 2001; Yick et. al., 2000). This indicated that these molecules play an important 
role in contributing to the growth-inhibitory environment in CNS.  
 Another contributor to the non-permissive growth conditions in CNS is the 
oligodendrocytes themselves (Schwab and Caroni, 1988). Oligodendrocytes are 
responsible for myelination of axons in CNS, analogous to the myelination of PNS 
axons by Schwann cells. Upon CNS injury, debris that originated from the myelin 
structures ensheathing the neurons before lesion remains at the vicinity of the injury 
site (Fig 1.1). This means that the severed axons are exposed to the myelin debris 
present. Myelin produced by oligodendrocytes has been reported to have an inhibitory 
effect on neuronal regeneration.  
The first important hint that myelin could play a major role in the inhibition of 
neuronal regeneration was from the studies performed by Schwab and Thoenen 
4 
 
described above, where a CNS (optic nerve) explant but not one from PNS (sciatic 
nerve) inhibited axonal regeneration (Schwab and Thoenen, 1985). More evidence 
came from the report where newborn rat DRG neurons and NG-108-105 cells were 
plated onto human CNS myelin patches coated on 96-well plates. Myelin patches 
were found to strongly inhibit neurite outgrowth, with this inhibition requiring direct 
contact between myelin and the neurites (Ng et. al., 1996). Embryonic chick 
sympathetic neurons also showed poor neuronal outgrowth on white matter regions 
compared to the grey matter ones when cultured on freshly frozen adult rat brain or 
spinal cord sections (Crutcher, 1989), or on adult spinal cord sections subjected to 
injury by ex vivo crushing prior to freezing (Pettigrew et. al., 2001). The same 
conclusion was reached in animal studies, where an increase in regeneration of 
lesioned neurons was observed in myelin-free spinal cord (Savio and Schwab, 1990) 
or optic nerve (Weibel et. al., 1994), or for myelin-immunized mice that had 
circulating antibodies to myelin (Huang et. al., 1999).  
 Subsequently, several myelin-associated inhibitory molecules that are able to 
inhibit neuronal regeneration are identified. These include Nogo (Chen et. al., 2000; 
GrandPré et. al., 2000; Prinjha et. al., 2000), myelin-associated glycoprotein (MAG) 
(McKerracher et. al., 1994; Mukhopadhyay et. al., 1994) and oligodendrocyte myelin 
glycoprotein (OMgp) (Kottis et. al., 2002; Wang et. al., 2002b). Exposure of these 
myelin-associated inhibitors present in the myelin debris to severed axons at the 
injury site may explain the loss of, or limited, neuronal regeneration in these damaged 
axons, and hence a lack of function recovery after CNS injury.  
 
1.1.3 Nogo-A present in myelin acts as a neurite outgrowth inhibitor 




Fig 1.1 Inhibition of axonal regeneration upon CNS injury. (A) In mature CNS, 
myelin-associated inhibitors from oligodendrocytes and CSPGs from astrocytes act on 
the axons to limit plasticity and sprouting. (B) Upon injury, the distal end of the 
severed axon degenerates while the proximal end forms a dystrophic growth cone. 
Recruitment of reactive astrocytes, oligodendrocyte precursors, microglia and 
meningeal cells to the injury site forms a glial scar that acts as a barrier for axonal 
growth. In addition, myelin-associated inhibitors present in the myelin debris also act 
on the axons to prevent regeneration.  
 
when it is found to be the antigenic target of IN-1, a monoclonal antibody raised 
against rat myelin that could neutralize CNS myelin‟s inhibitory effect on neurite 
outgrowth. Caroni and Schwab (1988a) had extracted CNS myelin from rats and 
isolated crude fractions from this myelin extract which contained two membrane 
proteins of molecular sizes 250 and 35 kilodaltons (kDa) (NI-250 and NI-35), which 
accounted for most of CNS myelin‟s inhibitory effect on neurite outgrowth and 
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fibroblast spreading. The group proceeded to raise antibodies against these two 
membrane protein fractions, and found that the IN-1 monoclonal antibody raised 
against NI-250 (likely the longest isoform of Nogo, Nogo-A), as well as IN-2 
antibodies which was against NI-35 (suggested to be Nogo-B), were able to neutralize 
CNS myelin‟s inhibitory effect and allowed neurites to extend into optic nerve 
explants (Caroni and Schwab, 1988b). 
 Importantly, the IN-1 antibody, when applied to experimental spinal cord 
injury models, was able to enhance neuronal regeneration and functional recovery in 
the injured animals (Bregman et. al., 1995; Fouad et. al., 2001; Thallmair et. al., 
1998). Conversely, transgenic expression of Nogo-A in Schwann cells, which were 
devoid of Nogo-A, was able to override the growth-promoting and permissive PNS 
environment to result in prevention of regeneration (Pot et. al., 2002). This 
strengthened the notion that Nogo-A in CNS myelin plays an important role in the 
inhibition of neurite outgrowth.  
 
1.2 Molecular characterization of Nogo-A 
1.2.1 Nogo: part of the Reticulon family 
Identification and characterization of the gene encoding IN-1 antigen, Nogo-
A, was aided by the report from Spillmann et. al. (1998), where the group published 
sequence information of six peptides obtained from a bovine ortholog of NI-250, bNI-
220, purified from extracted bovine myelin. In 2000, three groups concurrently 
identified and cloned Nogo-A (Chen et. al., 2000; GrandPré et. al., 2000; Prinjha et. 
al., 2000) from cDNA libraries using this valuable information. 
  Nogo belongs to the Reticulon (RTN) family that has three previously known 
mammalian paralogs, RTN1-RTN3 (Oertle et. al., 2003b; Yang and Strittmatter, 
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2007). Nogo, the latest of the RTNs to be reported, is therefore termed RTN4. RTNs 
are variable in their N-terminal regions but share a highly conserved C-terminal 
domain. This reticulon homology domain (RHD; Pfam PF02453) is about 200 amino 
acids (aa) long and comprises of two putative transmembrane (TM) domains 
sandwiching a hydrophilic loop (about 60-70 aa) followed by a short C-terminal tail. 
The latter harbors an endoplasmic reticulum (ER) retention signal - a dilysine motif 
(KXKXX). RTNs are termed reticulons as a majority of the proteins (>95%) are 
localized at the ER (van de Velde et. al., 1994). 
RTN1, also called neuroendocrine-specific protein (NSP), was the first 
reticulon to be discovered and exhibited specific expression in neural tissues 
(Wieczorek and Hughes, 1991; Roebroek et. al., 1993; van de Velde et. al., 1994). 
RTN2 was isolated based on its homology to RTN1 (Roebroek et. al., 1998). RTN3 
was isolated during a subtractive cloning project to look for transcripts differentially 
expressed between macula and peripheral retina (Moreira et. al., 1999). Each of the 
RTNs has several splice isoforms, which are divergent in terms of exon usage at the 
N-terminus.  
 
1.2.2 The Nogo gene and its splice isoforms  
 Nogo has been mapped to human chromosome 2 (2p16.116.3 (Nagase et. 
al., 1998) and 2p14p13 by radiation hybrid mapping (Yang et. al., 2000)). The gene 
locus spans approximately 75 kb, contains at least two promoter regions,  14 exons 
and 8 introns, and gives rise to three major splice isoforms (Nogo-A, -B and -C) and 
several other minor splice isoforms (Oertle et. al., 2003a). Amongst these, an isoform 
was found to be expressed specifically in the testis (Zhou et. al., 2002).  
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Nogo-A and -B are generated by alternative splicing using the first Nogo gene 
promoter and both contain exon 1A, which covers the 5‟UTR and the N-terminal 184 
aa of Nogo-A and -B. This N-terminus contains an acidic domain and a proline-rich 
domain. Nogo-A, in addition, contains the 2.4 kb exon 3 that is uniquely present in 
this isoform only. The exon 3 has consensus sequences for PEST domains, SH3-
ligands and WW-ligands. Indeed, Nogo-A has been shown to be able to bind to a 
SH3-containing adaptor protein, Nck2 (Liu et. al., 2006), and a WW domain-
containing E3 ubiquitin ligase, WWP1 (Qin et. al., 2008). Nogo-C is produced by a 
differential promoter usage and contains exon 1C, which has the 5‟ UTR of Nogo-C 
and the N-terminal 11 aa residues specifically found in Nogo-C. All three isoforms 
contain exons 4-9 that encode the RHD domain common to them, with exons 4 and 5 
encoding a stretch of hydrophobic sequence constituting a putative TM domain 1 
(TM1) and a 66-aa hydrophilic loop (Nogo-66). This is followed by exons 6-7 
encoding a second putative TM domain (TM2) that contains a leucine zipper-like 
motif, and exons 8 and 9 encoding the C-terminus with the ER retention signal and 
the 3‟ UTR. An illustration of the domain structures of Nogo-A, -B and -C is shown 
in Fig 1.2A.  
 Nogo-A is the longest of the three major isoforms, with a coding region of 
3579 base pairs (bp)/ 1192 aa (estimated molecular size of 220 kDa). Nogo-B has a 
coding region of 1122 bp/ 373 aa (est. 50 kDa) while Nogo-C is the shortest, with 600 
bp/ 199 aa (est. 25 kDa).    
 
1.2.3  Subcellular localization, topology and structure of Nogo 
 As mentioned in section 1.2.1, the majority of Nogo proteins are localized at 
the ER (GrandPré et. al., 2000). The lack of a canonical signal peptide at the N-
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terminus for directing the proteins to ER suggested that internal ER targeting signals 
may be present. Their subsequent ER retention could be due to the presence of the 
dilysine motif situated at the C-terminus of Nogo proteins. However, it was suggested 
that TM2 was enough for ER localization since its deletion, but not that of the dilysine 
motif, disrupted Nogo‟s ER localization (Oertle et. al., 2003c). Besides the ER, Nogo 
proteins have also been shown to be present on the plasma membrane (Dodd et. al., 
2005; GrandPré et. al., 2000) and Golgi complex (Oertle et. al., 2003d). 
 Nogo-A could adopt at least two membrane topologies (Fig 1.2B). The first 
predicted topology has a horse-shoe like orientation, with both the N and C termini 
facing the cytoplasmic region and the Nogo-66 loop being extracellular/lumenal. This 
topology was supported by data showing that antibodies targeting both termini of 
Nogo-A were unable to detect Nogo-A by immunocytochemistry (ICC) on surface of 
unpermeabilized cells, while that against Nogo-66 were able to do so (GrandPré et. 
al., 2000). A second topological prediction has the N-terminus facing the 
extracellular/lumenal region, as a result of the putative TM1 flip-flopping in the 
membrane without transversing the lipid bilayer. The looping back of the putative TM 
domain is possible as this hydrophobic sequence is longer (approximately 35 aa) than 
a typical 20 aa TM domain. This topology was suggested when similar ICC 
experiments were performed with cultured oligodendrocytes (Oertle et. al., 2003d). It 
is proposed that the first topology is typically adopted by majority of Nogo-A, 
especially at the ER, while a fraction of Nogo-A at the cell surface may adopt the 
second one (Oertle et. al., 2003d). The second topology could explain how the N-
terminus of Nogo-A, which itself contains two growth inhibitory domains, works 
hand in hand with Nogo-66 to inhibit neurite outgrowth (Oertle et. al., 2003d). 
Additional evidence for the N-terminus of Nogo facing extracellularly came from the 
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study of the topology of Nogo-B on the surface of endothelial cells (Acevedo et. al., 
2004). Nogo-A has also been postulated to adopt other topologies (Voeltz et. al., 
2006). The exact membrane topology of which Nogo-A adopts on the various 
membranous compartments it traverses or resides in its lifetime remains debatable. 
 Studies on the structure of Nogo-A have been carried out in the hope of 
understanding its function, and more importantly, discovering important structural 
domains for the design of antagonists that might aid in neuronal regeneration. 
However, it seems that Nogo-A domains are generally unstructured in solution (Li 
and Song, 2007; Zander et. al., 2007), except for perhaps the fragments Nogo-40, -54 
and -60, which are truncated forms of Nogo-66 (Li et. al., 2004a; Li et. al., 2006; Li 
et. al., 2008). A recent report in which the group employed a membrane-like 
environment to show that Nogo-66 forms a unique structure only upon binding to a 
phosphocholine surface, has allowed structural insights for the design of antagonists 
that might disinhibit Nogo-A‟s inhibitory effect on neuronal regeneration (Vasudevan 
et. al., 2010).  
 
1.2.4 Tissue distribution of Nogo 
 The expression pattern of Nogo proteins, especially Nogo-A, in various tissues 
has been extensively studied by others and us (see chapters 3 and 4). Nogo-A is 
highly enriched, and has a widespread expression, in the CNS. It is also found to be 
expressed at lower levels in the cochlea, heart, testis, gastrointestinal tract and visual 
system (Caelers et. al., 2009; Huber et. al., 2002; Osborne et. al., 2004; Xiao et. al., 
2009). Analysis at RNA and protein levels have pinpointed the expression of Nogo-A 
largely to oligodendrocytes and neurons. Nogo-B is more ubiquitously expressed, 
with presence in CNS as well as other tissues such as the lung, spleen and kidney. 
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Nogo-C is mainly found in the skeletal muscle, with lower expression in the brain, 
heart and adipocytes (Huber et. al., 2002; Morris et. al., 1999). 
 
 
Fig 1.2 Domain structure and topology of Nogo. (A) A schematic diagram of the 
three major splice isoforms of Nogo (Nogo-A, -B and -C) and their domain structures, 
with their aa sizes indicated. Nogo-A and -B share the same 1-184 aa N-terminus 
domain, while Nogo-C has a different N-terminus domain (blue box) that is generated 
by differential promoter usage. acidic = acidic domain. proline-rich = proline-rich 
domain. L-L-L = leucine zipper-like motif. KXKXX = ER retention signal. (B) Three 
of the proposed topologies of Nogo-A. Topology (1) is proposed by GrandPré et. al. 
(2000), topology (2) is suggested by Oertle et. al. (2003d) while topology (3) is 




 The high expression of Nogo-A in oligodendrocytes is expected because of its 
known association with myelin and its inhibitory role on neurite outgrowth. Nogo-A 
was found to be expressed in the cell bodies and processes of oligodendrocytes, 
including the outer myelin sheath surrounding myelinated axons, and at the inner 
adaxonal sheath where myelin and axon came into contact with each other (Wang et. 
al., 2002). This role of Nogo-A at the axoglial junction has not been elucidated. 
However, it is possible that it could have similar function as that of OMgp, whose 
enrichment at the same location stabilized the node and prevented axonal sprouting 
(Huang et. al., 2005). Association of Nogo-A with tubulin and myelin basic protein 
(MBP) suggested another possible function of Nogo-A in oligodendrocytes, which is 
to aid in the maturation of the myelin sheath (Taketomi et. al., 2002).  
In addition, Nogo-A was also present in several types of neurons, such as 
motor neurons, sympathetic neurons, Purkinje cells, DRG neurons and cortical 
neurons (Liu et. al., 2002b; Hunt et. al., 2003). Expression of Nogo-A in neurons was 
found to precede that in oligodendrocytes during early stages of mouse development, 
and it was suggested to play a role in axonal guidance and architecture organization of 
neural networks (Meier et. al., 2003). Within the neuron, the protein was localized to 
multiple substructures, including growth cones (Tozaki et. al., 2002) and postsynaptic 
active zone (Liu et. al., 2003). The function of Nogo-A in neurons is still unclear at 
present, and results presented in this thesis shall attempt to address an aspect of this 
function. 
 Interestingly, Nogo-A has very recently been reported to be expressed on the 
surface of neural stem cells (NSCs) derived from cerebral cortex and spinal cord of 
newborn rats (Hou et. al., 2010). NSCs are self-renewing, multipotent and can 
differentiate into the different cell lineages in the nervous system. Nogo-66 was 
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shown to promote differentiation of these cells into astrocytes (Wang B et. al., 2008). 
Whether Nogo-A expression influences the type of cell lineage that NSCs may 
differentiate into, and whether this expression in NSCs is the reason for the failure of 
transplanted NSCs to improve CNS regeneration, require further exploration. 
 
1.3 Functions of Nogo-A 
1.3.1 Role of Nogo-A, after physical injury in adult CNS, as a myelin-associated 
inhibitor of neuronal regeneration 
1.3.1.1 Growth inhibitory domains of Nogo-A  
 Inhibitory activity of Nogo-A is exhibited by both its N terminal as well as the 
Nogo-66 domains. A more widespread, non-cell type specific inhibitory activity was 
associated with the N-terminal domain, while Nogo-66‟s inhibitory activity appeared 
fairly specific for neurons (Fournier et. al., 2001; GrandPré et. al., 2000). The fact 
that antibodies against the N-terminus were able to neutralize the inhibitory effect of 
CNS myelin in vitro (Chen et. al., 2000) and enhance adult rat Purkinje axonal 
sprouting in vivo (Buffo et. al., 2000) implies the important role of this region in 
Nogo-A‟s inhibitory function in neuronal regeneration.  
There are at least two regions in the N-terminus of Nogo-A that were found to 
exert growth inhibitory effects. Together with Nogo-66, these three domains acted to 
restrict growth by different mechanisms (Oertle et. al., 2003d). The first inhibitory 
region in the N-terminus, aa 59-172, is present in both Nogo-A and -B. It was shown 
to be able to inhibit spreading of 3T3 fibroblasts. The second domain in the N-
terminus, aa 544-725 (also known as Nogo20), is found in the Nogo-A specific 
region encoded by exon 3, and this could strongly inhibit neurite outgrowth, cell 
spreading and induce growth cone collapse in both neuronal and non-neuronal cells. 
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Importantly, the soluble dimeric form of this region, but not its monomeric form, 
caused growth cone collapse in DRG neurons. Nogo-66 was able to induce growth 
cone collapse and neurite outgrowth in DRG neurons as well as differentiated rat 
pheochromocytoma PC12 cells. Nogo-66 was also shown to be able to prevent 
adhesion and migration of human glioma cells (Liao et. al., 2004). GrandPré et. al. 
(2000) has further narrowed down the inhibitory region in Nogo-66 to aa 31-55. 
Interestingly, aa 1-40 of Nogo-66 (Nogo-40, or NEP1-40) was shown to be 
antagonistic to Nogo-66‟s binding to its receptor (GrandPré and Strittmatter, 2002) 
(see section below). It is possible that the Nogo-A specific inhibitory domain and 
Nogo-66 play different roles in vivo, with the former more involved in limiting 
outgrowth, regeneration and the latter functioning in axonal guidance. 
 
1.3.1.2 Nogo-A and its neuronal receptors  
 Oligodendroglial Nogo-A requires a neuronal receptor that it could interact 
with to cause inhibition of regeneration in the neurons. While the Nogo-66 domain 
has been clearly shown to be extracellular, the orientation of the N-terminus of Nogo-
A is still unclear. The former region would most likely convey an „inhibitory 
message‟ from oligodendrocytes to neurons via a receptor. Yet-to-be-discovered 
receptors that bind to the N-terminus of Nogo-A may also transduce the growth-
inhibitory signal of Nogo-A. Two neuronal receptors for Nogo-66 have been 
discovered to date. One is the Nogo-66 receptor, NgR (Fournier et. al., 2001), and the 







NgR is a brain-enriched glycosylphosphatidylinositol (GPI)-linked cell surface 
protein that is 473 aa long and contains eight leucine-rich-repeat (LRR) domains. It 
belongs to the superfamily of LRR domain-containing proteins, and has two other 
paralogues NgR2 (or NgRH1) and NgR3 (or NgRH2) (Barton et. al., 2003; Lauren et. 
al., 2003; Pignot et. al., 2003), which are also brain-enriched. NgR was first identified 
by a Nogo-66 affinity based screen (Fournier et. al., 2001). In situ hybridization and 
IHC showed widespread expression of NgR in the adult brain, with observed levels in 
neurons of the cerebral cortex, hippocampus, cerebellum, substantia nigra, amygdala 
and pons (Fournier et. al., 2001; Hunt et. al., 2002; Nyatia and Lang, 2007). NgR was 
exclusively detected in neurons (cell surface, cell bodies, growth cones and processes) 
but not in oligodendrocytes or astrocytes (Josephson et. al., 2002). Interestingly, 
mRNA of NgR was initially detected in the spinal cords of human and mouse fetus 
but its levels were downregulated in adulthood (Josephson et. al., 2002).  
 In addition to the Nogo-66 domain, a stretch of 24 aa on the N-terminus of 
Nogo-A specific to this isoform (aa 995-1018), which is situated just N-terminus to 
TM1, was shown to bind to NgR (Hu et. al., 2005). This region was able to bind to 
the receptor with high affinity, but could not inhibit neurite outgrowth or cell 
spreading. Covalent linkage of this domain with Nogo-66 enabled better binding 
affinity with NgR than Nogo-66 alone, and its fusion with a truncated form of Nogo-
66 (1-32), an antagonist of Nogo-66, resulted in agonistic neurite outgrowth inhibition 
in DRG neurons. These two Nogo-A inhibitory domains may therefore bind NgR in a 
co-operative manner. NgR interacts with Nogo-66 via its LRR domains (Fournier et. 
al., 2002; He et. al., 2003), with several residues between LRR3 and LRR5 having 
been identified to directly bind to Nogo-66 (Schimmele and Plückthun, 2005). 
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It is evident that Nogo-66 functions through NgR to elicit its inhibition on 
neurite outgrowth. Expression of NgR in embryonic day (E) 7 retinal ganglion cells, 
originally insensitive to Nogo-66‟s inhibitory effect, was able to cause Nogo-66-
induced growth cone collapse in these cells (Fournier et. al., 2001). The LRR domains 
in NgR is important in eliciting the inhibitory signal since a truncated form of NgR 
containing only the region C-terminus of the LRR domains was unable to induce 
growth cone collapse, suggesting an involvement of LRR domain-required 
conformational change, or receptor aggregation, in activating downstream signals.  
Interestingly, NgR also interacts with the other two known myelin-associated 
neurite outgrowth inhibitors, MAG (Liu et. al., 2002a; Domeniconi et. al., 2002) and 
OMgp (Wang et. al., 2002b), and these molecules effect their growth inhibitory 
signalling through NgR. Additionally, NgR binds gangliosides (Williams et. al., 
2008) and a neuronal membrane protein, Myelin-Associated Neurite-outgrowth 
Inhibitor (MANI) (Mishra et. al., 2010), to convey their neurite outgrowth inhibitory 
signals. Interaction of NgR with the secreted LRR protein leucine-rich glioma 
inactivated (LGI1), which antagonizes myelin-based growth inhibition, has also been 
reported (Thomas et. al., 2010). 
 
1.3.1.2.2 PirB 
 As NgR knockout did not show complete disinhibition of axonal regeneration 
after injury (which shall be discussed in detail in section 1.3.4), presence of 
alternative receptors for Nogo-A and the other myelin-associated inhibitors was 
hypothesized. Indeed, another molecule, PirB was later found to be a second receptor 
for Nogo-66. It could also bind MAG and OMgp, with binding affinities similar to 
that of NgR (Atwal et. al., 2008). PirB is a mouse ortholog for the human leukocyte 
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immunoglobulin (Ig)-like receptor B2 (LILRB2), with ~50% similarity between them. 
It is a typical type 1 transmembrane protein which localizes mainly on the plasma 
membrane, and contains six Ig-like repeats in its extracellular domain and four 
immunoreceptor tyrosine-based inhibitory motifs in the cytoplasmic region. The 
region that interacts with Nogo-66 lies in the ectodomain of PirB, as a soluble 
ectodomain of PirB was able to prevent Nogo-66‟s inhibition of neurite outgrowth in 
postnatal day (P) 7 cerebellar granule cells (Atwal et. al., 2008). However, it was also 
shown that only partial disinhibition of neurite outgrowth was achieved with neurons 
from PirBTM mice (containing a loss-of-function PirB allele). PirB may work in 
concert with NgR to mediate neurite outgrowth inhibition. 
PirB is expressed widely in the neurons in the brain, with significant levels 
observed in the cerebral cortex, cerebellum, hippocampus and olfactory bulb. It has 
been shown to have an inhibitory role in receptor signalling within B cells, mast cells 
and dendritic cells, via its binding to the protein tyrosine phosphatases (SHP-1 and -2) 
and the polyphosphate inositol 5-phosphatase (SHIP) via its cytoplasmic inhibitory 
domains (Bléry et. al., 1998), or upon phosphorylation and activation by the src 
family kinases Hck and Fgr (Zhang et. al., 2005). It could also negatively regulate 
integrin signalling, thereby reducing adhesion and spreading of neutrophils and 
macrophages (Pereira et. al., 2004), and limit plasticity in the visual cortex both 
during and after a critical developmental period (Syken et. al., 2006). It is 
hypothesized that these inhibitory signalling pathways may also be activated upon 





1.3.1.3 The growth-inhibitory signalling pathways elicited by Nogo-A to induce 
neuronal regeneration inhibition 
 The best known inhibitory signalling pathway associated with myelin 
inhibitors is the Nogo-66-NgR axis. Being a GPI-linked protein, NgR does not 
transverse the plasma membrane and therefore needs to recruit membrane spanning 
co-receptors in order to engage cytoplasmic signalling intermediates for its growth 
inhibition signalling. In fact, a co-receptor complex of two molecules may be 
necessary to interact with NgR for activation of growth inhibitory signalling 
pathways. The two proteins are p75, which binds directly with NgR (Wang et. al., 
2002a; Wong et. al., 2002), and the LRR and Ig domain-containing, Nogo Receptor-
interacting protein (LINGO-1) that binds to both NgR and p75 (Mi et. al., 2004). p75, 
the low affinity neurotrophin receptor, belongs to the tumour necrosis factor (TNF) 
receptor superfamily and has a restricted expression pattern in adult CNS, with only a 
few subpopulations of mature neurons expressing it. It could interact and activate 
RhoA to modulate axonal and dendritic growth (Yamashita et. al., 1999), and also 
play additional roles in apoptosis and myelination besides neurotrophin signalling and 
neurite outgrowth. LINGO-1 is a transmembrane protein containing twelve LRR 
motifs and an Ig domain, and is CNS-specific, with expression in neurons and 
oligodendrocytes but not astrocytes. Absence of either of the two co-receptors would 
prevent inhibition effected by NgR binding to the myelin-associated inhibitors from 
occurring.  
 An alternative co-receptor for NgR that belongs to the same family as p75 has 
also been discovered. This molecule, TAJ/TROY, shows wider expression than p75 in 
adult brain and is able to bind both NgR and LINGO-1 as well to form the ternary 
complex responsible for activating downstream signalling pathways to inhibit neurite 
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outgrowth (Park et. al., 2005; Shao et. al., 2005). The presence of a second co-
receptor for NgR possibly explains the inefficient CNS neuronal regeneration 
observed in p75 knockout mice (Song et. al., 2004). 
 The downstream mechanism upon binding of Nogo-A to NgR leading to 
neurite outgrowth inhibition appears to involve more than one signalling pathway (Fig 
1.3). Nogo-66‟s interaction with the tripartite receptor complex led to activation of 
RhoA and its substrate, Rho-associated protein kinase (ROCK), and a concomitant 
antagonistic inhibition of Rac1 (Madura et. al., 2004; Niederöst et. al., 2002). This 
could be due to the release of RhoA from its inhibitor, Rho GDP dissociation inhibitor 
(Rho-GDI), by the binding of p75 to Rho-GDI (Yamashita and Tohyama, 2003). 
RhoA activation was known to cause growth cone collapse and axon guidance 
repulsion (Luo, 2000). LIM kinase, a downstream effector of ROCK, and the 
phosphatase Slingshot have been shown to be regulated by Nogo-66 that led to an 
inactivation of cofilin and hence actin depolymerisation (Hsieh et. al., 2006). 
Reagents targeting RhoA and ROCK, such as C3 transferase (which causes ADP 
ribosylation of the effector domain on RhoA) and Y27632 (which inhibits ROCK), 
allowed enhanced regeneration of corticospinal tract (CST) axons and improved 
recovery of function (Dergham et. al., 2002; Fournier et. al., 2003).  
Nogo-A may also inhibit growth signalling by affecting/negatively regulating 
the cAMP pathway, which is induced by neurotrophins. cAMP could abrogate RhoA 
activation and Rac1 inactivation by Nogo-A, thereby disinhibiting neurite outgrowth 
inhibition (Bandtlow, 2003). Signalosomes (signalling-active endosomal structures) 
containing Nogo20 generated by pincher-dependent endocytosis were retrogradely 
transported from neurites to cell bodies. These were able to activate RhoA along the 
way and also inhibit cAMP-dependent activation of cAMP response element-binding 
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protein (CREB) (Joset et. al., 2010). It is likely that Nogo-A could act analogously to 
MAG, which inhibited cAMP accumulation by activating G protein-coupled receptors 
(GPCRs) via p75, and their Gi proteins (Cai et. al., 1999).  
  Another GPCR related signalling pathway involving that of Ca
2+
 and protein 
kinase C (PKC) may also be engaged by the Nogo-NgR interaction. Nogo-A was 
shown to trigger an intracellular elevation of Ca
2+
 and PKC activation (Hasegawa et. 
al., 2004). The balance between inositol 1,4,5-triphosphate (IP3)/Ca
2+
 and PKC seems 
crucial in determining the regulation of axon regeneration by the myelin-associated 
inhibitors.  
Several other possible mechanistic inhibitory pathways are also implicated in 
NgR-mediated downstream signalling. A particularly prominent one is the epidermal 
growth factor receptor (EGFR) pathway. EGFR inhibitors were able to block the 
neurite outgrowth inhibitory effects of myelin-associated inhibitors including Nogo-A 
to promote regeneration of injured optic nerve fibers (Koprivica et. al., 2005). A 
recent study has shown that LINGO-1 exhibited enhanced interaction with WNK1, a 
serine-threonine kinase, upon Nogo-66 treatment, and this interaction led to activation 
of RhoA supposedly via WNK1‟s interaction with Rho-GDI (Zhang et. al., 2009). 
Nogo-66 was also shown to interact with necdin to sequester it in the cytoplasm, 
thereby suppressing its role in enhancing neurite outgrowth (Liu et. al., 2009). 
Additionally, the N-terminus of Nogo-A has been reported to inhibit integrin 
signalling (Hu and Strittmatter, 2008) and may also inhibit Akt1 activation (Deng et. 
al., 2010), thereby inhibiting neurite outgrowth and cell adhesion.   
 Some mechanisms that further regulate Nogo-A‟s inhibitory signals have been 
reported. Cholesterol depletion could effectively inhibit Nogo-66 signalling, since it 




Fig 1.3 Neuronal regeneration inhibitory signalling pathways activated by Nogo-
A. Some of the reported pathways described in the text are illustrated in this 
schematic diagram. Nogo-66 binding to NgR-p75-LINGO-1 ternary receptor complex 
leads to activation of RhoA via the interaction of p75 with Rho-GDI and release of 
RhoA. Rac1 inactivation is also resulted (not shown here).  LINGO-1 is also able to 
mediate RhoA release by interacting with WNK1 which then binds to Rho-GDI. 
RhoA activates ROCK, which activates LIM kinase that phosphorylates cofilin, 
leading to actin depolymerisation and neurite outgrowth inhibition and growth cone 
collapse. PKC and IP3-Ca
2+
 are also activated by Nogo-66 but the upstream molecules 
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involved are unclear (dotted lines). PKC activation leads to inhibition. Apparently, 
intramembrane cleavage of p75 by secretases is PKC-dependent. Transactivation of 
EGFR by Ca
2+
 induced activation of Erk1/2 which also seemingly causes inhibition. 
The N-terminus of Nogo-A is able to inhibit integrin signalling, thereby preventing 
growth.  
 
2004). Also, the ectodomain of NgR, which was essentially the entire LRR domains, 
could be shed from the plasma membrane via cleavage by zinc metalloproteinases and 
could be detected in the human brain cortex and cerebrospinal fluid (CSF) (Walmsley 
et. al., 2004). Shedded NgR ectodomains could act in a dominant-negative manner, 
and this shedding may be regulated to allow axonal regeneration to occur. NgR could 
also be regulated by phosphorylation, and Nogo-66‟s binding to NgR was inhibited 
when it was phosphorylated by extracellular casein kinase II (Takei, 2009). Cleavage 
of p75 by α- and γ-secretase in a PKC-dependent manner upon ligand-binding was 
found to be necessary for RhoA activation and neurite outgrowth inhibition 
(Domeniconi et. al., 2005). A different form of cleavage of p75 and NgR, this time by 
TNFα converting enzyme (TACE), has however the opposite effect (Ahmed et. al., 
2006).  
 
1.3.1.4 Therapeutic interventions targeting the Nogo-A-NgR signalling axis 
 Although the Nogo-A-NgR signalling pathway is proposed to be a major 
cause for neurite growth inhibition in the adult CNS, knockout studies of Nogo-A and 
NgR have not been very supportive of this notion. Deletion of Nogo or NgR achieved 
at most a moderate enhancement of neuronal regeneration in some cases, but no 
improvement at all in other cases upon spinal cord injury. Nogo knockout animal 
strains with different modes of targeted gene disruption of Nogo isoforms have been 





 mice, Simonen et. al. (2003) saw only moderate CST neuronal regeneration in 
Nogo-A
-/-
 mice while a third group did not obtain any improvement in all their three 
lines of knockout mice (Lee et. al., 2009; Zheng et. al.; 2003). The second group of 
investigators, by backcrossing their Nogo-A deficient mice to two different parent 
genetic backgrounds, achieved better regeneration in the backcrossed 129X1/SvJ 
Nogo-A mice compared to their original C57BL/6 ones (Dimou et. al., 2006), 
suggesting genetic background differences to be a reason for the varied regeneration 
capabilities shown by the different knockout mice. NgR knockout studies did not 
yield much enhancement of CST regeneration either (Kim et. al., 2004; Zheng et. al., 
2005), although Kim et. al. (2004) did report observing some regeneration in 
raphespinal and rubrospinal axons.  




 mice were shown 
to exhibit enhanced axonal growth (Su et. al., 2008; Su et. al., 2009). An interesting 
and counterintuitive result was obtained in traumatic brain injury, where Nogo-A/B
-/-
 
mice showed impaired recovery from neurological and cognitive deficits as compared 
to the wild type (Marklund et. al., 2009), suggesting that Nogo-A may play a 
protective role in these type of injuries.   
 As there may be redundancy and synergism in the inhibitory functions of 
Nogo-A, MAG and OMgp that could possibly explain the negative results from Nogo 
knockout studies, two groups have recently attempted to delete all three of these, and 
have obtained contrasting results after spinal cord injury. One group of investigators 
showed enhanced axonal growth and locomotive function in the triple mutant mice 
compared to Nogo-A mutant (Cafferty et. al., 2010), while the other group did not 
observe improvement in axonal growth even after deleting all three inhibitors (Lee et. 
al., 2010).   
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 Despite the surprising observations from the knockout studies targeting 
deletion of the Nogo-A-NgR axis which may not significantly improve axonal 
regeneration and recovery of function in spinal cord injuries, various reagents against 
Nogo-A, NgR and other components in their implicated signalling pathways have thus 
far achieved very positive results in vitro. Most importantly, these also enhance 
regeneration and function in CNS injuries in vivo. These reagents include antibodies 
against Nogo-A (IN-1 (Emerick and Kartje, 2004; Liebscher et. al., 2005; Seymour et. 
al., 2005), 11C7 and 7B12 (Müllner et. al., 2008; Wiessner et. al., 2003)), NgR 
(7E11) (Li et. al., 2004c) and LINGO-1 (Lv et. al., 2010); the NgR antagonist, NEP1-
40 (Gou et. al., 2010; GrandPré et. al., 2002; Li and Strittmatter, 2003); soluble 
proteins containing the ectodomains of NgR (Fournier et. al., 2002; Lee et. al., 2004; 
Li et. al., 2004b; Peng et. al., 2010) and LINGO-1 (Ji et. al., 2006); protein vaccines 
of Nogo-A/MAG (Sicotte et. al., 2003) and NgR (Yu et. al., 2008); RNA aptamers 
binding to NgR (Wang et. al., 2010); and reagents against RhoA and ROCK 
(Dergham et. al., 2002; Fournier et. al., 2003). Combinatory  treatments, such as 
NEP1-40 with the anti-inflammatory drug methylprednisolone achieved better 
survival of neurons and oligodendrocytes, and locomotion function in spinal cord 
injury (Wu et. al., 2010), and may be more effective in dealing with CNS injuries. 
More clinically relevant studies have been extended to adult primates. Monkeys 
treated with IN-1 antibodies upon spinal cord injury exhibited enhanced axonal fiber 
sprouting and functional recovery (Fouad et. al., 2004; Freund et. al., 2006).  
 In fact, a humanized anti-Nogo-A antibody (AI355) has been tested in phase I 
clinical trial that started in 2006. Excitingly, no side effects were observed in the 
subjects tested and phase II trials would commence this year (2010) to check for the 
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efficiency of the antibody treatment in patients after spinal cord injury (Zörner and 
Schwab, 2010). 
 
1.3.2 Role of Nogo-A in pathological conditions of CNS 
Nogo-A and NgR have both been connected to neurological disorders. 
Findings in this regard are highlighted in this section. 
 
1.3.2.1 Alzheimer’s disease (AD) 
 Alzheimer‟s disease (AD) is the most common neurodegenerative disease 
affecting subjects above 65 years old, and it is characterized by the presence of senile 
plagues and neurofibrillary tangles in brain. The aggregation of hydrophobic β-
amyloid peptides (Aβ) leads to the formation of extracellular plagues, which is a 
pathological hallmark of AD. Aβ is formed after the sequential cleavage of amyloid 
precursor protein (APP), first by the type 1 membrane-bound aspartyl protease β-site 
APP cleaving enzyme 1 (BACE1), followed by the γ-secretase complex (Cole and 
Vassar, 2007). Soluble Aβ oligomers are now known to initiate AD, impairing 
cognitive function through synaptic mechanisms.  
The first evidence implicating a possible role for Nogo in AD was from the 
report by He et. al. (2004), where Nogo-B, along with RTN3, was shown to interact 
with BACE1 and inhibit its enzymatic activity, thereby reducing Aβ1-40 generation. 
Another study has obtained the same conclusion, and in addition, showed binding of 
Nogo-C with BACE1 (Murayama et. al., 2006). As Nogo-A and BACE1 are both 
brain-enriched, the above evidence suggests that Nogo-A could also possibly interact 
with BACE1. It was further found that BACE1 bound preferably to monomeric RTN3 
and the interaction required the C terminus of BACE1 and a highly conserved triplet 
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aa QID motif on the reticulons (He et. al., 2006). The tertiary structure formed by the 
two TM domains of reticulons seemed important for their binding with BACE1 as 
well (Kume et. al., 2009).  
 Nogo-A‟s receptor, NgR, has also been shown to interact with APP (via the 
central 15-28 aa of Aβ), and prevent its binding with BACE1 and therefore reducing 
Aβ secretion (Park et. al., 2006a). Importantly, subcutaneous administration with the 
soluble ectodomain of NgR reduced  amyloid plague deposition in APPswe/PSEN-
1(9) double-transgenic mice (an AD mouse model) while increasing serum Aβ 
levels and improved spatial memory in the mice (Park et. al., 2006b). 
 Nogo-A has been found to be overexpressed in hippocampal neurons in post-
mortem human AD brains and was associated with the Aβ deposits in senile plagues 
(Gil et. al., 2006). Interestingly, Nogo-A may possibly play a role opposite to that of 
RTN3 and NgR, as suggested by the evidence that Nogo-A‟s inhibition on neurite 
sprouting aided the progression of AD (Masliah et. al., 2010). 
 
1.3.2.2 Amyotrophic lateral sclerosis (ALS) 
 Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease 
characterized by motor neuron loss and muscle wasting. Finding a biomarker for the 
disease would allow early diagnosis and also development of effective treatments. 
Nogo isoforms have been implicated as potential biomarkers for ALS, since the 
expression level of Nogo-A was found to be increased in muscle biopsies of ALS 
patients, with a concomitant decrease in Nogo-C, the muscle-enriched Nogo isoform. 
Importantly, Nogo-A levels varied according to the severity of the disease (Dupuis et. 
al., 2002). Nogo-A expression could be used to predict the progression of lower motor 
neuron syndrome to full ALS with an accuracy of 91% (Pradat et. al., 2007). Invasive 
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procedures may be needed to obtain CSF for analysis of Nogo-A‟s levels since serum 
Nogo-A level was found not to be increased in ALS patients (Harel et. al., 2009). One 
contrasting report, however, showed that Nogo-A may not be an accurate biomarker 
for ALS, as an increase in Nogo-A expression level was observed in several muscle 
diseases with diverse etiology (Wojcik et. al., 2006). 
 It has been suggested that Nogo-A aids in disease progression in ALS, since 
deleting Nogo-A in a mouse model of ALS (SOD1(G93A)) improved survival and 
reduced muscle denervation, while overexpression of the protein resulted in shrinkage 
of the postsynapse and retraction of the presynaptic motor ending (Jokic et. al., 2006). 
Nogo-A may act to induce repulsion and destabilization of motor nerve terminals, 
leading to the eventual degeneration of the motor neurons. However, Nogo-A has also 
been implicated in the survival of motor neurons when Nogo-A and NgR levels were 
found to increase transiently only in these neurons from an ALS model (Miyazaki et. 
al., 2009). A mechanism underlying Nogo-A activity in ALS was recently proposed. 
Nogo-A expression redistributed the ER chaperone protein disulphide isomerase 
(PDI) from the ER to a yet-to-be-identified punctuated membrane compartment (Yang 
et. al., 2009). The investigators also showed a strong correlation between Nogo-A 
expression and survival against ALS, as deleting a single copy of Nogo-A/B gene in 
SOD1(G93A) mice sped up disease onset and progression while deleting both copies 
further worsened the disease. Understanding the exact role of Nogo-A in ALS would 







1.3.2.3 Multiple sclerosis (MS) 
 Multiple sclerosis (MS) is a neuroinflammatory disease partly caused by an 
auto-immune response to CNS myelin, leading to demyelination and other symptoms. 
Nogo-A was first implicated in MS when serum IgM antibodies against its N-terminal 
inhibitory domain were detected in MS and also other acute inflammatory and non-
inflammatory neurological diseases (Reindl et. al., 2003). Inconsistent results have 
however indicated that CSF Nogo-A may not be useful as a biomarker for MS 
(Lindsey et. al., 2008; Jurewicz et. al., 2007).  
Despite this, Nogo-A may still play an important causative role in MS. Its 
expression was upregulated in surviving oligodendrocytes at chronic demyelinating 
lesions, where it was suggested to interact with NgR on reactive astrocytes and 
microglia (Satoh et. al., 2005). Immunization with a peptide from the N-terminus of 
Nogo-A (aa 623-640) induced a strong T cell response that promoted recovery in rats 
with spinal cord injury (Hauben et. al., 2001), and also attenuated demyelination, 
axonal damage and other clinical signs associated with experimental autoimmune 
encephalomyelitis (EAE), a  rodent model of MS (Karnezis et. al., 2004). DNA 
vaccination (using plasmid driven Nogo-A expression) in a bid to generate antibodies 
against Nogo-A also did not exacerbate EAE (Bourquin et. al., 2008). Immunization 
with peptides from the Nogo-66 domain in EAE-susceptible mice suggested that a 
specific antibody response generated could spread to other encephalitogenic myelin 
antigens, and that some Nogo-66 epitopes could ameliorate established EAE while 
others may be encephalitogenic (Fontoura et. al., 2004). Importantly, improved 
functional recovery as a result of axonal growth and /or sprouting was observed upon 
silencing of Nogo-A via siRNA (Yang et. al., 2010). This indicates that targeting 




 Epilepsy is a chronic neurological disorder characterized by recurrent 
unprovoked seizures. Nogo-A was found to be upregulated in the hippocampus of 
mouse at the same time with the re-expression of the regeneration associated GAP-43 
protein after kainite-induced seizures (Meier et. al., 2003), and in hippocampus of 
human patients suffering from temporal lode epilepsy (Bandtlow et. al., 2004).  
The role of Nogo-A in epilepsy is unclear as yet. In a recent paper, where the 
authors showed increased expression of Nogo-A in the ipsilateral but not the 
contralateral hippocampus of amygdale kindling rats, suggested that seizures did not 
by themselves induce Nogo-A, and that Nogo-A may partially control aberrant 
synaptic reorganization during epilepsy (Takeda et. al., 2007). 
 
1.3.2.5 Schizophrenia 
 Correlation between Nogo and schizophrenia was first established by the work 
of Tallerico and colleagues (Novak et. al., 2002), where they reported an elevation of 
Nogo mRNA in schizophrenia samples. A more recent paper by the investigators 
suggested that the different Nogo isoforms may have different consequences. Nogo-C 
upregulation may have a role in schizophrenia, decreased Nogo-B contributing to the 
clinical condition of depression, while Nogo-A did not seem to play a significant role 
in schizophrenia or depression (Novak and Tallerico, 2006). The CAA insert 
polymorphism at the 3‟-untranslated region of Nogo was initially thought to be 
correlated to the disease (Novak et. al., 2002), but others have reported otherwise 
(Chen et. al., 2004; Covault et. al., 2004; Gregório et. al., 2005; Xiong et. al., 2005). 
Implications of NgR in schizophrenia were made after genetic variants of NgR were 
discovered which may influence the patients‟ response to drug treatment (Sinibaldi et. 
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al., 2004) and failure to induce myelin-associated axonal inhibition (Budel et. al., 
2008). This suggests that the NgR signalling pathway plays a part in schizophrenia. In 
addition, Nogo-A knockout mice exhibited schizophrenia-related endophenotypes but 
neutralizing Nogo-A with antibodies in adult wild type mice did not generate the 
same schizophrenia-related phenotype, hinting that Nogo-A was functioning in 
neurodevelopment that may result in schizophrenia (Willi et. al., 2010). 
 
1.3.3 Nogo-A and its cell autonomous functions  
1.3.3.1 Apoptosis 
 Nogo-B was initially regarded as a tumour suppressor, when its mRNA level 
was found to be reduced in small cell lung carcinomas (Qin et. al., 2001). Its ectopic 
expression led to apoptosis especially in cancer cells. However, the classification of 
Nogo-B as a tumour suppressor for all cancers were disputed after high levels of 
endogenous Nogo-B was found in several other cancer cell-lines (Oertle et. al., 2003). 
Nogo-B was thought to interact with B-cell lymphoma protein-2 (Bcl-2) and Bcl-xL, 
thereby localizing them to the ER and reducing their anti-apoptotic activities (Tagami 
et. al., 2000). Its interaction with downregulated by v-src (Drs), a tumour suppressor, 
increased apoptosis more than Drs alone (Tambe et. al., 2004).  
 Three other reticulons have also been shown to have pro-apoptotic activities. 
Nogo-C was observed to be downregulated in human hepatocellular carcinoma 
samples and overexpression in a cell-line of the same cancer type promoted apoptosis, 
presumably by translocating p53 to the cytoplasm and decreasing expression of c-Fos 
and heat shock protein 70 (Hsp70) (Chen et. al., 2005). Its overexpression in human 
embryonic kidney (HEK) 293 cells also induced cell death by activating caspase-3 
and p53 through the Janus N-terminal kinase (JNK)-c-Jun-dependent pathway (Chen 
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et. al., 2006). RTN3 was able to deplete ER Ca
2+
 stores, thereby inducing ER stress 
and mitochondrial dysfunction and eventually cell death (Kuang et. al., 2005). RTN3 
may induce cell death by recruiting the death adaptor protein, Fas-associated death 
domain protein (FADD), to the ER, thereby activating the caspase-8 cascade (Xiang 
et. al., 2006). Alternatively, RTN3 may induce death by upregulating death receptor 5 
(DR5) and downregulating of cellular FLICE-like inhibitory protein (c-FLIP) to 
enhance TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis (Lee et. 
al., 2009). Interaction of RTN3 with a cell adhesion protein, cysteine rich with EGF 
like domains 1(CRELD1), was shown to localize RTN3 to the cell surface and its 
apoptotic effect was therefore reduced (Xiang and Zhao, 2009). RTN-1C was able to 
sensitize cells to ER stress inducers while protecting them against genotoxic drugs (Di 
Sano et. al., 2007). The former effect was due to acetylation modification on RTN-1C 
which was proposed to affect its binding to DNA (Fazi et. al., 2009). 
 There are hints that reticulons could have anti-apoptotic effects as well. Nogo-
B was able to reduce sensitivity of cells to tunicamycin treatment, where cells stably 
expressing Nogo-B showed lower cell death as compared to wild type or cells stably 
expressing RTN3 (Oertle et. al., 2003). Activation of ER stress as a result of Nogo-
B‟s stable expression was suggested to be involved in its protective response (Kuang 
et. al., 2006).  
  
1.3.3.2 Organization of endoplasmic reticulum (ER) and formation of nuclear 
envelope (NE)  
 Nogo-A, its isoforms and fellow reticulons are largely localized to the ER and 
a function on this organelle has long been suspected. Indeed, Nogo-A was discovered 
to play an important role in shaping the tubular ER (Voeltz et. al., 2006). The 
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elaborate ER membrane consists of the nuclear envelope (NE) and the peripheral ER. 
The NE has two continuous membranes, the outer and the inner nuclear membrane, 
which are connected by nuclear pores. The peripheral ER, on the other hand, is made 
up of high curvature tubules and flat sheets. Nogo-A was found to localize exclusively 
in the tubular ER. The group used an in vitro system of Xenopus membranes to 
demonstrate ER reticular network formation regulated by Nogo-A. They showed that 
blocking of Nogo-A by its antibodies abolished this network formation while 
overexpressing Nogo-A resulted in longer tubules in COS cells. Interaction of Nogo-
A with itself, its isoforms or other fellow reticulons and another tubular ER-localized 
protein, deleted in polyposis (DP1), was essential for the maintenance of the high 
membrane curvature tubular ER, with the proteins probably adopting an “” 
orientation where the first TM domain and likely the second one forming hairpin 
structures in the membrane. Voeltz and colleagues went further to show that 
oligomerization resulted in lower immobility of the proteins, and was essential in their 
localization in the tubular ER and their ability to form tubules (Shibata et. al., 2008). 
A recent paper which characterized five plant reticulons also suggested ER membrane 
shaping properties for these (Sparkes et. al., 2010).  
The importance of maintaining the tubular ER was evident in the observation 
that positioning of the mitotic division plane was defective in cells that lacked this ER 
network (Zhang et. al., 2010). This implies that the tubule ER aids in limiting the 
region for actomyosin ring assembly at exactly the cell equator. 
 The ability of Nogo-A to stabilize the tubular ER also has implications on NE 
formation. The same antibodies used in Voeltz et. al. (2006) could inhibit growth of 
the nucleus and prevent NE assembly (Kiseleva et. al., 2007). Another study 
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suggested that Nogo-A may be involved in the assembly of nuclear pore complex and 
de novo nuclear pore formation (Dawson et. al., 2009). 
 
1.4 Rationale of my current work 
 Nogo-A has been identified about a decade ago as an inhibitor of neuronal 
regeneration associating with oligodendrocytes and myelin. Most investigation has 
been on the non-cell autonomous inhibitory function of Nogo-A, as indicated by the 
vast literature on this topic. However, Nogo-A‟s function in the cell, especially in 
neurons, has remained relatively unexplored. Hence, my thesis aims to elucidate some 
of the cell autonomous functions of Ngo-A. 
 In order to perform investigations on the molecule, the first thing that we did 
was to generate Nogo-A specific antibodies. The antibodies that we have generated 
were proven to be specific for Nogo-A and essential in all of the subsequent 
experiments that we performed. Nogo-A was detected in cells and various parts of the 
CNS by these antibodies with high specificity. Interestingly, Nogo-A was found to be 
expressed in both oligodendrocytes and neurons. Additionally, Nogo-A was found to 
be specifically concentrated at the paranodal region at the Node of Ranvier. These 
results on Nogo-A expression and localization are presented in chapter 3. 
 We asked if paranodal Nogo-A from the oligodendrocyte membranes could 
interact with the paranodal protein Caspr. We also checked if Nogo-A played a role in 
the formation of the architectural organization at the Node of Ranvier. Nogo-A‟s 
binding to another neuronal reticulon, RTN3, was also investigated, with the 
interacting domains between the two proteins delineated. These studies are described 
in chapter 4. 
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 We and others have previously observed that Nogo-A expression was 
upregulated in CNS neurons upon injury. We hypothesized that this upregulation may 
be part of the cell‟s response to injury. The role of Nogo isoforms and RTN3 in 
protecting neural cells against various cell death-inducing treatments is therefore 
investigated. Interestingly, Nogo-A and -B could efficiently protect these cells against 
diverse forms of apoptotic insults, including oxidative stress by hydrogen peroxide 
(H2O2). The possible mechanisms behind this protection were explored, and we have 
in this connection examined possible pro-survival signalling, mitochondrial-
associated proteins, ER stress response, and other pathways. These investigations are 
detailed in chapters 5 and 6. 
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Chapter 2 Materials and Methods 
 
2.1 General reagents 
All fine chemicals were from Sigma-Aldrich (Saint Louis, Missouri, USA) or 
BDH Chemicals Ltd (Poole, Dorset, UK) unless otherwise stated. Primers (listed in 
Appendix 1) were synthesized by 1
st
 Base Pte Ltd (Singapore). All enzymes 
(restriction enzymes, polymerase, phosphatase and ligase) used for cloning were 
obtained from Promega (Madison, Wisconsin, USA) or New England BioLabs 
(Ipswich, Massachusetts, USA). The apparatus and reagents employed in sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and western 
transfer were mostly obtained from Bio-Rad Laboratories (Hercules, California, 
USA). Antibodies were bought from Santa Cruz Biotechnology Inc. (Santa Cruz, 
California, USA) unless stated otherwise. 
 
2.2 DNA manipulation 
2.2.1 Design of constructs 
2.2.1.1 Nogo-A constructs 
 Full-length human Nogo-A coding sequence (CDS) was obtained from the 
KIAA0886 complementary DNA (cDNA) clone (Kazusa original clone product ID: 
ORK00673) (Kazusa DNA Research Institute, Chiba, Japan). The clone contained a 
4053 bp cDNA inserted into pBluescript II SK (+) vector (pBSK) at the Sal1 and 
Not1 restriction enzyme (RE) sites via a Sal1 adaptor (5' TCGACCCACGCGTCCG 
3') at the 5‟ end. 
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To clone Nogo-A into pCIneo vector (Promega) for protein expression in 
mammalian cells, the cDNA insert was retrieved from the KIAA0886 clone using 
Xho1 and Not1, and directly inserted into the pCIneo vector at the Xho1-Not1 site.  
 Myc-Nogo-A was obtained by cloning only the CDS of Nogo-A (3579 bp) 
into pDmyc vector. pDmyc was generated by a modification of pCIneo, with an 
insertion of two tandem myc epitope coding sequences at the Nhe1-Xho1 site. The 
cloning resulted in Nogo-A fusing at its 5‟ terminus with two myc tags 
(EQKLISEEDL), which is a polypeptide protein tag derived from the c-myc gene 
product. As amplification of the long Nogo-A CDS would increase chances of point 
mutations during polymerase chain reaction (PCR), a shorter fragment (bp 4-347) of 
the N-terminus designed to be fused in-frame with the myc tag was first generated 
instead. The primer set used was A-P1/A-P2. This fragment was cloned into the 
KIAA0886 construct at the Xho1-Sal1 site, replacing the original sequence present at 
that site. Xho1 site was present at the 5‟ end of the Nogo-A CDS while Sal1 was an 
internal site available at bp 342 of Nogo-A. The now myc-tagged full-length Nogo-A 
was then retrieved from this construct by Xho1 and Not1 and inserted into pDmyc.  
Several myc-Nogo-A truncation constructs were also generated to investigate 
the interaction between Nogo-A and RTN3 (section 4.2). These constructs are: (1) 
myc-Nogo-A (-cyto), (2) myc-Nogo-A (-TM1), (3) myc-Nogo-A (-TM2), and (4) 
myc-Nogo-A (-TMS). Full-length myc-Nogo-A was used as a PCR template in the 
generation of these truncation constructs. Besides being a template for PCR, myc-
Nogo-A was cut with Sac1 (at bp 2504 of Nogo-A CDS) and Not1 (behind the stop 
codon) to be linearized and acted as the vector backbone for subsequent insertion of 
the truncation sequences. This cut vector (termed 5‟ Nogo-A (pDmyc)) contained 
only bp 1-2504 of Nogo-A. The strategy was to minimize point mutations generated 
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during PCR of long sequences, as explained earlier. For myc-Nogo-A (-cyto), a DNA 
fragment of bp 2505-3489 that excluded the cytoplasmic tail after the putative TM2 
was amplified by PCR using A-P3/A-P4 and cloned into 5‟ Nogo-A (pDmyc) at the 
Sac1-Not1 site. Myc-Nogo-A (-TM1) did not contain the putative TM1 and the 3‟ 
KAE motif, and was produced by cloning two DNA fragments sequentially into 5‟ 
Nogo-A (pDmyc). The first fragment (amplified using A-P3/A-P5) was from bp 
2505-3051, and was inserted into the vector at the Sac1-Xba1 site while the second 
one (amplified using A-P6/A-P7) was from bp 3163-3567 and was inserted at the 
Xba1-Not1 site. As for myc-Nogo-A (-TM2), the putative TM2 and cytoplasmic tail 
of Nogo-A were absent in the construct and only consisted of bp 1-3360, with the 
DNA fragment of bp 2505-3360 inserted into 5‟ Nogo-A (pDmyc) at the Sac1-Not1 
site after amplification with A-P3/A-P8. Myc-Nogo-A (-TMS) contained only the N-
terminus region of Nogo-A, with the whole RHD being truncated, and the amplified 
N-terminus fragment was inserted at the Sac1-Xba1 site. The primer set A-P3/A-P9 
was employed for this construct. 
 Ng1V2 (pGEX4T1) was constructed to generate a glutathione S-transferase 
(GST) fused Nogo-A specific peptide to be used in the production of specific 
antibodies for Nogo-A. The Ng1V2 region, bp 667-1196 (aa 223-399), was selected 
to be the epitope for antibody generation since it was specifically found in Nogo-A 
only, and not Nogo-B or -C. An amplified product of this region was obtained by 
PCR using A-P10/A-P11 and cloned into pGEX4T1 vector (GE Healthcare, 
Buckinghamshire, UK), which contained a GST sequence 5‟ of its multiple cloning 
site, via the EcoR1-Xho1 site.   
 To delineate the region of Nogo-A that interacted with Caspr, the whole 
Nogo-66 domain and two other shorter forms of it, Nogo-35 and -40, were fused to 
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GST and used for GST pull-down assays (section 4.1.3). Nogo-35 (bp 3133-3167), 
Nogo-40 (bp 3133-3182) and Nogo-66 (bp 3133-3360) were amplified by primer sets 
A-P12/A-P13, A-P12/A-P14 and A-P12/A-P15 respectively, and cloned into 
pGEX4T1 at the EcoR1-Xho1 site.  
 
2.2.1.2 Nogo-B constructs 
 The first construct of Nogo-B generated was myc-Nogo-B. As Nogo-B 
contained the same bp 1-555 as that of Nogo-A, myc-Nogo-A was used as a PCR 
template. Two human Nogo-B fragments (bp 1-555 and bp 556-1122) were obtained 
by PCR using primer sets B-P1/B-P2 and B-P3/B-P4 respectively, and pieced together 
by sticky end ligation at one end with pDmyc, and blunt end ligation at the alternative 
splicing site at the center. The first fragment was cloned into the vector at the EcoR1 
site at its 5‟ end, while the 3‟ end of the second fragment was cloned into Not1 site on 
the vector.  
 HA tagged Nogo-B used in the generation of SH-SY5Y HA-Nogo-B stable 
cell-lines was constructed by simply retrieving the Nogo-B insert out from pDmyc 
and ligating it into pDHA vector (also modified from pCIneo, containing two 
hemagglutinin (HA) epitopes (YPYDVPDYAS) instead of myc tags in pDmyc) at the 
EcoR1-Not1 site.  
 Untagged Nogo-B was constructed by performing PCR with B-P4/B-P5 to 
generate a Nogo-B open reading frame that contained a start codon at the N-terminus, 
followed by cloning into pCIneo at the EcoR1-Not1 site.  
 For checking of the role of the N-terminus of Nogo-B in protection against 
cell death, two additional Nogo-B truncation constructs, Nogo-B (1-200) and Nogo-B 
(N-TM1), were created. For both, the amplified DNA fragment was directly ligated 
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into pCIneo at the EcoR1-Not1 site. Nogo-B (1-200) fragment (600 bp) was amplified 
by B-P5/B-P6 while Nogo-B (N-TM1) (717 bp) was by B-P5/B-P7. 
 
2.2.1.3 Nogo-C constructs 
 Full-length human Nogo-C was obtained by PCR using Nogo-A (pCIneo) as a 
template. The primer set employed here was B-P5/C-P1. The PCR product was 
inserted into pCIneo at the EcoR1-Not1 site. This untagged Nogo-C construct was 
used to generate SH-SY5Y Nogo-C stable cell-lines. N-terminus myc tagged Nogo-C 
was also generated by inserting Nogo-C into pDmyc vector. This construct was useful 
as a control while checking for antibodies that could detect Nogo-C. This construct 
was made by ligating in-frame Nogo-C PCR product (amplified by B-P5/C-P2) into 
the vector at the EcoR1-Not1 site. 
 
2.2.1.4 Reticulon 1 and 2 constructs (RTN1 and 2) 
 Expressed sequence tags (ESTs) of mouse RTN 1 (GenBank accession no: 
BU152315; IMAGE clone ID: 6334636) and 2 (GenBank accession no: BG296036; 
IMAGE clone ID: 4507150) were obtained from Invitrogen (Carlsbad, California, 
USA) and found to contain full-length CDS by DNA sequencing. Both RTNs were 
fused with myc tags at the N-terminus to facilitate detection of expressed proteins by 
anti-myc antibodies. PCR was performed using the ESTs as templates. The primer 
sets used for RTN1 and 2 were 1-P1/1-P2 and 2-P1/2-P2 respectively. The amplified 
DNA fragments obtained were cloned into pDmyc vector at the Xho1-Sal1 site to 





2.2.1.5 Reticulon 3 constructs (RTN3) 
Mouse RTN3 EST clone (GenBank accession no: BM461074; IMAGE clone 
ID: 5503813) was obtained from Invitrogen. Unlike RTN1 and 2 ESTs, sequencing 
results of RTN3 EST clone showed that it lacked the first twelve bases (which 
encoded the first four aa). In the construction of HA- and myc- RTN3, these bases 
were added in by PCR. RTN3 was tagged with HA and myc via cloning into pDHA 
and pDmyc respectively at the EcoR1-Sal1 site. The primer set for generating full-
length RTN3 in-frame with the tags in these vectors was 3-P1/3-P2.  
 An untagged RTN3 construct was also generated which was used to generate 
SH-SY5Y RTN3 stable cell-lines. A direct transfer of the full-length RTN3 CDS from 
the myc-RTN3 construct to pCIneo vector was carried out via digestion and ligation 
using EcoR1 and Sal1 RE. This was possible since the RTN3 gene in the former 
construct already contained a Kozak sequence and a start codon.  
 To investigate which domains of RTN3 were important for its interaction with 
Nogo-A, four HA tagged RTN3 truncation constructs were generated: (1) HA-RTN3 
(-N), (2) HA-RTN3 (-TM1), (3) HA-RTN3 (-TM2), and (4) HA-RTN3 (-TMS). For 
(1), the N-terminus of RTN3 was removed from the full-length gene by performing 
PCR with 3-P2/3-P3 and the amplified DNA fragment (bp 172-714) was inserted into 
pDHA at the EcoR1-Sal1 site. For (2) to (4), two or three DNA fragments were 
produced by PCR and first inserted into pQE30 vector (Qiagen, Valencia, California, 
USA) to piece them together to produce the specific RTN3 truncation genes. This 
strategy made use of a RE site (Sac1) that was absent in the RTN3 gene but 
conveniently present between the EcoR1 and Sal1 sites in the vector (and also in 
pDHA where the gene would eventually be cloned into). Upon confirming that the 
sequences of the truncation genes were correct after sequential cloning into pQE30, 
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they were re-cloned into pDHA at the EcoR1-Sal1 site. (2) was formed by two DNA 
fragments, fragment 1 (bp 1-183) and fragment 2 (bp 222-714) which were amplified 
by 3-P1/3-P4 and 3-P2/3-P5 respectively. (3) was also the product of two DNA pieces 
ligated, with the first fragment (bp 1-492) amplified by 3-P1/3-P6 and the second 
fragment (bp 610-714) being amplified by 3-P2/3-P7. (4) required three parts, the first 
being the first DNA fragment of (2), the second being bp 222-492 (amplified by 3-
P5/3-P6) and the third being the second DNA fragment of (3).  
 
2.2.1.6 Caspr and Caspr 2 constructs 
 Human Caspr cDNA was generously provided by Dr Elior Peles (Weizmann 
Institute of Science, Rehovot, Israel). The construct contained CDS of Caspr cloned 
into pRK5 vector at the Xba1 site. A construct whereby GST was fused to aa 1308-
1377 (bp 3922-4131) of human Caspr was generated for the production of specific 
Caspr antibodies. The fragment was amplified by the primer set Caspr-P1/Caspr-P2 
and cloned into pGEX4T1 at EcoR1-Xho1 site.  
 Full-length human Caspr 2 cDNA was obtained from the KIAA0868 clone 
(Kazusa original clone product ID: ORK04596) (Kazusa DNA Research Institute). A 
digestion of the KIAA clone was performed to obtain the cDNA for direct ligation 
into pCIneo at the Sal1-Not1 site. As for the generation of a GST fusion protein 
containing aa 1284-1331 (bp 3850-3993) of Caspr 2 for use in antibody production, 
the DNA fragment was amplified with the primers Caspr2-P1/Caspr2-P2 and cloned 






2.2.2 Molecular cloning procedure 
 The expression constructs described in section 2.2.1 were obtained by first 
performing PCR with a TPersonal Thermocycler (Biometra, Goettingen, Germany) to 
amplify the DNA fragment of interest, in a reaction containing KIAA or EST clones 
as templates, the high fidelity pfu DNA polymerase, a specific pair of forward and 
reverse primers (final concentration of 20 µM) and dNTPs (dATP, dGTP, dTTP and 
dCTP each at a final concentration of 10 mM; Promega). A typical PCR program was: 
(1) 95C, 5 min (2) 95C, 1 min (3) 50C, 2 min (4) 72C, 3 min (5) 72C, 10 min, 
with the reaction cycling from steps (2)(4) for 45 times.  
Amplified products were checked by DNA gel electrophoresis on 1% agarose 
gels (agarose from BioWhittaker Molecular Applications, Rockland, Maine, USA) 
that contained 0.5 µg/ml of ethidium bromide (Bio-Rad Laboratories). The 2-log 
DNA marker (New England BioLabs) was used to confirm the fragments‟ sizes. The 
gels were run for 30 min at a constant voltage of 120 V in a Tris-acetate-EDTA buffer 
(40 mM Tris, 20 mM Na-acetate and 1 mM EDTA; pH 8.2) before they were viewed 
using the image analysis software, KODAK 1D LE v3.6, under UV light with a 
KODAK EDAS 290 (Eastman Kodak Company, Rochester, NY, USA).  
Observed bands of amplified products were excised and purified by QIAquick 
Gel Extraction Kit (Qiagen). The amplified products, together with required vectors, 
were digested with appropriate REs overnight at 37C. The linearized vectors were 
additionally incubated with Calf Intestinal Alkaline Phosphatase for 45 min at 37C to 
remove the phosphate group at the 5‟ end so as to lower the chances of self-ligation. 
After purification using the QIAquick Gel Extraction Kit, the amplified DNA and 
vectors were ligated by T4 DNA ligase overnight at 16C.  
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The ligation mixture was then transformed into Escherichia coli (E. coli) 
DH5α strain competent cells (Subcloning EfficiencyTM DH5αTM Competent Cells; 
Invitrogen) by the following steps. It was first incubated with the bacterial cells for 30 
min on ice, followed by heat-shock for 1 min at 42C. Following that, the cells were 
placed on ice for another 1 min, before 1 ml of SOC medium (2% Bacto
TM
 Tryptone 
(Difco Laboratories Inc., Detroit, Michigan, USA), 0.5% Bacto
TM
 Yeast Extract 
(Difco), 2.5 mM NaCl, 10 mM MgCl2, 10 mM MgSO4 and 0.4% glucose) was added 
and recovery of the cells was allowed for 45 min at 37C. Finally, the cells were 
plated onto Luria-Bertani Broth (LB) agar (Bio Basic Inc., Markham Ontario, 
Canada) containing 100 µg/ml of ampicillin (Sigma-Aldrich) and incubated overnight 
at 37C. Cells transformed with the plasmid would survive in the presence of 
ampicillin due to an ampicillin resistance gene found on the vector and would form 
colonies observable on the next day.  
After expanding these colonies in ampicillin-containing LB, plasmid DNA 
were extracted from these bacterial cells using Wizard
®
 Plus SV Minipreps DNA 
Purification System (Promega). Insertion of gene in the plasmid was checked by 
analytical restriction digestion and DNA gel electrophoresis, before sequencing of the 
constructs was carried out. This step was to confirm that the inserted gene contained 
the correct sequence. Large-scale preparation of the plasmids, whenever necessary, 
was performed using Pureyield
TM
 Plasmid Midiprep System (Promega).  
 
2.3  Protein work 
2.3.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 SDS-PAGE was carried out using a Mini-PROTEAN 3 system, with the 
discontinuous polyacrylamide gels casted using its gel casting frames. 8-15% 
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resolving gels were accordingly prepared with 8-15% of an acrylamide/bisacrylamide 
mixture (30%, with a ratio of 29:1) in 0.375 M Tris-Cl and 0.1% sodium dodecyl 
sulphate (SDS) (pH 8.8). The stacking gel was made up of 5% 
acrylamide/bisacrylamide in 0.125 M Tris-Cl and 0.1% SDS (pH 6.8). For both gels, 
ammonium persulphate (Sigma-Aldrich) and N, N, N, N-Tetramethy-
Ethylenediamine (TEMED) (Invitrogen) were added at a final concentration of 
0.025% and 1:400 ratio respectively to aid in the polymerization of acrylamide.  
Protein samples were prepared as described. Cells and tissue samples were 
lysed in ice-cold lysis buffer (50 mM Tris, 1 mM EDTA and 150 mM NaCl; pH 8) 
containing 1% Triton X-100 (Tx-100), 0.1 mM phenylmethylsulphonyl fluoride 
(PMSF) (Sigma-Aldrich) and 1X protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, Indiana, USA). For experiments where phosphorylated proteins were 
being investigated, the phosphatase inhibitors, sodium orthovanadate (Sigma-Aldrich) 
and sodium fluoride (Sigma-Aldrich), were added at a final concentration of 1 mM 
and 5 mM respectively. The lysates were rolled overnight at 4C to allow for 
complete lysis. An additional homogenization step using a Dounce homogenizer after 
addition of lysis buffer was required for tissue samples. Cell lysates were spun at 
16,000 g for 5 min at 4C while tissue samples were ultra-centrifuged at 100,000 g for 
1 hr at 4C to spin down the debris. The lysates‟ concentrations were then measured 
with the Bio-Rad Protein Assay (Bio-Rad Laboratories) using a GeneQuant pro 
spectrophotometer (GE Healthcare). Appropriate amounts of lysates were diluted in 
phosphate buffered saline (PBS) (1
st
 Base) to achieve equal volumes before the 
addition of freshly prepared 5X SDS sample buffer (250 mM Tris-Cl (pH 6.8), 100 
mM dithiothreitol (DTT) (Bio-Rad Laboratories), 10% SDS, 50% glycerol and 0.5% 
bromophenol blue (Sigma-Aldrich)). The protein samples were subsequently 
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denatured for 10 min at 70C before loading into the gels. The protein marker, 
Precision Plus All Blue Standards (Bio-Rad Laboratories), was loaded into all gels to 
indicate protein sizes. Gels were run at a constant voltage of 120 V for 80 min in a 
buffer containing 0.3% Tris-base, 1.44% glycine and 0.1% SDS.  
 
2.3.2 Coomassie Blue staining and destaining of SDS-PAGE gels 
 In some experiments, the gels were stained with Coomassie Blue to visualize 
the proteins. This was carried out by soaking the gels for 30 min at room temperature, 
with shaking, in a Coomassie Blue staining solution (0.2% Coomassie Brilliant Blue 
R-250 (Bio-Rad Laboratories) in 40% methanol and 10% acetic acid). Destaining of 
the gels was then performed in two steps, first for 10 min in a stronger destaining 
solution (50% methanol and 10% acetic acid), followed by a milder one (10% 
methanol and 10% acetic acid) until the background staining was removed and bands 
could clearly be seen. 
 
2.3.3 Western transfer and blotting 
 Proteins resolved in SDS-PAGE gels were transferred to Hybond
TM
-C Extra 
nitrocellulose membranes (GE Healthcare) using a Mini Trans-Blot® Electrophoretic 
Transfer Cell. The transfer was performed in 0.3% Tris-base and 1.44% glycine at a 
constant voltage of 100 V for 80 min. To check the efficiency of protein transfer to 
the membranes after western transfer, the membranes were reversibly stained with 
Ponseau S after a brief incubation with the staining solution (0.2% Ponseau S (Sigma-
Aldrich) in 0.5% acetic acid). Background staining was removed by rinsing the 
membranes with deionized water. Complete removal of Ponseau S staining was 
achieved by washing in 0.05% Tween-20/PBS. 
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  Following this, the membranes were blocked with 5% skim milk (in 0.05% 
Tween-20/PBS) for 1 hr at room temperature. Membranes were then incubated with 
specific primary antibodies (diluted in 3% bovine serum albumin (BSA) (Sigma-
Aldrich) in 0.05% Tween-20/PBS) overnight at 4C. The primary antibodies that were 
employed were listed in Appendix 2. -tubulin (1:5000; Sigma-Aldrich) was generally 
probed as a loading control, and for normalization purpose in protein band 
quantification. Secondary antibodies conjugated to horse radish peroxidase (HRP) 
were diluted in the blocking buffer stated above and incubation with the membranes 
took place for 1 hr with shaking at room temperature. Donkey anti-goat HRP (Santa 
Cruz) was usually diluted 1:3000 while goat anti-rabbit and -mouse HRP (Thermo 
Fisher Scientific, Waltham, MA, USA) were usually diluted 1:5000. Membranes were 
washed three times with 0.05% Tween-20/PBS at 5 min per wash after each antibody 
incubation. The membranes were finally incubated for 5 min with gentle rocking in a 
solution of a chemiluminescent substrate, SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Fisher Scientific), before visualization of the protein bands was 
achieved upon developing exposed films (China Lucky Film Corporation, Hebei, 
China) with a Kodak X-OMAT 200 processor (Eastman Kodak Company). 
 
2.3.4 Production of GST fusion proteins 
 GST tagged-Nogo 1V2, -Caspr and -Caspr 2 were produced as antigens for the 
generation of antibodies specific to Nogo-A, Caspr and Caspr 2 respectively. GST, 
GST-Nogo-35, -40 and -66 were generated for GST pull-down experiments in the 
determination of Nogo-A‟s interaction with Caspr (section 4.1.3). The required GST 




2.3.4.1 Preparation of GST-proteins for antigens 
 To produce GST fusion proteins as immunogens, 50 µl of fresh bacterial 
culture was inoculated into 200 ml of LB + 100 ug/ml ampicillin and grown overnight 
at 37C with shaking. This was topped up with 600 ml of fresh medium the next day 
and left to grow for another 2 hr for the bacteria cells to reach logarithm phase 
(optical density at a wavelength of 600 nm = 0.5-1.0).  
Isopropyl-β-D-thiogalactopyranoside (IPTG) (Invitrogen) was then added to a 
final concentration of 0.1 mM to induce protein expression via its action on the lac 
operon found on the vector pGEX4T1 in the bacterial cells. The culture was grown 
for another 4 hr before harvesting was carried out by centrifugation at 7,560 g for 10 
min. The pellet was resuspended in 80 ml of ice-cold PBS containing 0.1 mM PMSF 
and then sonicated on ice using a Sonics Vibra-Cell
TM
 VCX 130 ultrasonicator 
(Sonics & Materials Inc., Newtown, Connecticut, USA) with two rounds of 4 pulses 
lasting 10 s each and a 15 s rest period between each pulse. The bacterial suspension 
was allowed to cool on ice between the two rounds to prevent degradation of proteins 
as a result of heat generated from sonication. Lysed cells were spun at 36,000 g for 30 
min to collect the supernatant, which was then added with 800 µl of glutathione 
agarose beads (GE Healthcare) and subjected to rolling at 4C for 2 hr to allow 
complete binding of fusion proteins with the glutathione on the beads.  
After collecting and washing the beads with ice-cold PBS, elution of bound 
GST fusion proteins was carried out using freshly prepared ice-cold elution buffer (20 
mM reduced glutathione (Sigma-Aldrich), 50 mM Tris (pH 8.0) and 0.1% Tx-100 in 
PBS; pH 7-7.5). Eight 1 ml fractions were collected and analyzed by SDS-PAGE 
followed with Coomassie Blue staining. Only fractions with high amounts of proteins 
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were dialysed in three rounds of 600 ml of cold PBS at 4C, with a change of PBS 
every 8-15 hr, after which the proteins were stored at -20C.  
 
2.3.4.2 Preparation of GST-proteins for pull-down assays 
A similar procedure as described above (section 2.3.4.1) was used, except that 
the volume of bacterial culture required was halved. Also, the fusion proteins were 
bound to glutathione sepharose 4B beads (GE Healthcare) and not agarose. Instead of 
eluting out the GST-proteins bound to the beads, the beads were collected by 
centrifuging at 1,700 g for 2 min to remove the supernatant and washed four times 
with 1 ml of ice-cold PBS, with spinning at 2,500 g for 30 s after each wash to 
remove the PBS. The beads were then stored at 4C. To determine the concentration 
of bound fusion proteins, an aliquot of the beads was checked by SDS-PAGE and 
Coomassie Blue staining, using BSA as a loading control. 
 
2.3.5 Purification of antibodies 
 After collection of blood from immunized rabbits (as described in section 
2.5.1), the blood was first left to clot overnight at 4C. Serum was obtained by 
centrifuging the clotted blood at 4,100 g for 20 min at 4C. The serum was then 
diluted 1:1 with PBS before incubation with nitrocellulose membrane strips 
containing immobilized antigens overnight at 4C with rolling. The membrane strips 
were obtained by first running SDS-PAGE with antigens loaded into 2-well gels, 
followed by electroblotting the antigens onto nitrocellulose membranes by western 
transfer, staining the membranes with Ponseau S to visualize the antigen bands and 
finally cutting out these bands.  
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After the overnight incubation with serum, the membrane strips were washed 
with PBS before they were cut into small pieces and placed in a snap cap vial. 
Antibodies bound to the membrane were then eluted out with an IgG elution buffer 
containing Tris-HCl and glycine (pH 2.8) (Thermo Fisher Scientific). The eluent was 
neutralized to pH 7.0 with 1 M Tris-HCl (pH 8.0) before storage at -20C. 
 
2.3.6 Nuclear-cytosol fractionation 
 Cells were plated onto 100 mm dishes at a cell density of 3.75 X 10
5
. Fresh 
medium was given on the second day after plating and the cells were harvested the 
next day.  
Fractionation was performed as described by Qu et. al. (2004) with some 
modifications. Briefly, cells were washed twice with ice-cold PBS before being 
pelleted at 16,000 g for 30 s. The pellet was resuspended in 100 µl of ice-cold buffer 
A (10 mM HEPES-KOH (pH 7.5), 10 mM KCl, 1 mM DTT, 1 mM PMSF and 1X 
protease inhibitor cocktail) and incubated on ice for 15 min. 10% Nonidet P-40 (final 
concentration of 0.3125%) was then added, the mixture vortexed briefly and 
incubated on ice for another 10 min. The nuclei were pelleted by centrifugation at 
1,500 g for 5 min at 4C, while the cytoplasmic extracts (supernatant) were recovered 
by centrifugation at 13,000 g for 15 min at 4C. Nuclei were washed twice with 1 ml 
of ice-cold buffer A before resuspension in 12.5 µl of ice-cold buffer B (20 mM 
HEPES-KOH (pH7.5), 0.4 M NaCl, 1 mM DTT, 1 mM PMSF and 1X protease 
inhibitor cocktail). The mixture was incubated on ice for 30 min, with a brief vortex 
after every 10 min, before centrifugation at 18,000 g for 5 min at 4C to collect the 




2.4 Cell culture 
2.4.1 Mammalian cell culture 
 Human neuroblastoma SH-SY5Y cells, HEK293 cells and Chinese hamster 
ovary (CHO) cells were obtained from the American Type Culture Collection 
(ATCC) (Manassas, Virginia, USA). The cells were maintained in Roswell Park 
Memorial Institute (RPMI) medium (Caisson Laboratories Inc., North Logan, Utah, 
USA) with 10% fetal bovine serum (FBS) (Hyclone Laboratories Inc., South Logan, 
Utah, USA) and 1X antibiotics/antimycotics solution (containing 10,000 units of 
penicillin, 10,000 µg of streptomycin and 25 µg amphotericin B in 0.85% saline per 
ml) (Invitrogen) in a humidified 37C incubator with 5% carbon dioxide (CO2) 
atmosphere. Upon confluency, cells were washed once with PBS, trypsinized with 
0.05% trypsin/0.0076% EDTA (Invitrogen) and split at a ratio of 1:5. 
  
2.4.2 Transient transfection 
 Cells were plated onto 12 mm microscope cover glasses (Einst Technology 
Pte Ltd, Singapore) or in 6-wells for ICC or western blotting respectively. Transient 
transfection was performed using Lipofectamine
TM
 2000 (Invitrogen) when the cells 
were 60-80% confluent according to the manufacturer‟s instructions. In brief, 
Lipofectamine
TM
 2000 was incubated for 5 min in Opti-MEM
®
 I Reduced Serum 
Medium (Invitrogen) before addition to the DNA to be transfected which was also 
diluted in Opti-MEM
®
. A further incubation of the complex for 20 min was carried 
out before it was added to the cells. Cells were analysed 24 and 48 hr later for protein 





2.4.3 Generation of stable cell-lines 
 Stable cell-lines of SH-SY5Y (SH-SY5Y Nogo-A, Nogo-B, HA-Nogo-B, 
Nogo-B (1-200), Nogo-B (N-TM1), Nogo-C and RTN3); HEK293 Nogo-A and HA-
RTN3; and CHO Nogo-A were generated as described below. The respective wild 
type cells were plated into 6 wells the day before transfection. On the next day, cells 
were transfected using Lipofectamine
TM
 2000. 4 µg of the respective DNA constructs 
was mixed with Lipofectamine
TM





 and added to the cells. Medium was changed after 4 hr to 
minimize the toxicity of the transfection mixture.  
24 hr later, cells were trypsinized and plated into 100 mm dishes at a very low 
density. Geneticin or G418 (Invitrogen) was added to the cells the day after plating at 
a concentration of 0.5 mg/ml. G418 was gradually increased to 1.4 mg/ml with a 
change of medium every 4-5 days. G418-resistant colonies appeared approximately 2 
weeks later and were picked into 24 wells. After confirmation of protein expression 
by ICC and western blotting, the positive colonies were expanded, frozen and used for 
subsequent experiments. The stable cell-lines were then maintained in RPMI medium 
containing 0.8 mg/ml G418. 
 CHO expressing Caspr/F3 was generously provided by Prof. Xiao Zhi Cheng 
(Department of Clinical Research, Singapore General Hospital, Singapore).  
 
2.4.4 Primary culture of cortical neurons 
 C57BL/6 or Nogo-deficient pregnant mice on E15 were used for the 
harvesting of cortical neurons. The former was obtained from the Centre of Animal 
Resources (Singapore) while the latter was bred as described in section 2.5.2. The 
pregnant mother was first anaesthetized intraperitoneally with 300 µl of a 1:1 
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ketamine and xylazine mixture before a cervical dislocation was performed. 70% 
ethanol was used to swab the abdominal region and the skin cut to allow retrieval of 
the uterus with embryos to the harvest medium (10 mM HEPES (pH 7.4) (Sigma-





 (Invitrogen)). Amnia enclosing the embryos were removed, the heads 
decapitated and the cerebral hemispheres separated from skin and skull. Removal of 
the meninges layer and separation of the cortices from the other parts of the brain was 
performed under a microscope.  
Cortices were then minced in 2 ml of harvest medium, followed by the 
addition of 0.2 ml of 2.5% trypsin and 20 µl of 250 ug/ml DNaseI (Sigma-Aldrich). 
Enzymatic digestion was allowed to take place for 15 min at 37C, with mixing 
performed at every 5 min interval. 0.22 ml of FBS was added to the cortices to inhibit 
the trypsin and this was left to stand for 5 min at room temperature. The supernatant 
was carefully removed, followed by the addition of plating medium (0.05% NaHCO3 
(Sigma-Aldrich), 1 mM sodium pyruvate (Invitrogen), 0.6% glucose, 10% FBS and 
1X antibiotics/antimycotics in minimum essential medium (MEM) (Invitrogen)) and 
trituration using a glass Pasteur pipette. Volume of plating medium to be added 
depended on each harvest but typically 1 ml of plating medium was added for each 
brain harvested. Cell density of the suspension was determined by counting using a 
hemocytometer, and the cells were then plated onto 12 mm coverslips and 100 mm 
dishes at a cell density of 1.25 X 10
5
 and 8 X 10
6
 respectively. The coverslips and 100 
mm dishes were first coated with 10 µg/ml poly-L-lysine (PLL) before plating. On the 
following day after plating, the plating medium was replaced with maintaining 
medium (1X B-27 serum-free supplement (Invitrogen) and 10 mM L-glutamine 
(Invitrogen) in Neurobasal
TM
 medium (Invitrogen)) and the cortical neurons were 
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maintained in this medium with a change of medium every 4 days until 7 days in vitro 
(DIV7) for checking of Nogo-A expression in neurons, or DIV16 for cortical neuronal 
morphological differentiation studies (section 3.3). 
 
2.4.5 Primary culture of oligodendrocytes and astrocytes 
 Primary astrocytes were obtained from P1-2 C57BL/6 mice or Sprague 
Dawley rats. Primary oligodendrocytes were cultured from the latter only.  
The animals were first anaesthetized on ice before they were decapitated and 
the brains removed from the skull and placed in Dulbecco‟s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) (Invitrogen) containing 1 mM sodium pyruvate 
and 1% antibiotics/antimycotics. The brains were minced into small pieces after 
removing the meninges and subjected to tryptic digest for 30 min at 37C with 0.1% 
trypsin/versene (0.02% EDTA/PBS). Approximately 1 ml of trypsin/versene was used 
for each brain. Trypsin present was then inhibited by the addition of DMEM/F12 
supplemented with 10% FBS in a 1:3 trypsin:medium ratio.  
The trypsinized brains were triturated with a glass Pasteur pipette before 
filtration through a 70 µM BD Falcon nylon cell strainer (BD Biosciences, San Jose, 
California, USA). The mixed glial cell suspension was then plated onto T75 flasks (2 
brains per flask) precoated with 30 µg/ml of PLL in DMEM/F12 containing 10% 
FBS, 1 mM sodium pyruvate and 1% antibiotics/antimycotics, and medium was 
refreshed every 3 days. The mixed culture was also plated onto PLL-coated coverslips 
for ICC studies. 
 After 12-14 days when the culture reached confluency, the flasks were shaken 
in an orbital shaker at 220 rpm overnight to isolate oligodendrocytes from astrocytes. 
As oligodendrocytes were less adherent, they would dislodge into the medium after 
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vigorous shaking. The medium was centrifuged at 2,500 g for 3 min to collect the 
suspended oligodendrocytes which were then plated into PLL-coated 60 mm dishes 
for western blot analysis. The remaining astrocytes in the T75 flasks were trypsinized 
and re-plated onto 60 mm dishes as well. Both the oligodendrocytes and astrocytes 
were maintained in DMEM/F12 containing 10% FBS, 1 mM sodium pyruvate and 1% 
antibiotics/antimycotics, with the medium being refreshed every 3 days.   
 
2.5  Animal work 
2.5.1 Immunization of rabbits 
 500 µg of GST-Nogo 1V2, -Caspr or -Caspr 2 (preparation as described in 
section 2.3.4.1) in 2 ml of sterile PBS and mixed with 2 ml of Freund‟s Adjuvant 
(Sigma-Aldrich) to form an emulsion with 2 syringes connected through a Luer 
fitting. Complete Freund‟s Adjuvant was used for the first immunization while 
Incomplete Freund‟s Adjuvant was employed for subsequent booster injections. The 
mixture was then injected subcutaneously into specific pathogen-free (SPF) New 
Zealand White female rabbits under anaesthesia in compliance with the protocol 
approved by the National University of Singapore (NUS) Institutional Animal Care 
and Use Committee (IACUC). Booster immunizations were given at every two weeks 
interval after the first immunization.  
Two weeks after the fourth injection, 10 ml of blood was collected from the 
central ear artery of anaesthetized rabbits using a 25-gauge Surflo winged infusion set 
(Terumo Europe, Leuven, Belgium). Rabbits with positive response continued to 
receive a booster injection whereby two weeks after the booster injection, 20-50 ml of 
blood was taken from the animals. The rabbits were rested for a month after each 
bleed before the next immunization. 
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2.5.2 Maintenance and breeding of Nogo-deficient mice 
 Two pairs of Nogo-deficient mice (Zheng et. al., 2003) were obtained from 
Genentech, Inc. (South San Francisco, California, USA). These mice were deficient in 
all three isoforms of Nogo (termed Nogo-A/B/C mutant), as they were shown to 
express neither Nogo-A nor -B mRNA while expressing a shorter Nogo-C transcript 
(which most likely produced a non-functional protein). The knockout was designed 
such that the first exon of the six exons encoding the RHD was removed. After many 
rounds of breeding, a mouse colony was established. The mice were kept in the NUS 
Animal Holding Unit in individually ventilated cages in an environment in 
accordance to NUS IACUC policies and guidelines.  
 Periodic matings were carried out to maintain the mouse colony and also to 
provide pregnant E15 mice for primary cortical neuronal culture (section 2.4.4). For 
the latter, a female mouse was placed into a cage containing a male mouse overnight 
and on the next day, they were separated and the female mouse weighed. Three to 
four pairs of mating were set up each time. The day of separation was considered to 
be E0 (or E0.5). The female mice were weighed again on E12-13 to check for 
pregnancy before one pregnant mouse was sacrificed on E15 to obtain primary 
cortical neurons.   
 
2.5.3 Perfusion of C57BL/6 and Nogo-deficient mice 
 4-8 weeks old C57BL/6 and Nogo-deficient female mice were first sedated 
with an intraperitoneal injection of 300 µl of ketamine and xylazine mixture (1:1). 
The mice were then dissected to open the thoracic cavity to expose the heart. A 23-
gauge Surflo winged infusion set (Terumo Europe) was inserted into the left ventricle 
and a snip was performed at the right atrium. The animals were perfused with cold 
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Ringer solution (0.86% NaCl, 0.03% KCl and 0.033% CaCl2 in deionized water) to 
wash out the blood. When all blood had been washed out, as observed by the clear 
solution flowing out of the snipped atrium, cold 4% paraformaldehyde (PF) (Sigma-
Aldrich) in 0.1 M phosphate buffer (0.08 M Na2HPO4 and 0.02 M NaH2PO4; pH 7.3-
7.4) was then used to fix the animals for at least 30 min. The Ringer solution and PF 
were either freshly prepared or prepared the day before.  
When the whole animals were completely fixed, the brains and spinal cords 
were carefully retrieved and left to post-fix in 4% PF overnight. On the next day, the 
tissues were rinsed with PBS and soaked in 30% sucrose in 0.1 M phosphate buffer as 
a cryoprotective measure for 24 hr or until the tissues have sunken. 
 
2.6 Interaction studies 
2.6.1 GST pull-down assays 
 In vitro GST pull-down assays were employed to investigate the interaction of 
Nogo A with Caspr (section 4.1.3), with GST, GST-Nogo-35, -40 and -66 fusion 
proteins bound to glutathione sepharose beads acting as “baits”. GST was used as a 
negative control for the experiments. 20 µg of these “bait” proteins were incubated 
with 1.5 mg of cell lysates (containing stably or transiently expressed “prey” proteins) 
overnight with rolling at 4C. The lysates were first diluted 1:4 to obtain a final 
concentration of 0.25% Tx-100 present before the addition of glutathione sepharose 
beads. Total beads volume was topped up to 30 µl with glutathione sepharose beads 
whenever necessary. 
 Following this, the beads were pelleted at 2,500 g for 30 s and the supernatant 
removed. The beads were washed three times with 1 ml of ice-cold lysis buffer 
containing 0.25% Tx-100, and finally two washes with ice-cold lysis buffer without 
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Tx-100. Elution of proteins bound to the beads directly (the “bait”) or indirectly (the 
“prey”) was carried out with SDS sample buffer for 10 min at 70C before SDS-
PAGE and western blotting were performed to check for the presence of target 
proteins that interacted with and therefore pull-downed by the GST fusion proteins. 
 
2.6.2 Co-immunoprecipitation (Co-IP) 
 3 µg of antibodies specific for target antigens were added to 1.5 mg of lysates 
(containing Tx-100 at a final concentration of 0.25%) and the mixture was rolled 
overnight at 4C. 30 µl of protein A or G sepharose beads (GE Healthcare) was then 
incubated with the mixture the next day for 2 hr at 4C. The former was used to bind 
and pull-down rabbit antibodies while the latter was for mouse antibodies.  
After that, the beads were centrifuged at 2,500 g for 30 s to remove the lysates 
and excess antibodies. Non-specific binding of proteins was removed by washing the 
beads three times with ice-cold lysis buffer containing 0.25% Tx-100 and two times 
with ice-cold lysis buffer without Tx-100. Any proteins interacting with the target 
protein bound by the antibody would co-precipitate with the latter in a protein 
complex that was pull-downed by the beads. Finally, the bound proteins and 
antibodies were eluted with the addition of SDS sample buffer and the co-IP samples 
were subjected to SDS-PAGE followed by western blot analysis.  
 
2.7 Localization studies 
2.7.1 Immunocytochemistry (ICC) 
Cells were plated onto 12 mm microscope cover glasses coated with 30 µg/ml 
of PLL, and fixed with 4% PF for 15 min at room temperature the next day. For NF-
B p65 subunit translocation upon H2O2 or TNFα treatment, cells were plated into 6-
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wells (each containing 5 PLL-coated coverslips) at a cell density of 0.625 X 10
5
. Cells 
were treated as described in section 2.8.1 and a coverslip was taken out for fixation at 
each time point. The coverslips were then washed once in PBS, twice in 100 mM 
NH4Cl/PBS and once in PBS, for 2 min per wash with gentle shaking. After washing, 
cells were permeabilized with 0.05% saponin (in PBS) extracted from Quillaja bark 
(Sigma-Aldrich) or 0.2% Tx-100/PBS for 10 min at room temperature. Methanol 
fixation was also employed for specific antibodies, where cells were incubated on ice 
for 5 min with cold methanol. No further permeabilization was necessary and 
subsequent washing steps were carried out in PBS. 
The cells were then incubated with primary antibodies diluted in blocking 
buffer (2% BSA and 5% FBS in PBS) for 1 hr at room temperature. This was 
followed by washing twice in PBS. A third wash in 0.05% saponin /PBS or PBS alone 
was performed for cells permeabilized with saponin or Tx-100 respectively. 
Secondary antibodies (1:150) conjugated to fluorescein isothiocyanate (FITC) or 
Texas Red (TxR) (Jackson Immunoresearch Laboratories Inc., Westgrove, 
Pennyslvania, USA) were incubated with the cells for another 1 hr at room 
temperature. In experiments where a blocking control was performed, 0.3 µg of 
diluted Ng1V2 antibody (the amount that was usually used for one coverslip) was first 
incubated with 6 µg of GST-Ng1V2 (twenty times the amount of antibody used) 
overnight at 4C before the primary antibody incubation step. Finally, the cells were 
washed three times with PBS before the coverslips were mounted onto glass slides 
(Sail Brand, Jiangsu, China) with Vectashield mounting medium (Vector Laboratories 
Inc., Burlingame, California, USA) and sealed with nail polish. For staining of cells 
with Hoechst, Hoechst 33342 (Molecular Probes Inc., Eugene, Oregon, USA) was 
added in the ratio of 1:20,000 in the first wash. The cells were then viewed with a 
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Carl Zeiss LSM 510 confocal microscope (Carl Zeiss Inc., Thornwood, New York, 
USA).  
 The primary antibodies used for ICC were as listed below. The following 
antibodies required permeabilization with saponin: Ng1V2 rabbit polyclonal 
antibodies at a concentration of 1-2 mg/ml (1:500; “home-made”), AR2 rabbit 
polyclonal antibodies (1:500; a kind gift from Dr Luc Dupuis from Inserm U692, 
Strasbourg, France), anti-HA monoclonal antibody (1:100; 12CA5), and mouse 
monoclonal antibodies against Tuj (1:50; T8660; Sigma-Aldrich), 2‟, 3‟-cyclic 
nucleotide 3‟-phosphodiesterase (CNPase) (1:100; C6200X; USBiological, 
Swampscott, Massachusetts, USA) and glial fibrillary acidic protein (GFAP) (1:200; 
G3893; Sigma-Aldrich). Tx-100 was used for permeabilization for these antibodies: 
anti-glucose regulated protein 94 (GRP94) goat polyclonal antibodies (1:50; sc-1794) 
and anti-NF-B p65 mouse monoclonal antibodies (1:50; sc-8008). Methanol fixation 
was employed in ICC experiments using anti-RTN3 rabbit polyclonal antibodies 
(1:125; AB72814; Abcam, Cambridge, UK).     
 
2.7.2 Immunohistochemistry (IHC) 
Fixed brain and spinal cord tissues as prepared in section 2.5.3 were embedded 
and frozen in Tissue-Tek Optimum Cutting Temperature (O.C.T.) compound (Sakura 
Finetek USA Inc., Torrance, California, USA). The frozen tissues were cryosectioned 
into 20 µm parasagittal sections with a Microm HM 525 cryostat (Microm 
Laborgeräte, Bad Schwalbach, Germany) and placed onto glass slides coated with 5% 
glycerol. The sections were then stored at -80C. 
To perform immunohistochemistry (IHC), frozen sections were thawed and 
further fixed in 4% PF for 30 min at room temperature. Similar to the ICC procedure, 
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the sections were washed one time with PBS, two times with 100 mM NH4Cl/ PBS 
and one time with PBS with gentle shaking for 5 min per wash. Sections were then 
permeabilized with 0.2% Tx-100/PBS for 1 hr at room temperature, followed by an 
incubation with blocking buffer (4% BSA and 10% FBS in PBS) for another hr.  
After three washes with PBS at 10 min each, primary antibodies diluted in the 
blocking buffer were placed onto the sections and incubation took place in a 
humidified chamber overnight at 4C. For blocking controls in certain experiments, 
0.7 µg  of diluted Ng1V2 antibody (the amount used per section) was first incubated 
with 14 µg of GST-Ng1V2 (twenty times that of antibody used) for 4 hr or overnight 
at 4C before incubating the primary antibody with the sections. On the next day after 
primary antibody incubation, the sections were washed trice with PBS for 10 min per 
wash before incubation with respective secondary antibodies conjugated to FITC or 
TxR for 1 hr at room temperature.  
To stain the nuclei, the sections were placed in PBS containing Hoechst 33342 
(diluted 1:20,000 in PBS) for 10 min with gentle shaking. This was followed by three 
washes of PBS at 10 min each. The mounting medium Vectashield was then dropped 
onto the sections, and these were eventually overlaid with coverslips. Viewing of the 
sections was then carried out using a Carl Zeiss LSM 510 confocal microscope.  
The dilutions for Ng1V2 antibodies and those against Tuj, CNPase and GFAP 
used in IHC were the same as that for ICC studies. The “homemade” rabbit 
polyclonal antibodies against Caspr (at 0.2-0.5 mg/ml) were used in a dilution ratio of 
1:150. Monoclonal antibodies against Caspr (1:150; 75-001) and K
+
 channels (1:300; 
75-008) were obtained from US Davis/ National Institutes of Health (NIH) NeuroMab 




2.8 Apoptosis assessment assays 
2.8.1 Propidium iodide (PI) labelling/ flow cytometry 
 SH-SY5Y stable cell-lines were plated in triplicates at a cell density of 0.625 
X 10
5
 per 6-well. Fresh medium (without G418) was given to the cells after 40 hr of 
plating. The cells were treated with various drugs the following day and harvested at 
the required time points. For H2O2 treatment, cells were treated with 100 µM of 
stabilized H2O2 (Merck KGaA, Darmstadt, Germany) for 30 min before H2O2 was 
removed, the cells washed once and replenished with fresh medium. Serum 
withdrawal was performed by growing the cells in serum-free medium after washing 
them twice with the same serum-free medium. For the other treatments, cells were 
directly incubated in fresh medium containing the drugs. Staurosporine (A.G. 
Scientific Inc., San Diego, California, USA), etoposide (A.G. Scientific Inc.), 
tunicamycin (Sigma-Aldrich) and TNFα (Prospec-Tany TechnoGene Ltd, Rehovot, 
Israel) were given at a final concentration of 0.5 µM, 20 µM, 20 µg/ml and 10 ng/ml 
respectively. 
 In experiments where cells were treated with inhibitors prior to H2O2 
treatment, 50 µM of phosphoinositol-3-kinase (PI3K) inhibitor LY294002 (A.G. 
Scientific Inc.) and 10 µM of MEK 1/2 inhibitor U0126 (A.G. Scientific Inc.) were 
preincubated with the cells for 1 hr and 30 min respectively.  
 At the time of harvest, cells were collected together with the medium and the 
wells washed with 1 ml of ice-cold PBS to collect any residual cells. Cells were 
pelleted at 4,100 g for 5 min at 4C, washed with 1 ml of ice-cold 1% FBS/PBS and 
spun again at the same speed. The pellet was then resuspended in 100 µl of ice-cold 
1% FBS/PBS, and immediately fixed with 1 ml of ice-cold 75% ethanol to prevent 
clumping of cells. Fixing of the cells was carried out at 4C until flow cytometry was 
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to be performed. To stain the cells with propidum iodide (PI), they were first pelleted 
as stated above to remove the ethanol. The pellet was washed once with 1 ml of ice-
cold 1% FBS/PBS before resuspension in 500 µl of ice-cold 1% FBS/PBS containing 
PI (Sigma-Aldrich) and RNase A (Sigma-Aldrich) at a final concentration of 10 
µg/ml and 250 µg/ml respectively. The cells were incubated for 1 hr at 37C. Flow 
cytometry was performed using a BD FACSCanto
TM
 II flow cytometer (BD 
Biosciences) and data was analysed with BD FACSDiva
TM
 Software v5.0.2. Cell 
cycle profile histograms were drawn using the ModFit v2.9 software. The percentage 
of cell death was measured as the percentage of cells in sub G1 phase. 
 
2.8.2 Fluorimetric caspase activation assay 
 Cells were plated in triplicates onto 100 mm dishes at a cell density of 3.75 X 
10
5
 respectively, and treated as according to flow cytometry analysis (section 2.8.1). 
At the end of treatment, cells were harvested together with the medium and pelleted at 
4,100 g for 5 min at 4C. The pellet was washed once with 1 ml of ice-cold PBS 
before resuspension in 135 µl of Cell lysis buffer (BD Biosciences). The resuspension 
was kept on ice for 10 min before proceeding with the fluorimetric assay. The lysates 
were spun at 4,600 g for 5 min at 4C and the supernatants transferred into new tubes.  
40 µl of the supernatants were added into each 96-well containing 40 µl of 2X 
reaction buffer (0.188 mM HEPES (pH 7.4), 0.038 mM EDTA, 0.188 mM KCl, 0.028 
mM MgCl2, 6 mM DTT, 1 mM PMSF and 1X protease inhibitor cocktail) and 4 
nmoles of caspase substrate. Caspase-3 substrate (Ac-DEVD-AFC) was from A.G. 
Scientific Inc., while caspase-9 substrate (Ac-LEHD-AFC) was from AnaSpec Inc. 
(Fremont, California, USA). The proteolytic reactions were carried out in the dark for 
1 hr at 37C before fluorescence was measured using a SpectraFluor Plus 
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spectrofluorometer (Tecan Group Ltd., Männedorf, Switzerland) at an excitation 
wavelength of 400 nm and emission wavelength of 505 nm. Cleavage of the 
substrates by active caspases present would relieve the fluorophore AFC thereby 
generating a fluorescence signal. The relative fluorescence units (RFU) were 
normalized by the amount of protein for each sample (RFU/ µg). 
 
2.9 Data analysis 
2.9.1 Confocal image analysis 
 Presented ICC or IHC pictures were typically obtained from collapsing a Z-
stack of individual confocal images taken at different planes.  
Measurements of micrographs, such as the distances between the paired 
staining of Caspr and K
+
 channels at the node of Ranvier (section 4.1.5) was 
performed using a measurement feature in the AxioVision software. 
 
2.9.2 Densitometric analysis 
 Densitometry was performed using the ImageJ v1.43f software 
(http://rsbweb.nih.gov/ij/) that was available in public domain and developed by NIH. 
 
2.9.3 Statistical analysis 
 Experiments were typically carried out in triplicates and repeated at least three 
times. Data was analyzed with the parametric two-tail Student‟s t test available on the 
GraphPad QuickCalcs website (http://www.graphpad.com/quickcalcs/ttest1.cfm) and 
expressed as mean ± sd, with significance levels as P values indicated in each figure.  
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Chapter 3 Subcellular and tissue localization of Nogo-A 
 Nogo-A is the longest splice isoform generated from the Nogo locus and it is 
the most CNS-enriched form. In this chapter, Nogo-A‟s subcellular and tissue 
localization, particularly in the CNS, is described.  
 
3.1 Generation of Nogo-A specific antibodies 
 In order to specifically detect Nogo-A in cells and tissues, antibodies specific 
for Nogo-A were generated. A high affinity and specific antibody permits the study of 
the endogenous Nogo-A, as well as overexpressed, untagged form of the protein. The 
latter is especially crucial when tagging the protein could possibly result in a loss or 
alteration of function, as observed for N-terminal tagged Nogo-B as described in 
chapter 5.  
 Nogo-A specific antibodies were raised in rabbits using a GST fusion antigen 
that comprised of aa 223-399 of the human Nogo-A polypeptide. The sequence of the 
antigen is boxed in blue in Fig 3.1A. This region, termed Ng1V2, is encoded by part 
of exon 3 of Nogo and is uniquely present in Nogo-A but not in the other major splice 
isoforms, Nogo-B and -C, as illustrated in the schematic diagram of in Fig 3.1B. The 
peptide, after fusion with GST (29 kDa), has an approximate molecular size of 50 kDa 
(Fig 3.1C).  
 To confirm that the polyclonal Ng1V2 antibodies produced would detect only 
Nogo-A and not the other splice isoforms, a western blot was carried out using lysates 
of SH-SY5Y cells transiently overexpressing myc tagged Nogo-A, -B and -C as 
shown in Fig 3.2A. The monoclonal myc tag antibody, 9E10, detected all the three 
isoforms, Nogo-A (~220 kDa), Nogo-B (~50 kDa) and Nogo-C (~25 kDa), 
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confirming that the proteins were indeed expressed. Expectedly, Ng1V2 antibodies 
could only pick up the 220 kDa Nogo-A band.  
 
 
Fig 3.1 Amino acid sequence and protein size of the antigen used for the 
production of Ng1V2 rabbit polyclonal antibodies. (A) Amino acid sequence of 
human Nogo-A, with the Ng1V2 antigenic region demarcated by the blue box. (B) 
Schematic diagram of the Nogo isoforms, (Nogo-A, -B and -C). The Ng1V2 antigen 
region (aa 223-399) present solely in Nogo-A is indicated by the blue line. (C) The 
antigen, GST-Ng1V2, was resolved alongside with GST on a 9% SDS-PAGE gel and 
the gel was Coomassie Blue-stained to check for the protein‟s purity and size. 




The antibodies were then checked for their specificity in detecting endogenous 
Nogo-A by ICC (Fig 3.2B). Immunostaining with Ng1V2 antibodies showed that 
Nogo-A in interphase cells exhibited mainly ER labelling, which co-localized exactly 
with GRP94, an ER lumenal marker (Fig 3.2B; merge picture in the upper panel). 
This suggested that majority of Nogo-A resided at the ER. Plasma membrane staining 
of Nogo-A (edges of the cells pointed out by the arrowheads in Fig 3.2B), where 
GRP94 staining seemed absent, was also noted. Blocking of the antibodies with the 
antigen, GST-Ng1V2, (Fig 3.2B, lower panel) abolished the ER staining of Nogo-A, 
confirming that the labelling by Ng1V2 antibodies was specific for Nogo-A. 
 
 
Fig 3.2 Nogo-A was specifically detected by Ng1V2 antibodies. (A) SH-SY5Y cells 
were transiently transfected with pDmyc as vector control (v.c.), myc-Nogo-A (A), 
myc-Nogo-B (B) and myc-Nogo-C (C) with Lipofectamine 2000 for 24 hr before the 
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cells were harvested. 20 µg of lysates were resolved on a 10% SDS-PAGE gel and 
subjected to western blotting with 9E10 mouse monoclonal (anti-myc) or Ng1V2 
rabbit polyclonal (anti-Nogo-A) antibodies. Untransfected SH-SY5Y lysates (unt) 
were loaded as an additional negative control for blotting with Ng1V2 antibodies. (B) 
(Upper panel) SH-SY5Y Nogo-A (38) stable cells were fixed with 4% PF, 
permeabilized with 0.2% Tx-100/PBS and incubated with Ng1V2 (red) and anti-
GRP94 (green) antibodies, followed by TxR- and FITC-conjugated secondary 
antibodies. Arrowheads indicate plasma membrane staining of Nogo-A. (Lower 
panel) Blocking of Ng1V2 antibodies was carried out by incubating the antibodies 
with its antigen, twenty times the amount of the antibody, overnight at 4C before 
incubation with the cells. Bar = 20 µm. 
 
3.2 Nogo-A is highly enriched in the CNS 
 To be better-equipped to elucidate the physiological roles of Nogo-A, it is 
important to first understand where the protein is expressed. For this purpose, a tissue 
survey using adult C57BL/6 mice was performed by western immunoblot analysis. As 
shown in Fig 3.3A, Nogo-A was highly enriched in the CNS, namely brain and spinal 
cord. Nogo-A was also found in low levels in organs like the heart and small intestine, 
and at almost undetectable levels in the other organs tested.  
 Specific cell type localization of Nogo-A within the adult CNS was further 
probed by performing IHC using cryosections of adult C57BL/6 mouse brain and 
spinal cord (Fig 3.3B). Nogo-A was found to be widely expressed in the brain, with 
observed staining in the cortex, cerebellum, deep cerebellar nuclei and the 
hippocampus (all regions including dentate gyrus (DG), CA3 and CA1). Expression 
of Nogo-A was seen in both white and grey matter regions of the spinal cord, and 
could be found in cells that resemble both oligodendrocytes as well as neurons (see 
section 3.3 below). Nogo-A staining in Fig 3.3B was confirmed to be specific as the 
staining was abolished on cryosections probed with Ng1V2 antibodies that were 
previously blocked by its antigen, GST-Ng1V2 (data not shown).  
 In order to check if Nogo-A‟s expression level in the brain is developmentally 
regulated, rats from various late stages of brain development, from E18 to 6 months 
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old, were sacrificed and the respective brain lysates probed. Nogo-A was expressed in 
the developing rat brain at E18, and the expression levels were fairly sustained well 
into adulthood (Fig 3.4). 
 
 
Fig 3.3 Nogo-A was highly enriched in the brain and spinal cord. (A) 100 µg of 
adult C57BL/6 tissue lysates were resolved on 8% SDS-PAGE gels and subjected to 
western blotting with Ng1V2 antibodies. -tubulin was probed as a loading control. 
S.I. and L.I. denoted small intestine and large intestine respectively. Note that the 
western blot on the right showing spinal cord was carried out on a separate 
membrane. (B) Adult C57BL/6 mouse brain and spinal cord parasagittal sections (20 
µm thick) were immunostained with Ng1V2 antibodies (green), followed by 
secondary antibodies conjugated with FITC. Hoechst 33342 was used to stain the 
nuclei (blue). Bar = 20 µm. 
 
 
Fig 3.4 Expression of Nogo-A during brain development. 80 µg of rat brain lysates 
obtained from different developmental stages (Embryonic day (E) 18, postnatal days 
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(P) 1, 4 and 10, and postnatal months (m) 1, 2, 4 and 6) were resolved on an 8% SDS-
PAGE gel and western blotted with Ng1V2 antibodies for Nogo-A, using -tubulin as 
a loading control.  
 
3.3 Nogo-A is significantly expressed in both neurons and oligodendrocytes 
but not astrocytes 
  Nogo-A was first reported to be present in oligodendrocytes where it acted as 
a myelin-associated neurite outgrowth inhibitor. The presence of Nogo-A in the other 
major brain cell types, neurons and astrocytes, is not clear. Lysates from primary 
cultures of these three different cell types obtained from C57BL/6 mice and Sprague 
Dawley rats (Fig 3.5) showed that Nogo-A was indeed present in a significant amount 
in rat oligodendrocytes. Comparatively, astrocytes from the same source seemed to 
have very low levels of Nogo-A. Interestingly, it was found to be expressed in mouse 
cortical neurons. Mouse astrocytes also showed very low levels of Nogo-A 
expression. In fact, the presence of the low intensity band for Nogo-A in both the 
mouse and rat astrocytes could readily be explained by a contamination of 
oligodendrocytes in the primary astrocyte cultures. As the amount of primary 
oligodendrocytes obtained from mice was consistently low and insufficient for robust 
western blot analysis, oligodendrocytes from rats were used.  
 
 
Fig 3.5 Nogo-A was expressed in primary cortical neurons and oligodendrocytes 
but not astrocytes. 20 µg of lysates from the indicated samples were resolved on an 
8% SDS-PAGE gel and western blotted with Ng1V2 antibodies for Nogo-A, with -
tubulin as a loading control. Mouse brain lysate was obtained from adult C57BL/6 
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mice while respective primary cultures were obtained as described in section 2.4.4 
and 2.4.5. c.n. = cortical neurons. astro. = astrocytes. oligo. = oligodendrocytes.  
 
 Immunofluorescence microscopy analysis of primary cortical neuronal and 
mixed glial (containing both oligodendrocytes and astrocytes) cultures yielded results 
that were complementary to that of the immunoblots (Fig 3.6). Nogo-A (as observed 
from the immunostaining by Ng1V2 antibodies) co-localized with the neuronal 
marker Tuj, a neuron-specific class III β-tubulin, in the primary cortical neuronal 
culture in Fig 3.6A (upper panel). Nogo-A also co-localized with the oligodendrocytic 
marker, CNPase (indicated by arrows), but not GFAP (indicated by arrowheads), a 
marker for astrocytes (upper panels of Fig 3.6B and C respectively). To confirm that 
the immunofluorescence staining revealed by Ng1V2 antibodies was specific, controls 
were carried out by preincubating the antibodies with its antigen (GST-Ng1V2) prior 
to performing ICC. The specific Nogo-A staining of neurons and oligodendrocytes 
was effectively blocked in this manner (Fig 3.6A-C, lower panels). This reiterated the 
western blot results obtained earlier in Fig 3.5, and confirmed that Nogo-A was 
expressed at significantly high levels in neurons and oligodendrocytes while its 
expression in astrocytes, if any, was very low. 
 An investigation on the expression pattern of Nogo-A during the 
morphological differentiation of primary cortical neurons in culture was also 
performed. Primary cortical neurons were seeded and allowed to differentiate on PLL-
coated dishes and their lysates were collected at various time intervals until DIV16. 
Note that cortical neurons at DIV0 were obtained straight after harvesting in 
suspension without plating them onto dishes. Fig 3.7 showed that the amount of 
Nogo-A was low at the point of harvest. However, Nogo-A was steadily expressed 




Fig 3.6 Nogo-A co-localized with cortical neurons and oligodendrocytes but not 
astrocytes in primary culture. Mouse primary cortical neurons (DIV7) (A; upper 
panel) and mixed glial culture (B, C; upper panels) were fixed with 4% PF, 
permeabilized with 0.05% saponin and incubated with Ng1V2 (green) and anti-Tuj 
(A), anti-CNPase (B) or anti-GFAP (C) (red) antibodies, followed by FITC- and TxR-
conjugated secondary antibodies. Hoechst 33342 was used to stain the nuclei. 
Blocking of Ng1V2 antibodies (A-C; lower panels) was carried out by incubating 
Ng1V2 antibodies with its antigen, twenty times the amount of the antibody, 
overnight at 4C before incubation with the cells. Arrows indicate oligodendrocytes. 
Arrowheads indicate astrocytes. Bar = 20 µm.  
 
The decrease in Nogo-A observed at DIV16 was not due to a reduction in the number 
of cortical neurons present as a result of cell death. This is deduced from the fact that 
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the expression level of Tuj, which is a marker for neurons, was maintained at DIV16. 
The results suggested that Nogo-A may have a role during the differentiation of 
cortical neurons, with its levels downregulated at a late stage of neuronal maturation.  
 
 
Fig 3.7 Nogo-A expression during cortical neuronal differentiation. 15 µg of 
cortical neuronal lysates obtained at DIV0-DIV16 were run on an 8% SDS-PAGE gel 
and western blotted with Ng1V2 antibodies for Nogo-A. Tuj was blotted to act as a 
loading control for neurons. 
 
 To illustrate that Nogo-A was indeed present in the two CNS cell types 
physiologically, and not an artefact as a result of manipulation of the primary cultures 
in vitro, spinal cord parasagittal cryosections were immunostained for Nogo-A and 
the individual neuronal (Tuj), oligodendrocytic (CNPase) and astrocytic (GFAP) 
markers. As shown in Fig 3.8A, for the white matter of the spinal cord, there were 
some degree of co-localization of Nogo-A and Tuj at the myelinated axons (upper 
panel; block arrows). The oligodendrocytes also showed staining of Nogo-A by the 
co-localization of Nogo-A and CNPase at the cell bodies (middle panel; arrows). As 
expected, no co-labelling of astrocytes was observed (lower panel; arrowheads). 
Hence, Nogo-A expression was confirmed to be localized only to the neurons and 
oligodendrocytes but not astrocytes.  
 Interestingly, when spinal cord sections were labelled for Kv1.2 (K
+
) channels, 
which are selectively localized at the juxtaparanodes, it was observed that some of 
Nogo-A‟s expression was found located just beside the K+ channels‟ staining at the 
side nearer to the node of Ranvier, as pointed out by the arrows (Fig 3.8B). This 
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suggested that Nogo-A may possibly be enriched at the paranodal region of the axon-
glial junction. Further studies on this connection are reported in the next chapter.  
 
 
Fig 3.8 Nogo-A was present in the neurons, especially at the paranodes, and 
oligodendrocytes of the spinal cord. (A) Adult C57BL/6 mouse spinal cord 
parasagittal sections (20 µm thick) were immunostained with Ng1V2 (green) and 
anti-Tuj (upper panel), anti-CNPase (middle panel) or anti-GFAP (lower panel) (red) 
antibodies, followed by secondary antibodies conjugated with FITC and TxR. 
Hoechst 33342 was used to stain the nuclei. Block arrows indicate axons. Arrows 
indicate oligodendrocytes. Arrowhead indicates astrocyte. (B) Adult C57BL/6 mouse 
spinal cord parasagittal sections were incubated with Ng1V2 (green) and anti-K
+
-
channels (red) antibodies, followed by FITC- and TxR-conjugated secondary 
antibodies. Arrows indicate the paranodes. Bar = 20 µm. 
 
3.4 Discussion – Localization of Nogo-A and the implicated functions 
 We have generated specific antibodies for Nogo-A. The antibodies could 
detect endogenous Nogo-A in cells (at the ER and plasma membrane) and in the adult 
CNS tissues (brain and spinal cord). In addition, we showed that Nogo-A expression 
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was present in the rat brain from E18 all the way to adulthood. Similar observations 
have been made by others (Meier et. al., 2003).  
 Within the CNS, Nogo-A expression was present in both oligodendrocytes and 
neurons but strikingly absent in astrocytes. Nogo-A in adult CNS has been known to 
be associated with myelin to inhibit neuronal regeneration. Therefore, the neuronal 
expression of Nogo-A seems counterintuitive. With regards to this, Nogo-A on adult 
neurons may have other functions that were previously unsuspected.  One of these 
functions could be neuroprotection, which will be looked into in chapter 5.  
Most interestingly, Nogo-A was found to be enriched at the paranodes at the 
node of Ranvier. This observed staining in mouse closely resembled that observed in 
rat (Nie et. al., 2003), and this further strengthened the notion that Nogo-A is enriched 
at the paranode. The role of Nogo-A enriched at this location will be further probed in 
the following chapter. 
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Chapter 4 Studies on the interacting proteins of Nogo-A  
 The Nogo-A specific antibodies that we have developed have allowed us to 
investigate the interaction between Nogo-A and two of its interacting partners. The 
two are namely the paranodal Caspr, and RTN3. These studies are described below. 
 
4.1 Interaction of Nogo-A with Caspr, a paranodal marker 
 The observation that Nogo-A was enriched at the paranodes (Fig 3.8B) 
implied a possible function or activity of Nogo-A at the site. As Nogo-A at the 
paranodal region is most likely located at the oligodendroglial membrane, it is 
possible that there is a neuronal interacting partner for it at the axon-glia junction. The 
best-known receptor for Nogo-A, NgR, is not found to be enriched or even localized 
at the paranodes. As such, paranodal Nogo-A is unlikely to act by engaging NgR.  
 Caspr, a transmembrane protein which has an extracellular domain comprising 
of laminin-G-like domains and EGF repeats, is specifically localized at the paranodes 
on the neuronal membrane. Together with F3/contactin, Caspr has been shown to 
interact in trans with 155-kDa isoform of neurofascin (NF 155), which is on the 
oligodendroglial membrane, for the maintenance of the axoglial architecture at the 
paranodes (Charles et. al., 2002). We, in collaboration with Dr Xiao Zhi Cheng‟s 
laboratory (Singapore General Hospital), have therefore investigated whether Caspr 
could function similarly by acting as Nogo-A‟s receptor at the paranodes and also 
Nogo-A‟s possible role at this location. While the work by Dr Xiao‟s group was 
performed in rats (Nie et. al., 2003), we have focused our study in mice, as this model 
could draw benefit from comparative studies in the Nogo-deficient mouse model that 




4.1.1 Nogo-A co-localizes with Caspr at the paranodes 
 To determine if Caspr may be the neuronal receptor for paranodal Nogo-A, we 
first proceeded to confirm the localization of Caspr at the paranodes. An IHC staining 
of adult mouse spinal cord was carried out to double-label for Caspr and K
+
 channels 
at paranodes and juxtaparanodes respectively (Fig 4.1A). As seen in the merge panel 
in the figure, the paired red staining of Caspr were juxtaposed next to each paired 
green staining of K
+
 channels at the side proximal to the node. This confirms the 
paranodal localization of Caspr. 
 In order to check if Nogo-A and Caspr co-localized at paranodes, a similar 
IHC staining was performed with co-labelling of Nogo-A and Caspr. Fig 4.1B showed 
clear co-localization of these two proteins at the paranodes (arrows). Clear co-
localization in all paranodal regions that were in view was not observed. This is 
probably due to the fact that it may not be topologically possible to see all of Nogo-
A‟s signal, which was present in the inner- and outer-most layers of the myelin sheath 
wrapping around the axons, to coincide with that of Caspr in a spinal cord cryosection 
that was only 20 µm thick.  
 
4.1.2 Nogo-A co-immunoprecipitates with Caspr 
 To assess if Caspr is indeed a binding partner for Nogo-A, a co-IP experiment 
was conducted to check for their possible interaction in vitro (Fig 4.2). CHO cells 
stably expressing Caspr and F3/contactin (CHO Caspr/F3) were used to transiently 
express Nogo-A for this purpose. The expression of F3/contactin in the above 
mentioned double-stable cell-line was essential for the proper transport of Caspr to the 
cell surface (Faivre-Sarrailh et. al., 2000). It was also advantageous to use stable cell-




Fig 4.1 Nogo-A co-localized with Caspr at the paranodes. (A) Adult C57BL/6 
mouse spinal cord parasagittal sections (20 µm thick) were immunostained with anti-
Caspr (red) and anti-K
+
 channels (green) antibodies overnight, followed by secondary 
antibodies conjugated with TxR and FITC respectively. (B) Adult C57BL/6 mouse 
spinal cord parasagittal sections (20 µm thick) were immunostained with Ng1V2 (red) 
and anti-Caspr (green) antibodies overnight, followed by secondary antibodies 
conjugated with TxR and FITC respectively. Arrows in the merge panel point to clear 
cases of Nogo-A-Caspr co-localization, which appears yellow. Bar = 20 µm. 
 
expressing both of the proteins of interest. In comparison, we have noticed that the 
efficiency of having both proteins expressed in the same cells was much lower when 
the two were introduced together by transient transfection.  
The results showed that Ng1V2 antibodies could co-IP Caspr, suggesting that 
Nogo-A and Caspr could interact with each other when co-expressed in cells. The 
reciprocal co-IP experiment, using our “home-made” Caspr antibodies (refer to Fig 
4.3 for the antigenic region and the antigen‟s molecular weight), was attempted, but 
we did not have much success in co-precipitating Nogo-A (data not shown). One 
possible reason for this is that the antibodies we have generated against Caspr did not 
IP well. Another could be that the Caspr antibodies were blocking the interaction 
site/s between the two proteins. However, that Nogo-A and Caspr could be co-IP by 
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the Ng1V2 antibodies is indicative of a possible interaction between the two proteins 
in vivo.  
 
 
Fig 4.2 Nogo-A co-IP Caspr. CHO Caspr/F3 stably expressing cells were transiently 
transfected with untagged Nogo-A construct using Lipofectamine 2000 for 48 hr. 1.5 
mg of the lysates were then incubated with rabbit IgG (anti-IgG) as negative control 
or Ng1V2 (anti-Nogo-A) antibodies overnight before addition of protein A sepharose 
beads for 2 hr. The samples were resolved on an 8% SDS-PAGE gel and western-
blotted with anti-Caspr antibodies. Input was 1/15 of the amount used for co-IP. 
 
4.1.3 Nogo-66, in its entirety, is essential for Nogo-A’s interaction with Caspr 
 Caspr shares 50% similarity with another paralogue, Caspr 2. We asked if 
Nogo-A could interact with Caspr 2 as well. We have therefore also generated 
antibodies against Caspr 2 (see chapter 2).The amino acid sequence alignment of the 
two Caspr homologues, and the antigenic regions (boxed in blue) used for generating 
the two antibodies, are depicted in Fig 4.3A. The Caspr and Caspr 2 fragments were 
fused to GST and their respective sizes were approximately 37 and 34 kDa (Fig 4.3B). 
 For Nogo-A (on oligodendrocyte) and Caspr (on neuron) to interact in trans, 
the site on Nogo-A that may potentially interact with Caspr would likely be the Nogo-
66 domain which is postulated to face the extracellular region. To investigate this, an 
in vitro GST pull-down assay was performed using GST tagged Nogo-66 to check for 
any interaction with Caspr, employing the CHO Caspr/F3 stable cell-line which we 





Fig 4.3 Antigenic regions for Caspr and Caspr 2 antibodies. (A) Alignment of 
human Caspr and Caspr 2 using COBALT Multiple Alignment Tool from NCBI 
website (www.ncbi.nlm.nih.gov). Antigenic regions used for generation of the two 
antibodies are boxed in blue. (B) 2 µg of GST, GST-Caspr and GST-Caspr 2 were 
resolved on a 9% SDS-PAGE gel which was stained by Coomassie Blue to check for 






Fig 4.4 The entire Nogo-66 was required to pull-down Caspr. (A) 1.5 mg of 
lysates from CHO Caspr/F3 cells (left) or HEK293 cells transiently expressing Caspr 
2 (right) were incubated with 20 µg of GST as negative control or GST-Nogo-66 
bound to glutathione sepharose beads overnight. The beads collected were resolved on 
an 8% SDS-PAGE gel and western-blotted with anti-Caspr (left) or anti-Caspr 2 
(right) antibodies. Input was 1/20 of the amount used for the GST pull-down assays. 
(B) Amino acid sequences (top) and GST fusion protein sizes by Coomassie Blue 
staining (bottom) of Nogo-35, -40 and -66. (C) 20 µg of GST-Nogo-35, -40 and -66 
were incubated with 1.5 mg of CHO Caspr/F3 lysates and the samples were similarly 
checked as stated in (A) with anti-Caspr antibodies. GST proteins were used as 
negative control. Input was 1/30 of the amount used for the GST pull-down assays. 
 
66 could pull-down Caspr (left) but not Caspr 2 (right), illustrating that the Nogo-66 
domain was essential and sufficient for Nogo-A to however, that the pull-down assay 
for Caspr 2 was performed using lysates of HEK293 cells transiently transfected with 
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an untagged Caspr 2 construct. There remains, of course, the possibility that 
coexpression of Caspr 2 with F3 is required for its interaction with Nogo-66. 
Is the entire Nogo-66 domain required for the interaction with Caspr? To 
answer this, two truncation products of the Nogo-66 domain, Nogo-35 and -40, were 
generated tagged to GST. Their amino acid sequences are listed in Fig 4.4B alongside 
that of Nogo-66, together with their protein sizes in the gel image shown below the 
sequences. Although Nogo-35 is shorter than Nogo-40 in terms of the number of 
amino acids, the size of its GST fusion protein is actually larger than that of GST-
Nogo-40, probably because of differences in molecular shape. As above, GST pull-
down assays were performed using these GST fusion proteins. Interestingly, only 
GST-Nogo-66 but not the other two shorter forms, GST-Nogo-35 and -40, could pull-
down Caspr (Fig 4.4C). This suggested that the entire Nogo-66 domain was likely 
required for the interaction between Nogo-A and Caspr. 
 
4.1.4 Expression of Nogo-A and Caspr during development 
 Nogo-A has been shown earlier in section 3.2 (Fig 3.4) to be expressed in the 
brain from E18 to adulthood. To understand if Nogo-A and Caspr could function 
together during any stage of brain development, a check on Caspr‟s expression during 
this same period was performed.  
As seen in Fig 4.5, Caspr expression was barely detectable during embryonic stage 
(E18) up to P4 where the protein levels began to be upregulated, and maintained 
during adulthood. This implied that Nogo-A could possibly interact with Caspr only 
from P4 onwards. A Nogo-A-Caspr interaction may therefore have a postnatal 




Fig 4.5 Expression of Caspr during brain development. 80 µg of rat brain lysates 
obtained from different developmental stages (Embryonic day (E) 18, postnatal days 
(P) 1, 4 and 10, and postnatal months (m) 1, 2, 4 and 6) were resolved on an 8% SDS-
PAGE gel and western blotted with anti-Caspr antibodies, using -tubulin as a loading 
control.  
 
4.1.5 Nogo-A is not essential for the architecture organization at the node of 
Ranvier 
 The presence of Nogo-A at axo-glial junctions at the paranodes and its 
interaction with Caspr suggests a possible function for Nogo-A in the formation, or 
stabilization, of the architecture organization at the axo-glial junctions at the node of 
Ranvier. That Nogo-A is important for the formation of axo-glial junctions seems 
unlikely judging from the results obtained in the previous section. Nevertheless, 
Nogo-A may still be important in the second function. Specific segregation of 
proteins in the different domains at the node of Ranvier, such as Na
+
 channels at the 
node, Caspr at the paranode, and K
+
 channels and Caspr 2 at the juxtaparanode, 
requires tight regulation. It is possible that Nogo-A may somehow be involved in this.  
To investigate if Nogo-A plays an important role in this regard, wild type 
C57BL/6 and Nogo-deficient mice were examined for any differences in the 
placement of Caspr and K
+
 channels at the paranodes and juxtaparanodes 
respectively. Spinal cord cryosections were double-labelled for Caspr and K
+
 
channels (Fig 4.6A) and the distance between pairs of staining for each of the markers 
at each node of Ranvier was measured. Nogo-A expression was confirmed to be 
absent in the Nogo-deficient mouse spinal cord as evident by the lack of Nogo-A 
staining as compared to the wild type one (extreme right panel). As shown in Fig 
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4.6B, there were no significant differences in the distances of the two markers 
measured between wild type and Nogo-deficient mice. For Caspr, the distance 
between the pair of paranodal staining was at a 95% confidence interval of 0.84 ± 
0.06 µm for wild type mouse, while that of Nogo-deficient mouse was 0.82 ± 0.06 
µm. At the same confidence level, the distance between the paired juxtaparanodal 
labelling for K
+
 channels at each node of Ranvier for wild type mouse was 4.38 ± 
0.29 µm, while for Nogo-deficient mouse, the distance was 4.56 ± 0.25 µm. The 
absence of Nogo-A in mice therefore did not significantly affect the spatial 
organization of Caspr and K
+
 channels at the node of Ranvier. Hence, Nogo-A may  
  
 
Fig 4.6 Nogo-A did not affect the architecture organization at the node of 
Ranvier. (A) Adult C57BL/6 and Nogo-deficient mouse spinal cord parasagittal 
sections (20 µm thick) were immunostained with anti-Caspr (red) and anti-K
+
 
channels (green) antibodies overnight, followed by secondary antibodies conjugated 
with TxR and FITC respectively. Note that for the extreme right panel, a separate 
section was used to label with Ng1V2 antibodies (red) for checking of Nogo-A 
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expression. Bar = 20 µm. (B) The distances between each paired staining of Caspr or 
K
+
 channels in the immunolabelled sections were measured using the AxioVision 
software and presented in the graph (mean ± sd, n = 3).  
 
not have an essential role to play in establishing and maintaining the architecture 
organization at the axo-glial junctions at the node of Ranvier. 
 
4.2  Interaction of Nogo-A with RTN3, a fellow member of the Reticulon 
family  
 RTN3 is another reticulon family member which is found to be highly 
enriched in the brain, although its expression is present in other tissues as well. An 
earlier report had suggested an interaction between RTN3 and Nogo-B (Qi et. al., 
2003), at least in vitro. Since Nogo-A, like RTN3, is also expressed in neurons, their 
interaction may have a more physiological meaning than that between Nogo-B and 
RTN3. We therefore proceeded to investigate the possible interaction between Nogo-
A and RTN3. 
 
4.2.1 Nogo-A co-localizes with RTN3 at ER 
 As Nogo-A and RTN3 belong to the same Reticulon family, the domain 
structure of RTN3 is rather similar to that of Nogo-A. The RHD domain contains a 
66-aa hydrophilic loop sandwiched between TM1 and TM2, and it also harbors a 
dilysine motif at the C terminus (Fig 4.7A).   
To confirm the localization, or co-localization of the two RTNs, ICC analysis 
was carried out by simultaneous staining of Nogo-A and RTN3 using a SH-SY5Y cell 
line stably expressing Nogo-A and transiently transfected with a HA tagged RTN3 
expression construct. Fig 4.7B confirmed that the two proteins co-localized 





Fig 4.7 Nogo-A co-localized with RTN3 at the ER. (A) Sequence and domain 
structure of RTN3. TM domain 1 (TM1) and 2 (TM2) are indicated by the purple 
boxes and the 66 loop is boxed in red. The ER-retention signal is outline in the green 
box. (B) SH-SY5Y Nogo-A (38) stable cells transiently transfected with HA-RTN3 
were fixed with 4% PF, permeabilized with 0.05% saponin and incubated with 
Ng1V2 (green) and anti-HA (red) antibodies, followed by FITC- and TxR-conjugated 
secondary antibodies. Bar = 20 µm. 
 
4.2.2 Nogo-A co-immunoprecipitates with RTN3 
 To ask if Nogo-A could interact with RTN3, CHO cells stably expressing 
Nogo-A (CHO Nogo-A) were transiently transfected with myc tagged RTN3, and co-
IP assays were performed. Myc-RTN1 and 2 were also transiently expressed in this 
stable cell-line, and co-IP between Nogo-A and these two reticulons were 
concurrently carried out.  
 As shown in Fig 4.8A, Ng1V2 antibodies could co-IP all three fellow 
reticulons, RTN1, 2 and 3, but to different extents. Nogo-A was able to interact with 
RTN3 much better than RTN1 and 2, as evident by the denser RTN3 band co-
immunoprecipitated. A greater proportion of RTN3 was pull-downed by the same 
amount of Ng1V2 antibodies given that the starting amount of RTN1, 2 or 3 present 
in the lysates was about the same, judging from intensities of the input lanes. In fact, 
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the interaction between Nogo-A and RTN1 or 2 could be negligible, with Nogo-A 
immunoprecipitating less than 1% of RTN1 or RTN2 present in the lysates. This 
observation was corroborated by the reciprocal co-IP where 9E10 myc monoclonal 
antibodies pulling down myc-RTN3 co-immunoprecipitated significantly more Nogo-
A than RTN1 and 2 (Fig 4.8B). Hence, Nogo-A appears to interact with RTN3 with 
unusually high affinity compared to the other two reticulon family members, RTN1 
and RTN2.  
 
 
Fig 4.8 Nogo-A co-IP RTN3 to a better extent than with RTN1 and 2. (A) 1.5 mg 
of lysates from CHO Nogo-A stable cell-line transiently expressing myc-RTN1, 2 and 
3 were incubated with rabbit IgG (rIgG) as a negative control or Ng1V2 (anti-Nogo-
A) antibodies overnight before incubation with protein A sepharose beads for 2 hr. 
Vector control (v.c.) was CHO Nogo-A cells transiently transfected with pDmyc. A 
10% SDS-PAGE gel was run and western blotting using 9E10 antibodies (anti-myc) 
was performed. Input was 1/100 of the amount used for co-IP. (B) Using the same 
lysates as stated in (A), a similar experimental set-up as described in (A) was 
performed, except that the co-IP was performed using mouse IgG (mIgG) as a 
negative control or 9E10 (anti-myc) antibodies. The samples were resolved on an 8% 
SDS-PAGE gel and western blotting using Ng1V2 antibodies (anti-Nogo-A) was 
carried out. Input was 1/50 of the amount used for co-IP. 
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4.2.3 The region from TM1 to TM2 of Nogo-A is necessary for its interaction 
with RTN3 
 After confirming that Nogo-A was able to interact with RTN3 specifically by 
reciprocal co-IP analyses, it was of interest to determine the region on Nogo-A which 
was necessary for its interaction with RTN3. In order to delineate the domains that 
were important, several truncation expression constructs were generated to check if 
their interactions with RTN3 were impaired. For this purpose, HEK293 cells were 
transfected to generate a stable cell-line expressing full-length HA tagged RTN3 
(HEK293 HA-RTN3). HEK293 cells were used as these cells were well known for 
their high transfection efficiency. In addition, this provided a cell system that is 
different from the CHO cells employed in section 4.2.2 above (which were used to 
confirm Nogo-A and RTN3 interaction), thereby allowing us to find out if Nogo-A 
and RTN3 could interact with each other in more than one type of cellular 
environment. 
 HEK293 HA-RTN3 cells were transiently transfected with myc tagged 
truncated Nogo-A constructs (as illustrated in Fig 4.9A) and their lysates were used to 
perform reciprocal co-IP assays, with HA-RTN3 immunoprecipitating myc-truncated 
Nogo-A (Fig 4.9B) and vice versa (Fig 4.9C). As seen in the co-IP result presented in 
Fig 4.9B, HA-RTN3 was able to immunoprecipitate full-length Nogo-A (A fl), -B (B 
fl) and truncated Nogo-A without the cytoplasmic domain (A(-cyto)) to a similar 
extent. However, the absence of TM1 (A(-TM1)) in Nogo-A caused a reduction in the 
amount of HA-RTN3 immunoprecipitated. It was interesting to note that, in contrast, 
the truncation of TM2 (A(-TM2)) did not affect Nogo-A‟s interaction with RTN3 as 
much. This was inferred from the amount of input and proportion of RTN3 
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immunoprecipitated. Removal of the whole RHD (A(-TMS)) led to a complete loss of 
interaction between Nogo-A and RTN3.  
 The reciprocal co-IP results in Fig 4.9C showed similar findings as Fig 4.9B 
for all the Nogo-A truncation proteins, except for that of A(-cyto). For A(-cyto), there  
 
 
Fig 4.9 The region from TM1 to TM2 of Nogo-A was necessary for its interaction 
with RTN3. (A) Schematic diagram of the Nogo-A truncated proteins generated. (B) 
1.5 mg of lysates from HEK293 HA-RTN3 cells transiently expressing myc-truncated 
Nogo-A proteins were incubated with anti-HA antibodies (anti-HA) for co-IP. Vector 
control (v.c.) was HEK293 pDHA stable cells transiently transfected with full-length 
myc-Nogo-A. The samples were run on an 8% SDS-PAGE gel and western blotting 
was carried out with 9E10 antibodies (anti-myc). Input was 1/20-50 of the amount 
used for co-IP. (B) Using the same lysates as stated in (A), a similar experimental set-
up as described in (A) was performed, except that the co-IP was performed using 
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9E10 (anti-myc) antibodies. Vector control (v.c.) was HEK293 HA-RTN3 cells 
transiently transfected with pDmyc. A 10% SDS-PAGE gel was run and western 
blotting using anti-HA antibodies (anti-HA) was performed. Input was 1/50 of the 
amount used for co-IP. 
 
was instead an increase in the amount of HA-RTN3 immunoprecipitated. This 
anomaly could not be explained. 
The results obtained therefore suggested that the region on Nogo-A from TM1 
to TM2, including the Nogo-66 domain, was necessary for the interaction between 
Nogo-A and RTN3, with TM1 playing a more important role in the interaction with 
RTN3 than TM2. The role of Nogo-66 domain in this interaction could not be 
excluded. 
 
4.2.4 Both TM domains and possibly the N-terminus of RTN3 is involved in its 
interaction with Nogo-A 
 The findings from the previous section have delineated the domains on Nogo-
A which played a part in the binding with RTN3. Will the similar domains on RTN3 
be enough for its interaction with Nogo-A, or other parts of RTN3 may also be 
involved as well? To this end, truncation constructs of RTN3 were generated and as 
described earlier, the truncated proteins (depicted in Fig 4.10A) were transiently 
expressed and checked for their binding with full-length Nogo-A using HEK293 cells 
with stable expression of Nogo-A (HEK293 Nogo-A). 
  In Fig 4.10B, where Ng1V2 antibodies immunoprecipitated Nogo-A and co-
IP of truncated RTN3 was investigated, the lack of the N-terminus (3 (-N)), TM1 (3 (-
TM1)) and TM2 (3 (-TM2)) resulted in a decrease in the amount of the truncated 
RTN3 protein immunoprecipitated by Nogo-A. The removal of both TM domains (3 
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(-TMS)) caused a complete loss of interaction with Nogo-A. We arrived at the same 
conclusion from the reciprocal co-IP experiment as shown in Fig 4.10C.    
 
 
Fig 4.10 Both TM domains were essential for RTN3’s interaction with Nogo-A. 
(A) Schematic diagram of RTN3 truncation proteins used. (B) HEK293 Nogo-A cells 
were transiently transfected with HA-truncated RTN3 constructs and 1.5 mg of these 
lysates were incubated with Ng1V2 antibodies (anti-Nogo-A) for co-IP. Vector 
control (v.c.) was HEK293 pCIneo stable cells transiently transfected with full-length 
HA-RTN3. The samples were run on a 12% SDS-PAGE gel and western blotting was 
carried out with anti-HA antibodies (anti-HA). Input was 1/13.33-100 of the amount 
used for co-IP. (B) Using the same lysates as stated in (A), a similar experimental set-
up as described in (A) was performed, except that the co-IP was performed using anti-
HA (anti-HA) antibodies. Vector control (v.c.) was HEK293 pDHA cells transiently 
transfected with full-length Nogo-A. An 8% SDS-PAGE gel was run and western 
blotting using Ng1V2 antibodies (anti-Nogo-A) was performed. Input was 1/40 of the 
amount used for co-IP. 
 
Taken as a whole, the results suggested that both the TM domains worked in 
conjunction in the interaction of RTN3 with Nogo-A, since removal of one of the TM 
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domains only led to a reduction in interaction while removing both regions caused 
RTN3 to totally be unable to interact with Nogo-A. It could also be possible that the 
TM domains were necessary for RTN3 to be localized at the ER so as to be in close 
proximity with Nogo-A for their interaction to occur. Interestingly, the N-terminus 
may also play a supplementary role in RTN3‟s binding to Nogo-A. 
  
4.3 Discussion – Nogo-A’s interaction with Caspr and RTN3 
 The function of Nogo-A at the paranodes, first highlighted at the end of 
chapter 3, was further studied in this chapter. Nogo-A was found to co-localize and 
interact with the paranodal Caspr. The interaction between the two proteins appeared 
to involve, and require the entire Nogo-66 domain of Nogo-A. An investigation on the 
expression of Caspr during brain development revealed a postnatal expression time 
for Caspr. This implies that any functional interaction between Nogo-A and Caspr 
likely occurs in postnatal stages, and not during embryonic development. This notion 
is also supported by the fact that neither Caspr nor Nogo knockout mice are 
embryonic lethal or have severe developmental defects.  
 As Caspr has been implicated to play an important role in the molecular 
organization at the node of Ranvier, we hypothesized that Nogo-A could also be 
involved in a similar function. However, a detailed investigation on the architectural 
organization at the node of Ranvier in Nogo-deficient mice showed no significant 
changes to the different domains at the node of Ranvier. We examined closely the 
spatial localization of Caspr and K
+
 channels and found no significant differences 
between these in Nogo-deficient mice compared to wild type. At the moment, the 




 We also studied the interaction between Nogo-A and fellow members of the 
reticulon family. Co-IP experiments revealed that Nogo-A had an unusually high 
affinity for RTN3 compared to RTN1 and RTN2. From the molecular dissection 
analysis, their interactions required at least one of the two TM domains. Loss of both 
TM domains led to a complete loss of interaction between the two RTNs. The 
possible implications of the interaction between Nogo-A and RTN3, particularly in 
neurons will be discussed further in chapter 7. 
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Chapter 5 Nogo-A and other isoforms are protective against  
a variety of apoptotic insults     
 In the previous chapters, we have presented data indicating the presence of 
Nogo-A in neurons, and its interaction with Caspr and RTN3. All these results appear 
to have little, if anything, to do with Nogo-A‟s classical function as a myelin-
associated inhibitor. We have pondered on the possible physiological (as opposed to 
pathological) roles of Nogo-A in neurons. In particular, we ask what the cell 
autonomous function of the Nogo-A expressed in neurons may be. Interestingly, other 
workers in the laboratory have observed that Nogo-A levels are upregulated in 
neuronal cell bodies (but not obvious in oligodendrocytes) after spinal cord injury or 
brain ischemia induced by middle cerebral artery occlusion. Similar observations of 
Nogo-A upregulation in some CNS injuries have also been made by others (Eslamboli 
et. al., 2006; Marklund et. al., 2006; Meier et. al., 2003; Wang et. al., 2002c; Wang 
et. al., 2006).  
 We reason that this Nogo-A upregulation is a result of transcription profile 
changes of neurons at the site of injury, largely by those spared from immediate 
demise resulting from the injuries. If so, Nogo-A‟s elevated expression could simply 
be a result of co-elevation together with other injury response genes, and this 
elevation has no real purpose, but could instead result in an inhibition of regeneration 
at a later stage. Alternatively, Nogo-A may have a hitherto unappreciated role in 
neuronal survival, and its elevation could be part of a protective mechanism against 





5.1  Generation of SH-SY5Y cell-lines stably and moderately overexpressing 
Nogo-A, -B, -C and RTN3  
 To facilitate investigations on the cell autonomous function(s) of Nogo-A, SH-
SY5Y cell-lines stably expressing Nogo-A (SH-SY5Y Nogo-A) were generated. This 
neuroblastoma cell-line was chosen because it is a popular cell culture model for 
various “neuronal” processes such as neuritogenesis, neurotransmitter secretion, as 
well as neuronal cell death. Additionally, it has low Nogo-A levels. This is potentially 
advantageous as any effects on survival of the cells could be clearly observed upon 
manipulation of Nogo-A levels. For comparison, SH-SY5Y vector control 
(transfected with empty vector), Nogo-B, Nogo-C and RTN3 stably expressing cells 
were also created. Nogo-B and -C stables serve to check Nogo-A‟s specificity in 
protection, if any. RTN3 is included in the analysis to gauge if any effect seen with 
Nogo-A could be extrapolated to the other members of the RTN family.  
 A stable clone harbouring the empty vector and two stable clones each for the 
other constructs were selected and used for subsequent investigations. Expression 
levels of the stably expressing proteins were shown in Fig 5.1A, using -tubulin as a 
loading control. Both the different clones of Nogo isoforms and RTN3 showed 
varying levels of moderate protein expression. However, high expression as 
determined by western blot does not necessary correlate to a high percentage of 
expressing cells. Hence, ICC was performed in addition to visually gauge the 
percentage of cells stably overexpressing the transgenes (Fig 5.1B). A good majority 
(>85%) of the cells of the two SH-SY5Y Nogo-A stable clones, 16 and 38, were 
expressing Nogo-A. The stable cell-lines for Nogo-B (11 and 35), Nogo-C (1 and 23) 
and RTN3 (11 and 20), however, showed lower percentages of cells stably expressing 
their respective transgenes. 
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As clonal differences were not significant, only results of a representative 
clone each for Nogo-C and RTN3, which were acting as controls, would be presented 
in the subsequent sections.  
 
 
Fig 5.1 Stable protein expression profiles in SH-SY5Y stable cell-lines. (A) 20 µg 
of lysates from SH-SY5Y vector control (v.c.), Nogo-A (16, 38), -B (11, 35), -C (1, 
23) and RTN3 (11, 20) stable cell-lines were resolved on a 10% SDS-PAGE gel. 
Western-blotting was first performed with AR2 rabbit polyclonal antibodies to detect 
Nogo-A, -B and -C proteins. The membrane was subsequently probed with anti-
RTN3 or anti-γ-tubulin antibodies. (B) SH-SY5Y Nogo-A (16, 38), -B (11, 35) and -
C (1, 23) cells were fixed with 4% PF and permeabilized with 0.05% saponin/PBS. 
They were then incubated with AR2 antibodies, followed by FITC-conjugated 
secondary antibodies. For RTN3 stable cells (11, 20), they were fixed in ice-cold 
methanol before incubation with anti-RTN3 antibodies followed by secondary 





5.2 All three major Nogo isoforms and RTN3 protect against serum 
withdrawal-induced cell death 
 Serum withdrawal denies SH-SY5Y cells of essential growth factors and is 
known to cause cell death by apoptosis (Macleod et. al., 2001). To find out if Nogo-
A, -B, -C and RTN3 could modulate this apoptotic insult, the cells, together with the 
vector control cells, were subjected to serum deprivation (0% FBS) for 48 hr before 
PI staining and flow cytometry analysis.  
 Fig 5.2A showed the cell cycle profiles of these cell-lines after 48 hr of serum 
withdrawal. Proportion of cells dying by apoptosis is represented by the percentage of 
the sub G1 population, and was depicted in the graph and table in Fig 5.2B and C 
respectively. Vector control cells (v.c.) displayed a 95% confidence interval of 14.47 
± 1.51% for sub G1 population with a corresponding decrease in G1 population as 
seen from its cell cycle profile in Fig 5.2A, as compared to 4.6 ± 0.23% for its sub G1 
population at 0 hr. Comparatively, the sub G1 populations for all Nogo isoforms 
(Nogo-A 7.17-7.63%; Nogo-B 7.37-9.1%; Nogo-C 7.87%) and RTN3 (7.57%) 
expressing cells were significantly lower than vector control cells after serum 
deprivation (Fig 5.2B), and did not show as much an increase in their sub G1 
population as compared to their respective untreated cells at 0 hr (Fig 5.2C). 
Interestingly, as judged from the DNA content profile, Nogo-C expressing cells 
seemed to behave in a different manner from those expressing Nogo-A, -B and RTN3, 
with an increase in S phase-arrested cells instead of the typical G1 arrest exhibited by 
the other three RTNs (Fig 5.2A).  
 In any case, all Nogo isoforms and RTN3 appear to exert a significant degree 
of protection in SH-SY5Y cells from cell death induced by serum withdrawal/removal 




Fig 5.2 All Nogo isoforms and RTN3 protected SH-SY5Y against serum 
withdrawal-induced cell death. SH-SY5Y vector control (v.c.), Nogo-A (16, 38), -B 
(11, 35), -C (1) and RTN3 (11) cells were serum deprived for 48 hr before the cells 
were stained with PI and analysed by flow cytometry using FACS Canto II. Data is 
representative of three independent experiments. (A) Cell cycle profiling of the stable 
cell-lines after 48 hr of serum withdrawal using ModFit v2.9. (B) % of sub G1 
population in the serum-deprived stable cell-lines at 48 hr (mean ± sd, n = 3). *** P < 
0.01 compared with v.c. (C) The 95% confidence interval of sub G1 population of the 
stables when untreated at 0 hr and after 48 hr of serum withdrawal.  
 
5.3 All three major Nogo isoforms and RTN3 protect against staurosporine-
induced cell death 
 Another classical inducer of apoptosis, staurosporine, was tested for its ability 
to cause cell death in these stable cell-lines. Staurosporine is a general protein kinase 
inhibitor, which acts by binding to the kinases and competitively prevents ATP from 
binding. It causes cells to arrest at G2 phase and initiates apoptotic cell death. 
Staurosporine therefore presents a mechanistically different mode of apoptosis 
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induction compared to serum withdrawal, and an arguably harsher one. Cells were 
treated with 0.5 µM of the drug for 48 hr and then analysed for cell death.  
As shown in Fig 5.3, all the cell-lines stably expressing the Nogo isoforms and 
RTN3 have significantly reduced cell death induced by staurosporine, as compared to 
vector control cells. Staurosporine induced half of the population of vector control 
cells to die, achieving a 95% confidence interval of 45.03 ± 1.96% for its sub G1 
population. Comparatively, the Nogo isoforms and RTN3 were able to reduce cell 
death in SH-SY5Y by almost half. SH-SY5Y Nogo-A, -B, -C and RTN3 lines 




Fig 5.3 All Nogo isoforms and RTN3 protected SH-SY5Y against staurosporine-
induced cell death. SH-SY5Y vector control (v.c.), Nogo-A (16, 38), -B (11, 35), -C 
(1) and RTN3 (11) cells were treated with 0.5 µM of staurosporine for 48 hr before 
the cells were analysed by flow cytometry. Data is representative of three independent 
experiments. (A) % of sub G1 population in staurosporine-treated stable cell-lines at 
48 hr (mean ± sd, n = 3). *** P < 0.01 compared with v.c. (B) The 95% confidence 
interval of sub G1 population of the stables when untreated at 0 hr and after 48 hr of 






5.4 Nogo-A, -B and RTN3, but not Nogo-C, protect against etoposide-induced 
cell death  
 To check if the Nogo isoforms and RTN3 could similarly protect against cell 
death caused by DNA damage, the cells were treated with the common anticancer 
drug etoposide. Etoposide inhibits the enzyme topoisomerase II, thereby preventing 
rewinding of the DNA double helix strands and ultimately results in un-repairable 
breaks in DNA.  
The cell-lines were treated with 20 µM of etoposide for 72 hr before 
significant cell death was observed (Fig 5.4). The sub G1 population for vector 
control cells was, at a 95% confidence interval, 55.47 ± 3.3%. Similar to 
staurosporine treatment, Nogo-A, -B and RTN3 expression were able to protect the 
cells against etoposide-induced cell death by half or even more, with the cells 
displaying a sub G1 population of only 15.5-15.83%, 17.7-22.37% and 26.03% 
respectively. A G1/S cell  
   
 
Fig 5.4 Nogo-A, -B and RTN3 protected SH-SY5Y against etoposide-induced cell 
death, but not Nogo-C. SH-SY5Y vector control (v.c.), Nogo-A (16, 38), -B (11, 
35), -C (1) and RTN3 (11) cells were treated with 20 µM of etoposide for 72 hr before 
flow cytometry analysis was carried out. Data is representative of three independent 
experiments. (A) % of sub G1 population in etoposide-treated stable cell-lines at 72 hr 
(mean ± sd, n = 3). *** P < 0.01 compared with v.c. (B) The 95% confidence interval 
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of sub G1 population of the stables when untreated at 0 hr and after 72 hr of etoposide 
treatment.  
 
cycle phase arrest was observed in these cells while no such arrest was seen in the 
vector control cells. Comparatively, Nogo-A seemed to be able to provide the best 
protection. Nogo-C, however, was unable to provide the same protection as the other 
RTNs, with its cells dying almost as much as the vector control cells (~53.3%). 
 
5.5 Nogo-A, -B and RTN3, but not Nogo-C, enhance cell death induced by 
tunicamycin  
 Yet a different kind of cell death-inducing mechanism, this time via the 
induction of ER stress, was investigated in terms of the RTNs‟ protective ability. The 
drug tunicamycin acts by inhibiting N-linked glycosylation of proteins and causes 
proteins to accumulate in ER. This activates the unfolded protein response (UPR) in 
cells, and the prolonged ER stress eventually leads to apoptosis. 
 Cells were subjected to tunicamycin treatment at a concentration of 20 µg/ml 
for 72 hr before they were analysed by flow cytometry. As shown in Fig 5.5, vector 
control cells were actually not dying as yet at the 72 hr time point, with a sub G1 
population of 6.23% that was comparable to that at 0 hr, which was 5.63%. 
Interestingly, Nogo-A, -B and RTN3 stable cell-lines were dying more than that of 
vector control cells. They displayed 12.77-23.27%, 15.83-16.03% and 19.87% sub G1 
population respectively. SH-SY5Y Nogo-C, on the other hand, behaved like the 
vector control cells, with no increase in the sub G1 population at 72 hr when 
compared to 0 hr (5.27%).  
 It is noteworthy that ER stress induced by tunicyamycin resulted in cell death 
that was not protected by Nogo-A, -B and RTN3. Contrasting to the protection they 
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render against the other types of cell death induction described in the preceding 
sections, these reticulons actually enhanced tunicamycin-induced death. 
 
 
Fig 5.5 Nogo-A, -B and RTN3 enhanced SH-SY5Y cell death by tunicamycin 
while Nogo-C had no effect. SH-SY5Y vector control (v.c.), Nogo-A (16, 38), -B 
(11, 35), -C (1) and RTN3 (11) cells were treated with 20 µg/ml of tunicamycin for 72 
hr before cell death analysis was performed. Data is representative of three 
independent experiments. (A) % of sub G1 population in tunicamycin-treated stable 
cell-lines at 72 hr (mean ± sd, n = 3). *** P < 0.01 compared with v.c. (B) The 95% 
confidence interval of sub G1 population of the stables when untreated at 0 hr and 
after 72 hr of tunicamycin treatment.  
 
5.6 Only Nogo-A and -B could protect against H2O2-induced cell death  
Oxidative stress has been touted to be a crucial factor in the causation of many 
neurodegenerative diseases and also in the pathogenesis of cerebral ischemia and 





) and peroxynitrate (ONOO
-
) generated as a result of oxidative 
stress could cause perturbations to the membranes and proteins directly and also 
activate intracellular signalling pathways, eventually leading to neuronal cell death 
(Fatokun et. al., 2008).   
To study if Nogo could also protect against oxidative stress, the stable cell-
lines were treated with stabilized H2O2, which is commonly used to simulate 
oxidative stress in diseases and injuries. Cells were treated with 100 µM of H2O2 for 
102 
 
30 min and washed once to remove any traces of H2O2. The cells were then harvested 
for flow cytometry analysis after 48 hr, counting from point of H2O2 addition. As 
displayed in Fig 5.6, vector control, Nogo-C and RTN3 stable cell-lines all showed a 
similar percentage of sub G1 population (13.23-14.4%) after 48 hr of H2O2 treatment, 
with concomitant decrease in G1 population. However, there was only a slight 
increase in sub G1 population in Nogo-A (3.7%) and -B (5.5-6.97%) stable cell-lines 
as compared to their respective sub G1 population at 0 hr. 
These results suggested that Nogo-A and -B could rather specifically protect 
SH-SY5Y cells from H2O2-induced cell death, while Nogo-C and RTN3 were unable 
to provide the same protection. Interestingly, this indicates that the N-terminus of 
Nogo (which is the difference between Nogo-A/B and Nogo-C) is crucial for the 
protection against oxidative stress by H2O2. This also means that the N-terminus of 
Nogo-B, which is common in both Nogo-A and -B, is probably sufficient for the 
protection rendered by Nogo-A and -B. 
 
 
Fig 5.6 Nogo-A and -B specifically protected SH-SY5Y against H2O2-induced cell 
death. SH-SY5Y vector control (v.c.), Nogo-A (16, 38), -B (11, 35), -C (1) and 
RTN3 (11) cells were treated with 100 µM H2O2 for 30 min before H2O2 was washed 
off and the cells grown in complete RPMI medium until 48 hr from the start of 
addition of H2O2. Analysis of cell death was performed using flow cytometry. Data is 
representative of three independent experiments. (A) % of sub G1 population in the 
H2O2-treated stable cell-lines at the 48 hr time point (mean ± sd, n = 3). *** P < 0.01 
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compared with v.c. (B) The 95% confidence interval of sub G1 population of the 
stables when untreated at 0 hr and after 48 hr of H2O2 treatment.  
 
5.7 Discussion – Nogo-A’s role in neuroprotection 
SH-SY5Y cells with stable and moderate overexpression of Nogo-A, -B, -C 
and RTN3 were subjected to various treatments that induced apoptosis by different 
ways. All the Nogo isoforms and RTN3 were able to protect the cells against serum 
withdrawal and staurosporine. Interestingly, all except Nogo-C were able to provide 
protection against etoposide. The reverse was seen with tunicamycin, where all except 
Nogo-C enhanced cell death induced by the drug. Interestingly, only Nogo-A and -B 
were able to prevent cells from dying when subjected to oxidative stress induced by 
H2O2. 
The differing observations obtained with the various treatments suggest that 
the mechanisms by which the Nogo isoforms and RTN3 confer protection against cell 
death could be fairly complex. Investigations on the possible mechanisms involved in 
protection against the death insults will be elaborated in the next chapter. 
Nevertheless, the protective ability of Nogo-A against a wide range of apoptotic 
insults (except tunicamycin) is clearly illustrated. This has strong implications on the 




Chapter 6 Possible mechanisms involved in Nogo-A’s 
protection against H2O2-induced cell death 
Of all the protective effects and profiles reported in the previous chapter, 
Nogo-A and -B‟s rather specific ability to attenuate apoptosis induction by H2O2 has 
particular pathophysiological relevance. Not only is Nogo-A expressed in CNS 
neurons, but oxidative stress-induced neuronal death in either acute (injury) or chronic 
(neurodegenerative diseases) manners occurs in the CNS in vivo. We therefore chose 
to attempt to investigate the underlying mechanism of Nogo-A‟s protective effect 
against H2O2. 
 
6.1  Protection against H2O2 requires N-terminus of Nogo-A/B  
 As shown in the previous chapter, Nogo-A and -B, but not -C, were able to 
prevent SH-SY5Y cells from dying by H2O2 treatment. This suggested that the the N-
terminal region common to both Nogo-A and -B is the crucial determinant for the 
protective effect.  
To ascertain that this is indeed the case, three other SH-SY5Y stable cell-lines 
expressing Nogo-B tagged/truncation were created: (1) SH-SY5Y HA-Nogo-B, where 
a HA tag was fused to the N-terminus of full-length Nogo-B, (2) SH-SY5Y Nogo-B 
(1-200), which contained only the first 200 aa of Nogo-B and with the RHD domain 
deleted completely, and (3) SH-SY5Y Nogo-B (N-TM1), which contained the N-
terminus portion of Nogo-B up until the first TM domain. A schematic diagram of 
these constructs is depicted in Fig 6.1A. The stable protein expression levels in these 
cells were shown in Fig 6.1B (bottom). 
To investigate if these proteins had any differing effects on survival against 
H2O2, the stable cell-lines were treated the same way with H2O2 as before. As seen in 
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Fig 6.1B (top), HA-Nogo-B (3) exhibited an increase in sub G1 population in a way 
that resembled vector control cells. The former had 18.43% while the latter 16.5%. 
Untagged Nogo-B (11) stable clone, like before, better survived the H2O2 treatment 
(% sub G1 = 7.1%). This suggested that N-terminus fusion with the HA tag had 
attenuated Nogo-B‟s protection against H2O2. One possible explanation for this 
observation could be that a structural change of the N-terminal portion is effected by 
the HA epitope fusion. Interestingly, the other new Nogo-B truncation construct 
expressing stable cell-lines, Nogo-B (1-200) and (N-TM1), were not only not 
protected from H2O2 treatment, but showed a significantly higher increase in sub G1 
population of 20.8% and 24.67% respectively.  
 
 
Fig 6.1 The N terminus of Nogo-B was involved in protection against H2O2-
induced cell death. (A) Domain stucture of the different Nogo-B proteins expressed 
in the various Nogo-B stable cell-lines. (B) (Top) SH-SY5Y vector control (v.c.), 
Nogo-B (11), HA-Nogo-B (3), Nogo-B (1-200) (13.5) and Nogo-B (N-TM1) (6) cells 
were treated with 100 µM H2O2 for 30 min before H2O2 was washed off and the cells 
grown in complete RPMI medium until 48 hr from the start of addition of H2O2. 
Analysis of cell death was performed using flow cytometry. % of sub G1 population 
in the H2O2-treated stable cell-lines at 48 hr was as shown in the graph (mean ± sd, n 
= 3). ** P < 0.05 compared with v.c. *** P < 0.01 compared with v.c. Data is 
representative of three independent experiments. (Bottom) Expression levels of the 
various types of Nogo-B proteins in the stable cell-lines, probed with anti-Nogo goat 




The results suggested that the common N-terminus of Nogo-A/B may be 
important for Nogo-A/B‟s protective function against H2O2. However, this protection 
was exhibited only in a proper context in conjunction with the RHD domain.  
 
6.2 Protection by Nogo-A does not involve classical survival pathways 
6.2.1 Intrinsic differences in classical survival markers in the stable cell-lines 
 We next attempted to understand the underlying mechanism by which Nogo-A 
could protect against cell death induced by H2O2. As many neuroprotective agents act 
by inducing cellular survival pathways, we investigated if RTNs‟ expression in the 
stable cells has resulted in any intrinsic changes to the expression and activity of 
classical pro-survival molecules such as Akt and Erk. GSK3α/β was examined as well 
since it could be phosphorylated by Akt and has an influence on survival. From Fig 
6.2, it was observed that there were no significant differences in the levels of total as 
well as phosphorylated Akt, Erk1/2 and GSK3α/β between vector control and RTN-
expressing stable cell-lines.  
 
 
Fig 6.2 Total and phosphorylated protein levels of Akt, Erk and GSK3α/β were 
unaltered by RTNs’ expression. 50 µg of lysates obtained from SH-SY5Y vector 
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control (v.c.), Nogo-A (A(38)), -B (B(11)), -C (C(1)) and RTN3 (3(11)) were 
resolved on 10% SDS-PAGE gels and western blotted with antibodies against total 
and phosphorylated Akt, Erk1/2 and GSK3α/β. 
 
6.2.2 Activation of Akt and Erk upon H2O2 treatment 
 Although no intrinsic differences were found for the basal levels of total and 
phosphorylated Akt and Erk in the stable cell-lines, it may still be possible that Nogo-
A affects the activation of Akt and Erk by H2O2 thereby resulting in the survival 
effect observed.    
 To investigate this possibility, vector control and SH-SY5Y Nogo-A (38) cells 
were stimulated with 100 µM of H2O2 from 0 to 8 hr and their lysates harvested at 
various time points to check for Akt and Erk phosphorylation. The results were shown 
in Fig 6.3. Phosphorylation levels of Akt increased within 15 min and subsided after 
30 min for both cell types. Phosphorylated Akt continued to decrease to a minimal 
level after 8 hr for vector control cells, but returned to sustained basal levels in Nogo-
A stable cells. Similarly, Erk phosphorylation peaked at 15 min, was reduced by 30 
min and was maintained at a low level in vector control cells. As for Nogo-A cells, 
significant folds of increase in Erk phosphorylation was not observed, but there was a 
drastic reduction during 30 min to 1 hr. The levels of phospho-Erk returned to 
baseline by 2 hr. 
 The ability of Akt phosphorylation to be longer sustained in Nogo-A 
expressing stable cells but not vector control cells suggested that it could confer some 
pro-survival effect. However, the better sustained Akt phosphorylation at later time 
points could also simply indicate normal cell growth after the cells have survived 





Fig 6.3 Akt and Erk activation upon H2O2 treatment. (A) 50 µg of treated lysates 
obtained from SH-SY5Y vector control (v.c.) and Nogo-A (38) were resolved on 8% 
SDS-PAGE gels and western blotted with antibodies against total and phosphorylated 
Akt, Erk1/2, -tubulin and Nogo-A. (B and C) Densitometric measurements of (A) 
and data presented as phosphorylated/total Akt (B) or Erk (C) with respect to 0 hr.  
 
6.2.3 Inhibition of Akt and Erk do not influence Nogo-A’s protective ability 
 To further confirm if Akt and Erk play any roles in Nogo-A‟s protection, cells 
were pretreated with inhibitors of these two kinases. The inhibitors, LY294002 (LY) 
and U0126, act on the upstream regulators of Akt and Erk, namely PI3K and 
MEK1/2, respectively. Cells were pre-treated with 50 µM of LY for 1 hr or 10 µM of 
U0126 for 30 min before H2O2 treatment. Two types of inhibitor treatment regiment 
were carried out. One was a short-term inhibition, where the inhibitor was removed 
together with H2O2 after the 30 min H2O2 treatment. This aimed to answer if 
activation of Akt or Erk induced by H2O2 was important for protection by Nogo-A. 
The second type was a long-term inhibition, where cells were incubated with the 
inhibitor until harvest time. This would answer if the presence of Akt and Erk at the 8 
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hr time point as mentioned in the preceding section could explain the pro-survival 
effect of Nogo-A. 
 Results of Akt inhibition was shown in Fig 6.4. Phosphorylation of Akt at both 
ser473 and thr308 were efficiently blocked by LY, while Erk phosphorylation was 
unaffected (Fig 6.4A). As seen in Fig 6.4B, short-term inhibition of Akt actually made 
the vector cells more susceptible to H2O2-induced death. However, no significant 
changes were observed for Nogo-A stable cells. Long-term inhibition of Akt (Fig 
6.4C) caused G2 arrest in vector control cells, thereby preventing them from dying, 
while no significant differences were seen for Nogo-A cells. Notably, G2 arrest was 
more prominent in vector cells than Nogo-A ones. Another point to note was that 
incubation with LY alone without H2O2 for 48 hr increased cell death in both cells.  
   Erk inhibition did not cause Nogo-A to lose its protective effect as well. The 
Erk inhibitor, U0126, could completely abolish Erk1/2 phosphorylation while not 
affecting phosphorylation of Akt at ser473 (Fig 6.5A). Similar to Akt inhibition, 
inhibition of Erk in a short-term manner induced more vector control cells to die (Fig 
6.5B). This meant that Erk activation by H2O2 did have some protective role in these 
cells. Nogo-A stable cells did not show significant changes in cell death. Long-term 
Erk inhibition also resulted in G2 arrest in both cells, with the arrest more obvious in 
vector control cells than the Nogo-A expressing ones. This inadvertently led to a 
reduction of death in vector cells. As with LY, addition of U0126 alone for 48 hr in 
the absence of H2O2 was itself promoting cell death in the two cell-lines.  
 In summary, the inhibitor studies indicated that both Akt and Erk did not seem 







Fig 6.4 Inhibition of Akt did not enhance cell death in Nogo-A stable cells. (A) 50 
µg of lysates from SH-SY5Y vector control (v.c.) and Nogo-A (38) pretreated with 
vehicle (veh) and LY294002 (LY) were resolved on a 8% SDS-PAGE gel and 
western blotted with antibodies against total and phosphorylated Akt, Erk1/2, -
tubulin and Nogo-A. Note that p-Akt (ser473) and (thr308) blotting were on separate 
membranes. (B and C) Short-term (B) and long-term (C) inhibition of Akt. The 
histograms (left) were drawn using ModFit v2.9. Sub G1 populations of treated cells 






Fig 6.5 Inhibition of Erk did not enhance cell death in Nogo-A stable cells. (A) 50 
µg of lysates from SH-SY5Y vector control (v.c.) and Nogo-A (38) pretreated with 
vehicle (veh) and U0126 (U) were resolved on a 8% SDS-PAGE gel and western 
blotted with antibodies against total and phosphorylated Akt, Erk1/2, -tubulin and 
Nogo-A. (B and C) Short-term (B) and long-term (C) inhibition of Erk. The 
histograms (left) were drawn using ModFit v2.9. Sub G1 populations of treated cells 




6.3 Involvement of the mitochondria-associated intrinsic apoptotic pathway 
in Nogo-A’s protective effect 
 The mitochondria are the key organelles that mediate the intrinsic apoptotic 
pathway. Oxidative stress has been reported to induce apoptosis in neuronal cells 
through the mitochondrial pathway, where ROS-induced cytochrome c release from 
the mitochondria, and the subsequent caspase-3 activation eventually led to apoptosis 
(Annunziato et. al., 2003).  
 Investigations were carried out to understand if this compartment plays any 
role in modulating the protection by Nogo-A against cell death. Involvement of the 
extrinsic apoptotic pathway was not explored due to the fact that the caspases 
functioning in this pathway, caspases-8 and -10, were reported to be absent in SH-
SY5Y cells (Eggert et. al., 2001). 
 
6.3.1 Changes in the levels of mitochondrial death-associated proteins with 
Nogo isoforms and RTN3 expression  
 Many proteins have been implicated in the intrinsic apoptosis pathway, and 
the Bcl-2 family of proteins features prominently in this regard. Members of this 
family have well-documented roles in apoptosis at the mitochondria, either enhancing 
(pro-apoptotic) or preventing (anti-apoptotic) cell death.  
To find out if overexpression of Nogo isoforms and RTN3 have altered the 
basal expression status of these proteins and thereby influencing cell survival, the 
expression levels of the Bcl-2 family proteins were examined by western blot in the 
stable cell-lines (Fig 6.6). Levels of the anti-apoptotic Bcl-2 and Bcl-xL proteins were 
not significantly different between the vector control cells and those overexpressing 
Nogo-A, -B, -C and RTN3. Interestingly, the levels of total and activated pro-
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apoptotic Bax were upregulated to a significant extent in cells stably expressing 
Nogo-A, -B and RTN3. Nogo-C stable cells, however, had an expression level similar 
to the vector control cells. The levels of another known pro-apoptotic protein, Bid, 
was also examined. Truncated Bid (tBid), the cleaved product of full-length Bid, is 
known to translocate to the mitochondrion to induce apoptosis. Bid seemed to be 
cleaved to a moderately lower extent in all Nogo isoform and RTN3 stable cells 
compared to the vector control cells.  
In addition, another pro-apoptotic factor, the apoptosis inducing factor (AIF), 
which is released from the mitochondrion to induce cell death, was investigated. The 
Nogo isoform and RTN3 expressing cells appeared to have moderately lower AIF 
levels compared to vector control ones (Fig 6.6). 
 As Bax activation is a general determining step in the induction of apoptosis 
via the intrinsic pathway, the increased levels of activated and total Bax in Nogo-A, -
B and RTN3 expressing cells suggested that these cells should have intrinsically 
higher levels of cell death. Indeed, the levels of activated caspase-3 in these cells were 
higher than vector control and Nogo-C ones (Fig 6.7), with RTN3 cells having the 
highest level, followed by the Nogo-B and the Nogo-A cells. Notably, the activated 
caspase-3 levels correlated with the higher basal sub G1 population in untreated 
Nogo-B and RTN3 cells, as shown in chapter 5.  
As the Nogo isoform and RTN3 expressing cells are in general more resistant 
to apoptotic insults, their elevated basal levels of activated Bax and caspase-3, may, at 
the first glance, appear counterintuitive. However, as we shall discuss later, this may 
suggest a case of preconditioning that could help explain why these cells are more 





Fig 6.6 Expression levels of Bcl-2 family proteins and AIF in SH-SY5Y stable 
cell-lines. 50 µg of lysates from SH-SY5Y vector control (v.c.), Nogo-A (A(38)), -B 
(B(11)), -C (C(1)) and RTN3 (3(11)) were resolved on 12-15% SDS-PAGE gels and 
western blotted with antibodies against the proteins indicated. (Left) Western blot 
results of the probed proteins in the stable cell-lines. (Right) Densitometric results of 
total Bax and AIF normalized against γ-tubulin, and truncated Bid normalized against 
total Bid.  
 
6.3.2 Nogo-A and -B expression reduce H2O2-induced activation of caspase-3 
and -9   
 In order to check if the intrinsic apoptosis pathway plays a role in H2O2 




Fig 6.7 Intrinsic caspase-3 activation in SH-SY5Y stable cell-lines. Lysates of SH-
SY5Y vector control (v.c.), Nogo-A (A(38)), -B (B(11)), -C (C(1)) and RTN3 (3(11)) 
were subjected to caspase-3 activation assay. The fluorescence signal generated due to 
the cleavage of caspase-3 substrate by activated caspase-3 in the lysates was measured 
and plotted as relative fluorescence units (RFU) per µg of protein. 
 
investigated in the stable cell-lines. Caspase-9 is the initiator caspase responsible for 
the apoptosis triggered by the intrinsic pathway through cytochrome c release, while 
caspase-3 is downstream of caspase-9 and the major executioner caspase for caspase-
dependent apoptotic cell death.  
Cells were assayed for activated caspase-3 and -9 after being treated with 
H2O2 for 24 hr. In line with cell death assessed by sub G1 measurements, caspase-3 
(Fig 6.8A) and -9 (Fig 6.8B) were shown to be activated faster and at significantly 
higher levels in vector control, Nogo-C and RTN3 cells when compared to Nogo-A 
and -B cells. Activation of caspases upon H2O2 treatment also confirmed that the cell 
death induced by H2O2 in the former three cell-lines was by apoptosis. The results, 
taken together, suggested that Nogo-A and -B may somehow act to inhibit the 
intrinsic apoptosis pathway, thereby attenuating the activation of caspase-9 and 





Fig 6.8 Activation of caspase-3 and -9 in SH-SY5Y stable cell-lines upon H2O2 
treatment. Lysates of SH-SY5Y vector control (v.c.), Nogo-A (38), -B (11), -C (1) 
and RTN3 (11) treated with H2O2 were collected at 0 and 24 hr, and subjected to 
caspase-3 (A) and -9 (B) activation assays. The fluorescence signal generated due to 
the cleavage of caspase-3 and -9 substrates by respective activated caspases in the 
lysates was measured and plotted as relative fluorescence units (RFU) per µg of 
protein. 
 
6.4 The role of the unfolded protein response (UPR) or ER stress response in 
Nogo-A’s protective function 
 The ER can also induce cell death upon ER stress by activation of the UPR or 
ER overload response (EOR). To check if stable expression of the RTNs in SH-SY5Y 
activates the UPR pathway in the cells, lysates were checked for any upregulation of 
marker proteins of UPR such as GRP78 and GRP94. Both proteins are chaperones 
which are upregulated upon UPR induction to cope with the increased amount of 
unfolded proteins accumulating in ER. As shown in Fig 6.9A, there were no 
significant differences between the four cell-lines in their intrinsic basal levels of 
GRP78 and GRP94.  
Despite an absence of a clearly elevated adaptive response to ER stress, it is 
still possible that Nogo-A could affect UPR activation in a manner that enhances 
survival of cells. To check this possibility, vector control and SH-SY5Y Nogo-A (38) 
cells were treated with H2O2 and checked for the extent and kinetics of UPR 
activation through immunoblot analysis for GRP78, GRP94, and the phosphorylation 
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of eIF2α at ser51 by protein kinase R-like ER kinase (PERK). As shown in Fig 6.9B, 
no significant induction of UPR was observed in either of the cells upon H2O2 
treatment. The levels of phosphorylated eIF2α, GRP78 and GRP94 were not 
significantly elevated throughout the whole period investigated, even up to 48 hr for 
the two chaperones. Hence, it is unlikely that any UPR-based preconditioning or 
differential activation of UPR caused by Nogo-A expression could explain the 
protective effect of Nogo-A. 
 
 
Fig 6.9 Activation of UPR in SH-SY5Y stable cell-lines. (A) 50 µg of lysates from 
untreated SH-SY5Y vector control (v.c.), Nogo-A (A(38)), -B (B(11)) and -C (C(1)) 
were resolved on 10% SDS-PAGE gels and western blotted with antibodies against 
the proteins indicated. (B) SH-SY5Y vector control (v.c.) and Nogo-A (A(38)) were 
treated with H2O2 before the lysates were obtained at the specified timepoints and 







6.5 Investigations on changes in nuclear factor қB (NF-B)  
 The role of nuclear factor B (NF-B) in apoptosis in response to H2O2 has 
been fairly controversial. It has been reported by different groups to be both cell 
death-inducing, or protective against cell death in SH-SY5Y cells. Nogo-B 
overexpression has been reported by others to induce activation of NF-kB (Kuang et. 
al., 2006). This makes activation of the latter a possible mechanism underlying Nogo-
A‟s protective effect. Hence, we sought to investigate if NF-қB plays any roles in 
Nogo-A‟s protection against H2O2. The predominant forms of NF-қB signalling 
network component in neurons, as well as SH-SY5Y cells, are p65/RelA and p50. We 
have therefore focused our investigations on p65/RelA. 
 
6.5.1 Intrinsic differences of NF-B p65 subunit in the stable cells 
 Activation of NF-kB pathway results in a translocation of the p65 subunit into 
the nucleus. Firstly, an assessment of the basal levels of p65 in the total, cytosolic and 
nuclear fractions was carried out (Fig 6.10). Poly (ADP-ribose) polymerase (PARP) 
and Cu-Zn superoxide dismutase (SOD) were probed to check for the purity of the 
nuclear and cytosolic fractions respectively. Total p65 expressed in all cells were 
similar (Fig 6.10A). However, there seemed to be an increase in p65 levels in the 
nuclear fractions of the reticulon expressing cells as compared to vector control cells, 





Fig 6.10 Expression levels of NF-B p65 subunit in SH-SY5Y stable cell-lines. 
Total lysates (50 µg) (A), nuclear and cytosolic fractions (20 µg) (B) of SH-SY5Y 
vector control (v.c.), Nogo-A (A(38)), -B (B(11)), -C (C(1)) and RTN3 (3(11)) were 
resolved on 8% SDS-PAGE gels and western blotted with antibodies against the 
proteins as indicated.  
 
6.5.2 NF-B p65 nuclear translocation in SH-SY5Y cells induced by TNFα is 
affected by Nogo isoforms and RTN3 expression  
 NF-қB p65 subunit translocation and activation has been shown to be 
effectively induced by the cytokine tumor necrosis factor α (TNFα). To check if p65 
translocation and nuclear accumulation in SH-SY5Y is affected by Nogo isoforms 
and RTN3, TNFα was used to stimulate the cell-lines and p65 translocation was 
examined by ICC.  
As shown in Fig 6.11A, nuclear staining of p65 after 1 hr of TNFα stimulation 
was much more obvious in Nogo-A, -B and RTN3 stable cells than vector control or 
Nogo-C cells. In fact, translocation of p65 could be observed much earlier in Nogo-A, 
-B and RTN3 cells, with some nuclear staining already obvious after 30 min (data not 
shown). p65‟s nuclear staining peaked at about 2 hr before the basal pattern of 
distribution was resumed by 4 hr. There also seemed to be a sustained presence of p65 





Fig 6.11 TNFα-induced NF-B p65 subunit translocation in stable cell-lines did 
not lead to cell death. (A) SH-SY5Y vector control (v.c.), Nogo-A (38), -B (11), -C 
(1) and RTN3 (11) cells were treated with TNFα and fixed at 0, 1 and 4 hr with 4% 
PF and permeabilized with 0.2% Tx-100/PBS. They were then incubated with anti- 
NF-kB p65 antibodies, followed by FITC-conjugated secondary antibodies. Bar = 20 
µm. (B) Flow cytometry analysis of stable cells left untreated (-TNFα) or treated with 
TNFα (+TNFα) for 24 hr. % of sub G1 population was as shown in the graph (mean ± 
sd, n = 3). 
 
To examine if the observed p65 translocation induced by TNFα would affect 
cell survival, TNFα-treated cells were subjected to flow cytometry analysis (Fig 
6.11B). No significant differences in their sub G1 population were observed after 24 
hr of treatment with TNFα. 
121 
 
6.5.3 Translocation of NF-B p65 subunit upon stimulation with H2O2  
 We next investigated whether the extent of H2O2-induced p65 cytoplasmic-
nuclear translocation in the SH-SY5Y cell lines were different. Cells were treated 
with H2O2 and checked for p65 translocation by ICC. Interestingly, there was no 
observable nuclear accumulation of p65 in vector control cells at all. However, a good 
percentage of Nogo-A, -B and RTN3 stable cells exhibited p65 staining in the 
nucleus, beginning at about 90 min and obvious at about 3 hr (Fig 6.12). On the other 
hand, Nogo-C cells behaved like vector control cells and did not show any nuclear 
accumulation of p65.  
 
 
Fig 6.12 NF-B p65 subunit translocation in stable cell-lines upon H2O2 
treatment. SH-SY5Y vector control (v.c.), Nogo-A (38), -B (11), -C (1) and RTN3 
(11) cells were treated with H2O2 for 3 hr before fixation with 4% PF and 
permeabilized with 0.2% Tx-100/PBS. They were then incubated with anti- NF-kB 
p65 antibodies, followed by FITC-conjugated secondary antibodies. Bar = 20 µm. 
 
These observations, taken as a whole, implied that Nogo/RTN3 expression 
could enhance nuclear translocation of p65 and NF-қB activation upon induction by 
both TNFα and H2O2. As p65 is a mediator of canonical NF-қB signalling that could 




6.6 Discussion – mechanisms involved in Nogo-A’s protection against H2O2-
induced cell death 
From the data presented above, the N-terminus common to Nogo-A and -B 
was important in protecting SH-SY5Y cells against H2O2-induced cell death. 
However, this domain alone (aa 1-200) or a Nogo-B protein truncated after TM1 (N-
TM1) had no protective effect. This implied that the RHD played a supportive role for 
the N-terminus in preventing H2O2-induced cell death. It is unclear in this regard 
whether the RHD simply provides membrane anchorage and topological orientation 
for the protective function of the N-terminal region to be manifested, or the RHD 
domain itself has a direct accessory role. More insights await the identification of 
molecules that interact with these domains.  
Activation of classical pro-survival Akt and Erk signalling pathways were 
found not to be involved in Nogo-A‟s protection against H2O2. There were also no 
upregulation of anti-apoptotic proteins such as Bcl-2 and Bcl-xL in the stable cell-
lines. However, two pro-apoptotic molecules, truncated Bid and AIF, were found to 
be downregulated in all stable cell-lines. This might provide a partial explanation for 
an intrinsically enhanced resistance to apoptosis. Interestingly, there were 
significantly higher levels of total and activated Bax in Nogo-A,-B and RTN3 stable 
cells, but not in Nogo-C cells. Bax activation levels correlated with the basal amounts 
of activated caspase-3 in untreated cells. The sub G1 population in untreated Nogo-B 
and RTN3 cells were also higher than the rest. As shall be elaborated in chapter 7, the 
elevated basal levels of activated Bax and caspase-3 may reflect a preconditioned 
state that these cells are in. This may, in turn, allow the cells more tolerance against 
apoptotic insults.  
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Activation of caspase-3 and -9 upon treatment with H2O2, which implied that 
apoptosis was mediated by the intrinsic pathway, was found to occur in vector 
control, Nogo-C and RTN3 stable cells but not in Nogo-A and -B stable cells. This 
finding suggested that Nogo-A and -B may effect their protection by somehow 
attenuating the intrinsic apoptotic pathway. 
A clear adaptive response to ER stress induced by overexpression of RTNs 
was not observed in the cells. This mildly contrasted the report of others (Kuang et. 
al., 2006; Wan et. al., 2007) that reticulon expression may induce significant amount 
of ER stress. One reason for this could be because of the moderate level of transgene 
expression in our stable cells. Although clear elevation of the protective GRP78 and 
GRP94 were not observed, Nogo-A expressing cells may still be in some way 
preconditioned or primed. One evidence for this is that ER stress induced by 
tunicamycin heightened their death over vector control cells.  
Nogo-A, -B and RTN3 cell-lines exhibited moderately higher levels of NF-қB 
p65 subunit in the nucleus. H2O2 induction of p65 translocation occurred in Nogo-A, -
B and RTN3 stable cells, but not in Nogo-C. Notably, Nogo-A, -B and RTN3 were 
able to activate p65 translocation faster and cause more complete nuclear 
translocation during TNFα stimulation and H2O2 treatment than Nogo-C. The nuclear 
translocation of p65 was also sustained longer in these three cells. More efficient 
activation of NF-қB-mediated transcription of pro-survival genes may therefore play a 
part in the protective activity of Nogo-A, -B and RTN3. 
 Although these investigations did not provide an exclusive explanation as to 
how Nogo-A protected SH-SY5Y against H2O2, some hints to the possible 




Chapter 7 Discussions and Conclusions 
 
7.1 Localization of Nogo-A in CNS  
Our Nogo-A specific antibodies generated were able to detect ER and plasma 
membrane staining of endogenous Nogo-A within cells, and demonstrate its 
enrichment in adult CNS tissues. As Nogo is first identified from myelin extracts, it is 
assumed to be perhaps an exclusively myelin-associated protein. Contrary to what one 
may assume, Nogo-A expression appears to be rather widespread, and not limited to 
the myelin or white matter tracts. It was detected in the cerebral cortex, cerebellum, 
hippocampus and spinal cord, where it also labelled neuronal cell bodies.  
Expression of Nogo-A was also shown to be present in the developing rat 
brain from embryonic stage (E18) to adulthood. Although we did not check the 
developmental stages before E18, where neurogenesis began, we did show that 
differentiating cortical neurons in culture expressed Nogo-A. Nogo-A was indeed 
observed to be present during neurogenesis in chick early embryos (O'Neill et. al., 
2004). Together with others‟ results, this suggests either a role for Nogo-A in the 
differentiation of neurons, or simply a bystander, but not likely as an inhibitor of 
neurite outgrowth during this period.  
Nogo-A was found to be localized in the oligodendrocytes and neurons, but 
not astrocytes. Liu et. al. (2002) had additionally showed Nogo-A‟s expression 
excluded from microglia. Indeed, the expression of Nogo-A in oligodendrocytes fitted 
its classically perceived role as a myelin-associated inhibitor of neuronal regeneration. 
The role of neuronal Nogo-A has been mystifying though, as it is counter intuitive 
that a neuron should express a molecule that would inhibit its regeneration. O‟neill et. 
al. (2004) has showed that neuronal Nogo-A expression was downregulated upon 
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onset of myelination, and this could probably explained the ability of oligodendroglial 
Nogo-A to exert its neurite growth inhibitory function. Neuronal Nogo-A may 
function, as suggested, as an axonal guidance molecule during embryonic 
development, and a restrictor of aberrant neurite growth in the adult CNS (Yiu and 
He, 2006). An important point to note here is that Nogo-A acting in trans (ie. Nogo-A 
from oligodendrocyte membranes acting on neurons) is likely to be different from 
Nogo-A acting in cis (ie. Nogo-A on the neuronal membrane itself, performing a cell-
autonomous activity). 
In addition to Nogo-A expression in CNS, it is noteworthy that Nogo-A is also 
expressed, albeit at much lower levels, in the heart. The pathophysiological 
significance of Nogo-A in the heart was demonstrated by its upregulation in an animal 
model of heart failure, with a concomitant reduction in Nogo-B and Nogo-C levels. 
The changes in levels were normalized in a rescue model (Bullard et. al., 2008). The 
N-terminus common to Nogo-A and -B could promote endothelial cell migration, 
while inhibiting that of vascular smooth muscle cells (Acevedo et. al., 2004). In this 
connection, a role in regulating vascular remodelling has been implicated at least for 
Nogo-B (Acevedo et. al., 2004).   
 
7.2 Enrichment of Nogo-A at the paranode and its interaction with Caspr 
 Interestingly, Nogo-A was found to be enriched in the paranodal region of the 
node of Ranvier. We, in collaboration with others, have determined by electron 
microscopy that Nogo-A was present in the myelin sheath of oligodendrocytes rather 
than the neurons themselves (Nie et al., 2003). We showed in chapter 4 that Nogo-A 
interacted with the paranodal protein Caspr. The Nogo-A domain which interacts with 
Caspr is essentially Nogo-66, the region postulated to be extracellularly oriented. 
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Interaction between Nogo-66 and Caspr was specific, as Nogo-66 was found not to 
bind to another paralogue, Caspr2. Shorter, truncated forms of Nogo-66, Nogo-35 and 
-40, were unable to pull-down Caspr in GST pull-down assays. The advent of Caspr 
expression in rat brain only after P4 meant that the Nogo-A-Caspr interaction may 
only have a functional role after this developmental stage. 
 Although interesting, the role of Nogo-A-Caspr interaction has remained 
unclear. Caspr has been widely known for its essential role in the formation and 
stabilization of the paranodal axoglial junction. It functions by forming a complex 
with the neuronal protein contactin/F3 on the axolemma and interacts with NF 155 on 
the oligodendroglial membrane (Charles et. al., 2002).  Caspr also interacts with the 
cytoskeletal adaptor protein 4.1B to effectively generate a membrane barrier at the 
paranodal junction, such that distinct subregions are formed at the node, paranode and 
juxtaparanode (Horresh et. al., 2010). As such, the interaction of Nogo-A with Caspr 
was hypothesized to play a role related to this function of Caspr. Our collaborators 
(Nie et al., 2003) had actually explored this possibility by using demyelinating EAE 
rat and Shiverer mouse models. They found that in these animal models, Nogo-A‟s 
clustering at the paranode was barely detectable. They also observed that the K
+
 
channels were not only localized at the juxtaparanodes but also colocalizing with 
Caspr at the paranodes. Hence, they postulated that the absence of Nogo-A at the 
paranode in these demyelinating animals may have caused the architecture at the node 
to be disorganized due to a lack of interaction between Nogo-A and Caspr. As 
demyelination leads to all glial molecules localizing at the axon-glial junction to be 
absent, including NF155 that is known for stabilising the axon-glial junctions and 
necessary for the organization of the architecture at the node, a conclusive answer of 
whether Nogo-A is essential in this function could not be deduced. With the 
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availability of our Nogo-deficient mice, we ventured to investigate this hypothesis by 
comparing these mice with wild type mice. Our results, however, implied that Nogo-
A did not have an essential role in the architecture organization at the node of 
Ranvier. The spatial placement of Caspr and K
+
 channels at the paranodes and 
juxtaparanodes respectively were unaffected in the spinal cord of Nogo-deficient 
mice. It is still possible that Nogo-A functions in supporting or organizing the 
structures at the paranodal junction, but in a redundant manner. 
 Interestingly, a recent report has demonstrated that Caspr was inhibitory to 
neurite outgrowth (Devanathan et. al., 2010). Cerebellar neurons from Caspr
-/-
 mice 
exhibited longer neurites than wild type ones. It was suggested that neuronal Caspr 
could bind to some extracellular ligands and activate intracellular signalling pathways 
that led to neurite outgrowth inhibition. Can Caspr be a novel inhibitory receptor for 
Nogo-A to elicit its inhibitory signals to the neurons? This hypothesis would need 
further validation.  
 
7.3 Interaction of Nogo-A with RTN3 
 The earlier discovered RTNs have been known to interact and form dimers or 
complexes with one another (Senden et. al., 1994). Interaction between Nogo-B and 
RTN3 has been reported (Qi et. al., 2000). Nogo-B is more ubiquitous in its 
expression, with no enrichment in neurons, while RTN3 is brain-enriched. We 
hypothesized that a more physiological relevant RTN partner for RTN3 in the CNS 
neurons would be Nogo-A, and endeavoured to check the interaction between the two. 
Nogo-A could indeed be co-immunoprecipitated with RTN3 reciprocally. An 
interesting point to note from our findings was that Nogo-A was able to bind to RTN3 
much better than to RTN1 or 2. Our molecular dissection showed that the interaction 
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between Nogo-A and RTN3 requires at least one of the TM domains. The absence of 
one TM domain caused a reduction in interaction. A complete abolishment of 
interaction was observed when one of the proteins had both TM domains removed. 
These results suggested that Nogo-A-RTN3 interaction occurred only in a membrane-
associated context. 
 Several cellular roles have been postulated for RTN3. Binding of Nogo-A to 
RTN3 may have an effect on the latter‟s ability to carry out its functions. Shaping of 
the ER tubular structure required oligomerization of RTNs and complexing with DP1 
(Voeltz et. al., 2006). RTN3 has also been shown to regulate membrane trafficking 
between the ER and Golgi (Wakana et. al., 2005). Nogo-A may interact with RTN3 to 
function in these aspects. In our experience, however, transient expression of Nogo-A 
at moderately high levels did not significantly affect the markers of organelles of the 
secretory pathway (data not shown). 
 Another possibly relevant function of Nogo-A-RTN3 interaction is CNS 
specific. RTN3 was known to interact with the APP processing β-secretase BACE1, 
thereby reducing its enzymatic activity and decreasing Aβ generation (He et. al., 
2004). Nogo-B and -C were also identified as potential binding partners of BACE1 
and that they could similarly decrease Aβ generation (Murayama et. al., 2006). The 
fact that BACE1 preferred binding to monomeric RTN3 suggested the importance of 
oligomerization of RTNs in this aspect (He et. al., 2006). Preliminary results have 
shown that Nogo-A did not interact with BACE1 directly (data not shown). Hence, 
whether Nogo-A‟s binding to RTN3 would indirectly interfere with BACE1‟s 
cleavage of APP thereby affecting Aβ generation remains to be investigated. A role 
for RTN3 in the membrane transport of neurite outgrowth promoting molecules, 
synaptic adhesion-like molecules (SALMs), via their interaction was also suggested 
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recently (Chang et. al., 2010). More work is required to properly delineate Nogo-A‟s 
influence on the said functions and activities of RTN3. 
 
7.4 Neuroprotection by Nogo-A and the possible mechanisms involved  
 The upregulation of Nogo-A levels in neurons in models of CNS injury have 
prompted us to consider the possibility of Nogo-A having some neuroprotective 
activity. We have therefore explored the neuroprotective role of Nogo-A against 
various drugs/treatments that induce apoptosis in SH-SY5Y neuroblastoma cells. We 
found that protection by Nogo-A could be extended to a variety of apoptosis-inducing 
methods, including growth factor withdrawal, DNA damage, and oxidative stress, 
except for ER stress (see below).  
 The protection effect that we have seen could be classified into three types. 
The first is where all Nogo isoforms and RTN3 were protective, and these included 
cell death induced by serum withdrawal and staurosporine treatment. The second is 
where Nogo-A, -B and RTN3‟s effects were similar, but not Nogo-C. The difference 
could lie in the fact that Nogo-C has a shorter N-terminus (only 11 aa). The Nogo-A, -
B and RTN3 expressing cells were protected against etoposide but exhibited enhanced 
cell death with tunicamycin treatment. The third type is the effect against H2O2, where 
only Nogo-A and -B were able to render protection to the cells. The different 
protection effects observed suggested that the mechanisms activated by Nogo-A and 
the other RTNs to enable protection may be rather complex to begin with. 
 The N-terminus of Nogo-A/B was found to play an essential part in protecting 
cells against H2O2, with supporting roles from the RHD domain. As shown, protection 
was abolished with Nogo-B truncated proteins containing only the N-terminus region 
(1-200) or truncated after TM1 (N-TM1). Although (1-200) was cytosolic, (N-TM1) 
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was apparently still ER-associated (data not shown). Therefore, the loss of protective 
effect by the above mutants may not be simply due to a loss of membrane attachment. 
It could, at least in part, result from the loss of efficient dimerization/ oligomerization.  
 To further uncover the mechanisms underlying the protective effect, we 
explored several possibilities. Firstly, whether classical Akt and Erk survival 
pathways were activated by Nogo-A was scrutinized. Inhibition of both Akt and Erk 
did not lead to an increase in cell death in Nogo-A expressing cells after H2O2 
treatment. Therefore, these survival proteins were not essential for Nogo-A‟s 
protective function. A check on proteins acting in the intrinsic apoptotic pathway 
showed that the two anti-apoptotic proteins, Bcl-2 and Bcl-xL, were not intrinsically 
upregulated in Nogo-A cells. Truncated Bid and AIF were however shown to be 
downregulated in all the RTN expressing cells. Interestingly, total and activated Bax 
were present at significantly higher levels in Nogo-A, -B and RTN3 cells but not 
vector control or Nogo-C cells. Basal caspase-3 activity was also higher in these cells.  
 This apparent increase in basal activated Bax and caspase-3 activity may 
theoretically sensitize the cells to apoptotic insults. However, as we have seen, this is 
not the case, and the cells are actually more tolerant. Alternatively, the increased basal 
levels of Bax and caspase-3 could “precondition” the cells against a more severe 
insult by heightening the cells‟ survival response time and/or intensity. Although 
more evidence is required to firmly support this notion, we believe this may provide 
some explanation for the protective effect. In fact, the phenomenon of preconditioning 
in terms of neuronal death is widely known in experimental and pathophysiological 
contexts. Ischemic preconditioning, for example, refers to the observation that a mild 
and transient ischemic event could protect against neuronal demise induced by a more 
severe subsequent episode of ischemia. Ischemic preconditioning is equally applicable 
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to the heart. In a particularly interesting case of neuronal death preconditioning, 
lesioning of the peripheral branch of the dorsal root ganglion could protect the CNS 
branch of the neuron from subsequent lesioning (Fiblin, 2003).   
 It was also found that activation of caspase-3 and -9 were induced in H2O2- 
treated vector control, Nogo-C and RTN3 cells, which correlated with cell death, 
while Nogo-A and -B did not. This has strong implications for Nogo-A and -B to 
exert their protective functions by attenuating the activation of the intrinsic apoptotic 
pathway, thereby preventing subsequent caspase-dependent apoptosis.   
 Likewise, overexpression of RTNs has been proposed by others to induce ER 
stress by the activation of both UPR and EOR and hence apoptosis (Kuang et. al., 
2006; Wan et. al., 2007). In our stable cells moderately overexpressing Nogo-A, -B, -
C or RTN3, however, signs of any UPR induction were not obvious. There was no 
significant upregulation of the ER stress response molecular chaperones, GRP78 and 
GRP94. ER stress preconditioning has been suggested to have a protective function 
(Rutkowski et. al., 2006), but prolonged ER stress would also lead to apoptosis. No 
significant induction of UPR was observed in either the vector control or Nogo-A 
expressing cells after being treated with H2O2. There was no obvious elevation in the 
levels of PERK-mediated phosphorylated eIF2α, GRP78 and GRP94, even up to a 
timepoint of 48 hr. This shows that H2O2 is unable to induce UPR in the SH-SY5Y 
stable cells. The results also suggest that any UPR-based preconditioning is unlikely 
to account for Nogo-A‟s protection. An interesting point to note is the fact that 
apoptosis induced by tunicamycin, a classical activator of ER stress, is exacerbated in 
Nogo-A, -B and RTN3 expressing cells. It is possible that expression of these 
constructs have enhanced the degree of ER stress by tunicamycin to the point such 
that the cells are tipped towards death rather than being preconditioned for survival.  
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 As NF-қB plays an important role in neuronal survival, we sought to 
investigate its possible involvement in Nogo-A‟s protective function. All Nogo 
isoforms and RTN3 expressing cells seemed to have higher amount of the protein in 
the nucleus. It has been previously reported that Nogo-B overexpression could lead to 
an activation of NF-қB as a result of EOR induction (Kuang et. al., 2006). Hence, we 
suspect that the increased NF-қB activation observed in the Nogo isoforms and RTN3 
expressing cells is caused by an induction of EOR due to the stable expression of the 
RTNs. The expression of these proteins, with the exception of Nogo-C, also 
apparently enhanced p65 nuclear translocation induced by TNFα and H2O2. As the 
role of NF-B in apoptosis has been controversial, the higher p65 levels in the 
nucleus could not conclusively indicate that the cells were protected via this 
mechanism. However, p65 translocation upon TNFα stimulation did not lead to 
apoptosis in SH-SY5Y.Taken together, our results suggested that enhanced p65 
nuclear translocation may be part of the explanation for the protective effects seen. 
Our results were corroborated by a recent report which also implied that Nogo-A 
could have protective functions (Kilic et. al., 2010). Nogo-A
-/-
 mice exhibited 
decreased neuronal survival after focal cerebral ischemia. The authors suggested that 
Nogo-A maintained a low level of stress kinases p38/MAPK, SAPK/JNK1/2 and 
phosphatase-and-tensin homolog (PTEN) via RhoA activation, thereby promoting 
neuronal survival.  
Our results have thus strengthened the notion of the role of Nogo-A in 
neuroprotection. Although our investigations could not pinpoint an exclusive 
mechanism to account for Nogo-A‟s protective activity, we think that elevated 
expression of Nogo-A in neurons likely affects several pro-survival pathways. These 
would include some form of preconditioning either through mitochondrial or ER-
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stress associated factors, as well as sensitization of the cell to processes such as NF-
қB translocation (Fig 7.1). 
 
 
Fig 7.1 Possible mechanisms induced by Nogo-A and -B leading to survival. 
Several signalling pathways may be involved and work in concert in the protection 
against cell death rendered by Nogo-A and -B. These include induction and/or 
preconditioning of the ER stress response, inhibition of intrinsic apoptotic pathway, 
preconditioning by Bax and caspase-3, and activation of NF-κB. RhoA activation has 
also been shown to aid in survival conferred by Nogo-A (Kilic et. al., 2010). 
 
7.5 Concluding remarks 
 We have investigated Nogo-A in terms of cellular and tissue localization, 
interacting partners and its potential neuroprotective function. Much has been known 
about Nogo-A as an inhibitor of neurite outgrowth, but its cell autonomous function is 
basically unknown. Our investigations have therefore provided some insights on the 
other possible roles that Nogo-A may possess. Continuing the investigations of the 
mechanism underlying Nogo-A‟s neuroprotective activity would be an important 
pursuit in the immediate future. Our results may have also some important 
translational implications. They caution that any Nogo-directed interventions to 
enhance regeneration should aim to specifically disrupt Nogo-A‟s interactions that 
would transduce neurite growth inhibitory signals, but not its complete silencing or 
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deletion. The latter approach would likely deprive the neurons of Nogo-A‟s protective 
activity, and be contraindicative on the whole. 
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     Primers used for DNA constructs Appendix 1 
A1 
Primer name Primer sequence FW/RV RE  
A-P1 5’ GGTCCTCGAGGAAGACCTGGACCAGTCTCCTCTGG 3’ FW Xho1 
A-P2 5’ GGGCACGGTCGACGACACCGGGCTC 3’ RV Sal1 
A-P3 5’ GCAGATGGAGGAGCTCAGTACTGC 3’ FW Sac1 
A-P4 5’ GCCGTAGAGCTCGCGGCCGCTCACTGATGCCGTTCATA AATAAC 3’ RV Not1 
A-P5 5’ CCTCTCTCTAGAAGTCTTCTTAATGTCTTCC 3’ RV Xba1 
A-P6 5’ CTAGTGTCTAGAAGGATATACAAGGGTGTGATC 3’ Fw Xba1 
A-P7 5’ GAGCTCGCGGCCGCATCAGCGCTT 3’ RV Not1 
A-P8 5’ CTAAATGAGCTCGCGGCCGCTCACTTCAGAGAATCAACT AAATC 3’ RV Not1 
A-P9 5’ CCTCTCTCTAGATCAAGTCTTCTTAATGTCTCTCC 3’ RV Xba1 
A-P10 5’ GTTCGAATTCGATTTCCCATCTGTCCTGCTTG 3’ FW EcoR1 
A-P11 5’ GCTCCTCGAGTCAACTATCTTTCACTTCCCATACTCG 3’ RV Xho1 
A-P12 5’ CGGGAATTCAGGATATACAAGGGTGTGATCCAAGC 3’ FW EcoR1 
A-P13 5’ CGATCTCGAGTCACTGAACCAACTCCTCAGATATAGC 3’ RV Xho1 
A-P14 5’ CCCGCTCGAGTCAAGAATTACTGTACTTCTGAACC 3’ RV Xho1 
A-P15 5’ CATCTCGAGTCACTTCAGAGAATCAACTAAATCATC 3’ RV Xho1 
B-P1 5’ GGGAGAATTCAGAAGACCTGGACCAGTCTCCTCTGG 3’ FW EcoR1 
B-P2 5’ TGAGCCCGAGGAGCCCCTGCGCTTGGG 3’ RV - 
B-P3 5’ GTGGTTGTTGACCTCCTGTACTGGAGAG 3’ FW - 
B-P4 5’ CCTAGCGGCCGCTCATTCAGCTTTGCGCTTCAATCC 3’ RV Not1 
B-P5 5’ GGTCGAATTCATGGAAGACCTGGACCAGTCTCCTCTGG 3’ FW EcoR1 
B-P6 5’ CCTCTGCGGCCGCTCACACTCCAGTCTTCTTAATGTCTCTCC 3’ RV Not1 
B-P7 5’ GGTAGCGGCCGCTCACTTGTATATCCTAAAGCTGATGG 3’ RV Not1 
C-P1 5’ GAGGGAATTCAACCATGGACGGTCAGAAGAAAAATT GGAAGGACAAGGTTGTTGACCTCCTGTACTGGAG 3’ FW EcoR1 
C-P2 5’ GAGGAATTCAGACGGTCAGAAGAAAAATTGGAAGGACA AGGTTGTTGACCTCCTGTACTGGAG 3’  FW EcoR1 
1-P1 5’ CTAGCTCGAGGCCGCACCGCCGGATC 3’ FW Xho1 
1-P2 5’ GCGGGTCGACCTACTCAGCGTGCCTCTTGGCG 3’ RV Sal1 
2-P1 5’ CTTCCTCGAGGGGCAGGTCCTGCCGGTCTTC 3’ FW Xho1 
2-P2 5’ CCTAGTCGACTCATTCGGCTTTGGCTTTGGATCC 3’ RV Sal1 
3-P1 5’ CCTGGAATTCAACCATGGCGGAGTCGTCAGCGGCCACTC AGTCC 3’ FW EcoR1 
3-P2 5’ CGTTGTCGACTTATTCTGCCTTTTTTTTGGCGATTCCA GGAAGCTTTGC 3’ RV Sal1 
3-P3 5’ GGTTGAATTCAGTGAAGAAGACTGGGTTTGTCTTTGG 3’ FW EcoR1 
3-P4 5’ CTAAGAGCTCAGTCTTCTTCACATCTCGCCAGAAAATC 3’ RV Sac1 
3-P5 5’ GTGTGAGCTCAGAGTCTATAAGTCTGTCATTCAAGCTGTG 3’ FW Sac1 
3-P6 5’ GACCGAGCTCCTTCAAGGAGTCAACCAAGTCTTCTACCA G 3’ RV Sac1 
3-P7 5’ GTTAGAGCTCACACAGATTGACCACTATGTTGGGATTG 3’ FW Sac1 
Caspr-P1 5’ CCATGAATTCAATCATCGCTATAAGGGCTCCTACC 3’ FW EcoR1 
Caspr-P2 5’ CTTGCTCGAGTCAGATCTGGGGTAGGTTC 3’ RV Xho1 
Caspr2-P1 5’ CGGGAATTCCGGTACATGTTCCGCCACAAGGGC 3’ FW EcoR1 
Caspr2-P2 5’ CTTTCTCGAGTCAAATGAGCCATTCCTTTTTGCTTTC 3’ RV Xho1 
 
      Note: Underlined bases – RE site. FW – forward. RV – reverse. 
 





Antigen Antibody's cat no. (Co.) Dilution 
AIF sc-13116 1:1000 
p-Akt (thr308) 9275 (Cell Signaling Tech) 1:1000 
p-Akt (ser473) 9277 (Cell Signaling Tech) 1:1000 
Akt 9272 (Cell Signaling Tech) 1:2000 
AR2 a gift (refer to section 2.7.1) 1:5000 
Bax (activated) sc-493 1:1000 
Bax (total) sc-20067 1:500 
Bcl-2 551107 (BD Biosciences) 1:500 
Bcl-xL 2762 (Cell Signaling Tech) 1:1000 
Bid sc-6538 1:500 
Caspr - 1:1000 
Caspr 2 - 1:1000 
c-myc (9E10) sc-40 1:1000 
Cu/Zn-SOD 07-403 (Upstate) 1:1000 
p-EIF2α 9721 (Cell Signaling Tech) 1:1000 
EIF2α 9722 (Cell Signaling Tech) 1:1000 
p-Erk1/2 (thr202/tyr204) 9101 (Cell Signaling Tech) 1:1000 
Erk1/2 4696 (Cell Signaling Tech) 1:2000 
GRP78 sc-13968 1:500 
GRP94 sc-1794 1:1000 
p-GSK3α/β (ser21/9) 9331 (Cell Signaling Tech) 1:1000 
GSK3α 9338 (Cell Signaling Tech) 1:2000 
GSK3β 9315 (Cell Signaling Tech) 1:2000 
HA (12CA5) - 1:1000 
NF-κB p65 sc-8008 1:500 
Ng1V2 - 1:2000 
Nogo sc-11027 1:2000 
PARP 9532 (Cell Signaling Tech) 1:5000 
RTN3 AB72814 (Abcam) 1:2000 
Tuj T8660 (Sigma-Aldrich) 1:1000 
γ-tubulin T6557 (Sigma-Aldrich) 1:5000 
 
                  Note: Upstate (Charlottesville, Virginia, USA). 
                            Cell Signaling Technology (Danvers, Masachusetts, USA). 
                (-) refers to “homemade”. 
            
